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The last decade has witnessed an explosion of novel therapies that have heralded the 
era of interventional glaucoma. Minimally invasive glaucoma surgery (MIGS) has 
been the center piece of this movement, providing ophthalmologists and patients 
with an alternative to topical medications or traditional conjunctival surgery. These 
procedures share a common approach to minimize normal anatomical and physio-
logical disruption in an effort to reduce risks and hasten recovery and improve qual-
ity of life. While it remains to be seen what the impact of MIGS on reducing the 
global burden of glaucoma will be, this field has generated substantial interest in 
improving the outcomes of MIGS procedures.
With the vast array of MIGS options now available worldwide, there is a great 
need for a concise, easily accessible, and complete review of these procedures. 
Understanding the design, surgical technique variations, complications and man-
agement, and patient selection is essential for the successful incorporation of MIGS 
into clinical practice.
Edited by two well-respected internationally renowned glaucoma specialists, 
Chelvin Sng and Keith Barton, Minimally Invasive Glaucoma Surgery provides a 
comprehensive review of the field. A unique feature of this book is the global view 
of MIGS, with a wide international cast of experts contributing to this cutting-edge 
book. An overview and essential anatomy of the outflow pathways provides the 
reader with a firm basic foundation for MIGS as a starting point. One can then 
immerse oneself on a specific procedure with the latest techniques, evidence and 
results. MIGS procedures can be differentiated based on their outflow target 
(Schlemm’s canal/conventional outflow, suprachoroidal/uveoscleral, and subcon-
junctival). Minimally Invasive Glaucoma Surgery covers each approach with the 
necessary breadth and depth to assist the beginner, intermediate and advanced sur-
geon. The book finishes with both controversies and a global view of MIGS dis-
cussed in a thought-provoking manner.
vi
Sng and Barton have put together an excellent and comprehensive collection of 
topics on MIGS, authored by top global experts in the field. This book serves a great 
reference for those looking to better understand MIGS and the role it plays in glau-
coma management.
 Iqbal Ike K. Ahmed
Department of Ophthalmology 
and Vision Sciences
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The term, minimally- or micro-invasive glaucoma surgery (MIGS), first coined 
around 2008 (II Ahmed, personal communication) has entered common ophthalmic 
parlance and is playing an increasing role in the management of glaucoma patients. 
In common, the devices and procedures referred to, are safer, less tissue invasive 
and associated with faster recovery than traditional filtering surgery, such as trab-
eculectomy or aqueous shunt implantation [1]. While the term initially referred only 
to ab interno Schlemm’s canal bypass stents such as the iStent, it has expanded, 
though with somewhat inconsistent adoption, both by clinicians and by the manu-
facturers, not all of whom are enthusiastic about applying the MIGS label to their 
device, to encompass both ab externo and ab interno canal procedures, suprachoroi-
dal implants, external filtration devices and to some degree, even new types of 
cyclodestruction. On the horizon are also drug-eluting implants. The US Food and 
Drug Administration (USFDA) defines MIGS as devices or procedures that lower 
intra-ocular pressure (IOP) with either an ab interno or ab externo approach, associ-
ated with little or no scleral dissection and minimal or no conjunctival manipulation, 
though USFDA workshops and guidance have tended to consider only implantable 
devices [2, 3]. This book covers the techniques that are most commonly regarded as 
eligible to sit under the MIGS umbrella, whether or not industry or clinicians prefer 
to call them MIGS. Others, such as the Ex-PRESS shunt (Alcon Laboratories, Inc., 
Fort Worth, Texas, USA), SOLX Gold  Glaucoma  Shunt  (GGS, SOLX Ltd., 
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Waltham, MA, USA) and canaloplasty have some similarities to MIGS techniques 
and devices, but will not be covered in detail.
A number of MIGS devices and techniques have relatively modest efficacy but, 
potential utility in a very large group of glaucoma patients with disease that is insuf-
ficiently severe to justify the invasiveness of conventional filtration surgery and the 
consequent intensity of postoperative care, yet burdened with medication and the 
attendant side effects and compliance issues thereof. A simple additional technique 
at the time of cataract surgery could have significant quality of life benefits for a 
large number of these patients. On the other hand, some MIGS devices can poten-
tially achieve efficacy approaching that of traditional filtering surgery and are 
appropriate in selected individuals when larger IOP reductions are required, the 
exception being cases where glaucoma is very advanced.
Irrespective of the modest efficacy of many MIGS devices and techniques, the 
favourable safety profile lowers the threshold for early glaucoma surgery, especially 
when combined with cataract surgery, potentially delaying the requirement for more 
invasive surgery and associated risks. The additional reduction in the medication 
burden has the potential to reduce intolerance, improve quality of life and lower the 
long-term cost of medication while improving adherence.
MIGS can be categorized according to the tissue they target (or bypass): trabecu-
lar meshwork (TM) MIGS, subconjunctival MIGS, suprachoroidal MIGS and 
newer cycloablation procedures. MIGS devices include iStent Trabecular Micro- 
Bypass Stent and iStent inject (Glaukos Corporation, San Clemente, CA, USA), 
Hydrus Microstent (Ivantis Inc., Irvine, CA, USA), the XEN Gel Implant (Allergan 
plc, Dublin, Ireland) and PRESERFLO (formerly InnFocus) MicroShunt (Santen 
Pharmaceutical Co. Ltd., Osaka, Japan) (Table 1.1). At present, as a result of the 
Table 1.1 Procedures and implants that fall broadly within the minimally invasive category of 
glaucoma surgery though a number of those listed would not be typically described as MIGS
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withdrawal of the CyPass Micro-Stent (Alcon Laboratories, Inc., Fort Worth, Texas, 
USA), there are no commercially available devices that drain to the supra-choroidal 
space, though others are in development.
While there are a number of pathways targeted by MIGS devices, most MIGS 
procedures in which a device is not implanted, are designed to eliminate trabecular 
meshwork resistance from the outflow pathway: ab interno trabeculotomy 
(Trabectome; NeoMedix Corporation, San Juan Capistrano, CA, USA) and 
gonioscopic- assisted transluminal trabeculotomy (GATT). Newer surgical instru-
ments such as the Kahook Dual Blade (New World Medical, Rancho Cucamonga, 
CA, USA) and TRAB360 (Sight Sciences Inc., Menlo Park, CA, USA) are designed 
for ab interno removal of TM tissue to enhance physiological TM outflow system.
Ab interno canaloplasty (ABiC, Ellex Medical Pty Ltd., Adelaide, Australia) dif-
fers slightly in that it primarily dilates Schlemm’s canal, although a small cut is 
made through trabecular meshwork to access the canal.
Concurrent with the appearance of the MIGS genre, a number of new cycloabla-
tion procedures have also appeared including micropulse diode laser trans-scleral 
cyclophotocoagulation  (MicroPulse P3, IRIDEX IQ810 Laser System, Mountain 
View, CA, USA), applied externally via a new type of probe and High-Intensity 
Focused Ultrasound cyclocoagulation (EyeOP1 HIFU, EyeTechCare, Rillieux-la- 
Pape, France), applied externally but delivering a metered dose of ultrasound energy 
to the ciliary body. Endocylophotocoagulation (ECP), which was developed in the 
late 1990s, is analogous to conventional diode laser CPC, but applied via an ab 
interno approach and could also be considered in this category.
1.1  Trabecular Meshwork MIGS Devices and Techniques
Trabecular meshwork (TM) MIGS procedures and devices are numerous. They aim 
to eliminate trabecular meshwork resistance in the normal physiological outflow 
pathway in patients with mild-to-moderate glaucoma and ocular hypertension 
(OHT). They are indicated in combination with cataract surgery. In patients with 
chronic primary angle closure, the TM outflow system has likely long-standing and 
irreversible damage; TM MIGS procedures or implants should be approached with 
caution as the drainage pathway created whether stent or trabeculotomy, may 
occlude with iris because of the narrow angle. In angle closure, these procedures 
should generally be considered only after cataract surgery and confirmation that the 
angle has widened sufficiently that the risk of occlusion is low. In patients with 
advanced glaucoma, where the maximum possible pressure lowering is often desir-
able in order to minimize the risk of disease progression, TM MIGS procedures are 
not ideal as there is an opportunity cost in not achieving IOP control with the first 
surgical procedure.
All TM MIGS procedures involve direct gonioscopic visualization during sur-
gery. TM MIGS devices include iStent Trabecular Micro-Bypass Stent, iStent inject 
(Fig.  1.1) and Hydrus Microstent (Fig.  1.2) [4–6]. These three devices aim to 
enhance TM outflow by stenting the Schlemm’s canal. iStent Trabecular Micro- 






Fig. 1.1 Two iStent Trabecular Micro-Bypass Stents in the Schlemm’s canal of two different 
patients (a and b) and two iStent inject implants in the trabecular meshwork (c). (Copyright 
Moorfields Eye Hospital and Keith Barton; reproduced with permission)
a b
Fig. 1.2 The inlet of a Hydrus Microstent visible externally (a) and the Hydrus Microstent in the 
trabecular meshwork on gonioscopy (b). (Copyright Moorfields Eye Hospital and Keith Barton; 
reproduced with permission)
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iStent Trabecular Micro-Bypass Stent is a 1  mm long, L-shaped device with a 
120 μm lumen diameter. iStent inject is conically shaped, 360 μm in length and 
230 μm at its largest diameter. The Hydrus Microstent is made of nitinol and is a 
crescent-shaped trabecular scaffold of 8 mm in length with a variable lumen diam-
eter between 185 and 292 μm. Company-sponsored prospective randomized con-
trolled trials have compared the effect of cataract surgery on IOP when combined 
with the iStent Trabecular Micro-Bypass Stent or the Hydrus Microstent to the 
effect of cataract surgery alone [4, 6]. Both demonstrated a modest but more sus-
tained IOP-lowering effect in the group receiving cataract surgery combined with 
the TM MIGS device 2 years after surgery. All three are USFDA approved, at the 
time of writing, for implantation at the time of cataract extraction, but not for stand- 
alone surgery. In Europe, they are licensed for both.
Other TM procedures such as ab interno trabeculotomy (AIT) or Trabectome, 
GATT, Kahook Dual Blade and TRAB360 cut rather than stent the TM to varying 
degrees. Trabectome is the earliest FDA-approved TM removal procedure. It has a 
disposable 19.5-gauge handpiece with irrigation, aspiration and electrocautery 
combined. The tip of the Trabectome removes TM tissue and coagulates at the same 
time. Trabectome surgery is either performed at the beginning of cataract surgery or 
as a stand-alone procedure [7]. The Kahook Dual Blade is a disposable knife 
designed to remove a strip of TM tissue via a temporal incision. With a single inci-
sion, the Kahook Dual Blade and Trabectome can remove up to 120° of TM tissue, 
whereas GATT and TRAB360 (Sight Sciences, Menlo Park, CA, USA) can remove 
the entire TM tissue. GATT can be performed using either an illuminated micro-
catheter (iTrack, Ellex Medical Pty Ltd., Adelaide, Australia)—designed originally 
for ab externo canaloplasty procedure—or a 5-0 polypropylene or Nylon suture [8]. 
Under direct gonioscopic view, a micro vitreoretinal (MVR) blade is used to incise 
the TM wall, after which the catheter or suture is advanced to cannulate Schlemm’s 
canal through the incision. Complete 360° catheterization of Schlemm’s canal may 
not be possible in all eyes. A prospective non-comparative case series has reported 
sustained IOP lowering for up to 2 years after GATT [9]. As 360° trabeculotomy 
becomes a popular first-line intervention in primary congenital glaucoma, there has 
been some interest in treating juvenile open-angle glaucoma with GATT as a pri-
mary surgical option.
1.2  Subconjunctival MIGS Devices
The XEN Gel Implant (Allergan; formerly known as XEN Gel Stent, AqueSys Inc.) 
(Fig.  1.3) and PRESERFLO (formerly InnFocus) MicroShunt (Santen 
Pharmaceutical Co. Ltd.) (Fig. 1.4) are the two currently available subconjunctival 
MIGS devices [10, 11]. The XEN Gel Implant is a soft porcine-derived collagen 
implant that is inserted, ab interno, from the anterior chamber to subconjunctival 
space. Six millimetres long and with an internal diameter of 45 μm, the XEN is 
preloaded in an injector. Its major potential advantage over traditional filtering 
1 Overview of MIGS
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surgery is the avoidance of a conjunctival incision. However, the lack of conjuncti-
val dissection requires precise placement of the XEN under the conjunctival tissue 
as the lumen of the XEN is easily blocked by Tenon’s capsule. This explains a sig-
nificantly higher rate of needling with the XEN [12]. Similar to the XEN Gel 
Implant, the PRESERFLO MicroShunt is also a tube that diverts aqueous humour 
from the anterior chamber to the subconjunctival space. The MicroShunt differs 
from the XEN in that it is implanted via an ab externo approach, necessitating con-
junctival dissection. Unlike the XEN, the MicroShunt is of purely synthetic con-
struction—poly(styrene-block-isobutylene-block-styrene) or SIBS.  A randomized 
controlled trial comparing the MicroShunt with mitomycin C (MMC) to trabeculec-
tomy with MMC for primary open angle glaucoma (POAG) is currently ongoing 
a b
Fig. 1.3 XEN Gel Implant visible under the conjunctiva with a diffuse overlying drainage bleb (a) 
and the XEN Gel Implant visible in the anterior chamber (b). (Copyright Moorfields Eye 
Hospital and Keith Barton; reproduced with permission)
c
ba
Fig. 1.4 The PRESERFLO MicroShunt in the anterior chamber (a), an external view showing 
aqueous drainage during implantation and before conjunctival closure (b) and the device prior to 
implantation (c). (Copyright Moorfields Eye Hospital  and Keith Barton; reproduced with 
permission)
J. Wang and K. Barton
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(ClinicalTrial: NCT01881425). This is currently the only MIGS device that has 
been compared to trabeculectomy in a randomized clinical trial.
The IOP-lowering efficacy of subconjunctival MIGS, in selected cases, appears 
to approach that of traditional filtering surgery, thereby offering the possibility that 
they might have utility in more advanced or normal pressure glaucoma. On the other 
hand, subconjunctival MIGS are bleb-forming procedures and serious bleb-related 
complications such as infection, leakage and implant exposure have been 
reported [13].
1.3  Suprachoroidal MIGS Devices
Until recently, CyPass Micro-Stent was the only available suprachoroidal MIGS. It 
is a fenestrated micro-stent of 6.35 mm long with an external diameter of 510 μm 
and an internal diameter of 300 μm. It is made of a biocompatible polyamide mate-
rial. The COMPASS trial is a randomized controlled trial comparing the effect of 
combined cataract surgery and CyPass insertion to cataract surgery alone in 505 
POAG patients [14]. Two years after surgery, the IOP was lower on less medication 
in the group that underwent combined CyPass Micro-Stent implantation and cata-
ract surgery than those that had cataract surgery alone. A prospective series of 
CyPass Micro-Stent implantation as a solo procedure in POAG patients with uncon-
trolled IOP demonstrated effective IOP lowering and avoided conventional filtering 
procedures in 83% of patients at 1 year follow-up [15]. After the COMPASS study 
was extended to 5 years after surgery (COMPASS XT), there was a significantly 
higher rate of endothelial cell loss in the combined CyPass Micro-Stent and cataract 
group compared to the cataract group alone. For this reason, the manufacturer 
(Alcon Laboratories, Inc., Fort Worth, Texas, USA) voluntarily withdrew the CyPass 
Micro-Stent from the market in August 2018, although it is estimated that there are 
currently around 33,000 implanted CyPass Micro-Stents in the world and managing 
the risk of endothelial loss may be an ongoing concern for several years after the 
withdrawal [16].
The iStent Supra (Glaukos) is a suprachoroidal stent made of polyethersulfone 
and heparin-coated titanium with a lumen diameter of 165 μm. The iStent Supra is 
not commercially available and there have been no prospective published efficacy 
studies at the time of writing.
1.4  Cyclophotocoagulation (CPC) Procedures
Cyclophotocoagulation procedures are also minimally invasive though they differ in 
that they reduce aqueous production by coagulating ciliary body tissue and are often 
not included within the MIGS genre.
Endocyclophotocoagulation (ECP) is an ab interno cycloablative procedure. An 
endoscopic camera equipped with an 810 nm diode laser probe in a single 18–20 
gauge fibreoptic probe. The ciliary body epithelium is directly visualized during 
1 Overview of MIGS
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treatment; usually 240–300° of ciliary body are treated with one incision. Two inci-
sions are required for a full 360° treatment [17]. There is no prospective randomized 
controlled trial on the efficacy of ECP. A case series comparing ECP combined with 
cataract extraction and cataract extraction alone found slightly lower IOP in the 
combined group. A retrospective case series comparing ECP with a second glau-
coma drainage device (aqueous shunt) in patients with failed previous aqueous 
shunt surgery found similar IOP outcome at 1 year [18]. Post-operative complica-
tions of ECP include inflammation, hypotony, uncontrolled IOP, cystoid macular 
oedema (10%) and phthisis. Intracameral triamcinolone is suggested to prevent 
fibrinous inflammation after ECP. Despite its ab interno approach, ECP theoreti-
cally can cause significant tissue damage and serious complications such as phthi-
sis. Caution should therefore be taken in high-risk eyes.
Micropulse diode laser is a newer method of delivering diode laser to ocular tis-
sue. Conventional laser application is continuous with a single pulse that lasts from 
0.1 to 0.5 s. In conventional diode cyclophotocoagulation, the duration of a single 
laser pulse is usually as long as few seconds. Micropulse mode laser delivers the 
energy in pulses with pre-set on and off periods. The off period is longer than the on 
period allowing the tissue to cool down and minimize damage. Micropulse laser has 
been used in the  treatment of retinal diseases and glaucoma. In one prospective 
randomized series, micropulse cyclophotocoagulation is shown to be as efficient, 
resulting in similar IOP with less complications compared with conventional CPC.
1.5  Overview Summary
Subconjunctival drainage of aqueous humour has been the cornerstone of glaucoma 
surgery. MIGS devices targeting subconjunctival drainage achieve lower IOP than 
those targeting Schlemm’s canal and suprachoroidal drainage, at the cost of possible 
bleb-related and higher hypotony-related complications. MIGS targeting the tra-
becular outflow system such as iStent Trabecular Micro-Bypass Stent or iStent 
inject, Hydrus Microstent and AIT are best suited for patients with moderate OHT 
or mild to moderate POAG requiring cataract surgery. The IOP-lowering effect of 
these trabecular devices is limited by episcleral venous pressure (EVP) which limits 
the maximal IOP reduction to the mid-teens. Subconjunctival draining devices 
(XEN Gel Implant or PRESERFLO MicroShunt) can be used as solo glaucoma 
procedure and have better potential to achieve single digit IOP levels. The long-term 
efficacy of sub-conjunctival MIGS is still unknown as there are few published data 
on these devices. They both require anti-metabolite (MMC) use as subconjunctival 
scarring is inevitable with the diversion of aqueous humour to the subconjunctival 
space. Suprachoroidal drainage devices aim at a potential space where IOP lower-
ing is not limited by EVP and bleb formation is avoided. Scarring in the supracho-
roidal space remains an issue. Suprachoroidal devices can potentially be used as an 
adjunct to traditional glaucoma surgery if further IOP-lowering is required.
J. Wang and K. Barton
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2.1  Introduction
Minimally invasive glaucoma surgery (MIGS) encompasses a group of procedures 
aiming to lower intraocular pressure (IOP) with reduced surgical times, more rapid 
postoperative recovery and a better safety profile compared with traditional filtra-
tion surgery. Increasing aqueous humour (AH) outflow may be achieved either 
through facilitating the existing pathways of Schlemm’s canal and the suprachoroi-
dal space or to bypass the normal angle anatomy to create a full thickness fistula into 
the subconjunctival space. Because of the importance of the anterior chamber angle 
in the pathogenesis of glaucomatous damage, an understanding of angle anatomy 
and aqueous outflow structures is critical to surgical planning and device selection 
for particular glaucoma subtypes. This chapter reviews the clinically relevant anat-
omy and functionality of the outflow apparatus in the human eye.
2.2  Aqueous Humour Outflow
Intraocular pressure, the main risk factor for glaucoma, is determined by the pro-
duction, circulation and drainage of AH. The major drainage pathways are the tra-
becular outflow pathway (conventional outflow) and uveoscleral outflow pathway 
(unconventional outflow). Aqueous draining through the trabecular outflow system 
will traverse the trabecular meshwork, through the juxtacanalicular connective tis-
sue, into Schlemm’s canal and the collecting channels, and finally into the aqueous 
veins which then drain into the episcleral venous system. AH draining through the 
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uveoscleral route passes through the ciliary muscle bundles into the suprachoroidal 
space and then through the sclera into the orbital vessels [1].
The relative contribution of each of these outflow pathways is difficult to determine 
as it changes depending on the species studied and the method of measurement used. 
Nonetheless, it is clear that in humans, trabecular meshwork is the major pathway for 
aqueous outflow accounting for approximately 70–95% of drainage [2, 3]. Uveoscleral 
outflow in healthy subjects had traditionally been thought to represent a much smaller 
proportion of AH drainage in healthy humans than primates, though formal aqueous 
flow studies have reported a value of about 35% in young adults and 3% for individu-
als over 60 years of age [1, 4]. Aside from the relative contribution of outflow of the 
two pathways, there are a number of other important differences. Firstly, outflow from 
the anterior chamber across the trabecular meshwork into Schlemm’s canal is pressure 
dependent, whereas uveoscleral outflow is pressure independent in the physiological 
range [5, 6]. Secondly, with advancing age, both the trabecular meshwork and uveo-
scleral outflow facility gradually decline, although there is a relatively greater decline 
in the uveoscleral contribution to AH drainage overall [2]. To compensate for this, 
production of AH also decreases with age and therefore IOP is relatively unchanged 
in the healthy aging human eye [2]. In contrast, eyes with primary open-angle glau-
coma have higher outflow resistance in the trabecular outflow pathway than in age-
matched normal control eyes, while secretion of AH is not changed [7, 8].
2.3  Trabecular Meshwork
The main ocular structures related to the trabecular outflow pathways are located 
around the scleral sulcus, a circular groove of the inner sclera, adjacent to the corneo-
scleral limbus [9]. The sulcus begins at the peripheral termination of Descemet’s 
membrane and extends to the scleral spur, a ridge of inner scleral fibres that run 
parallel to the limbus, and project inward. This important landmark divides the con-
ventional from the unconventional or uveoscleral outflow. It is best viewed by goni-
oscopy as no imaging device yet consistently identifies the scleral spur. The scleral 
spur may also play a role in preventing the ciliary muscle from causing Schlemm’s 
canal to collapse [10]. Schlemm’s canal, a circular tube, lies in the outer aspect of the 
scleral sulcus, while the trabecular meshwork lies at its inner aspect. The trabecular 
meshwork comprises connective tissue beams or lamellae that are interconnected in 
several layers to form a porous structure (Fig. 2.1). Each trabecular beam is covered 
by flat epithelial-like trabecular meshwork cells thought to provide self- cleaning 
phagocytic activity to maintain the porous structure. Anteriorly, the trabecular beams 
are attached to the peripheral cornea near the end of Descemet’s membrane 
(Schwalbe’s line) and extend posteriorly to ciliary body stroma and scleral spur. The 
spaces of the trabecular meshwork range in size from 20 to 75 μm and progressively 
decrease in size posteriorly. The trabecular band covers the internal aspect of 
Schlemm’s canal and is relatively featureless in the unpigmented eye. However, 
when the meshwork is pigmented, the pigment is concentrated over the canal of 
Schlemm. Thus, the anterior nonpigmented portion of the trabecular meshwork does 
not filter, while the posterior pigmented portion of the trabecular meshwork does. 
K. Lam and M. Lawlor
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This is clinically important as any trans-trabecular devices should target the posterior 
pigmented trabecular meshwork if the goal is the maximize flow into Schlemm’s canal.
2.4  Schlemm’s Canal
Schlemm’s canal is an endothelial-lined circular tube with one of the highest 
hydraulic conductivities in the body [6]. Its pores, which range in size from 0.1 to 3 
μm in diameter, allow passage not only of AH but also of particulate matter such as 
cells and ferritin. Additionally, the endothelial lining of Schlemm’s canal changes in 
response to pressure gradient alterations. Elevated IOP leads to an increase in both 
the number and size of cellular out-pouchings or giant vacuoles while decreased 
IOP leads to a reduction [11]. AH is transmitted from the trabecular meshwork, 
through Schlemm’s canal, to the distal venous collector system. AH exits Schlemm’s 
canal through collector channels that are spaced at irregular intervals from the outer 
wall of the canal of Schlemm. They are approximately 25–30 in number and are 
predominately located in the nasal quadrants [12]. The collector channels ultimately 
lead to the episcleral venous system; there are two systems of intra-scleral channels: 
firstly, a direct system of four to six larger veins of Asher that drain directly into the 
episcleral venous system, and secondly, an indirect system of finer more numerous 
channels, which form an intrascleral plexus before ultimately draining into the veins 
of Asher. While the larger conjunctival veins of Asher are readily visible, the intra-
scleral plexus is difficult to examine.
Multiple studies suggest that dysfunction of the intrascleral outflow plexus is 








Fig. 2.1 Three layers of trabecular meshwork (shown in cutaway views): uveal, corneoscleral, 
and juxtacanalicular
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obstruction or atrophy [13] and functional outflow through human trabecular mesh-
work does not occur homogenously—there are regions of preferential flow adjacent 
to the location of collector channels. Corroborating this are studies showing that the 
total juxtacanalicular tissue adjacent to collector channels is expanded nearly two-
fold compared with the juxtacanalicular regions between collector channels [14]. As 
canal-based MIGS procedures aim to improve the flow of AH into the venous collec-
tor channels, estimating functionality preoperatively or intraoperatively would pro-
vide valuable information for both patient selection and prognostication. The finding 
of an “episcleral venous fluid wave”, seen as downstream visible blanching of veins, 
may be a surrogate marker of anatomic patency of the conventional outflow system 
from the anterior chamber to the episcleral and conjunctival collectors [15].
2.5  Uveoscleral Outflow
The second route for AH outflow within the eye is through the unconventional out-
flow pathway (or uveoscleral pathway). The characterization of this pathway was 
first provided by Anders Bill in his pioneering work that estimated the outflow using 
tracer studies [16]. Unlike the trabecular outflow route, the uveoscleral outflow 
route is not a distinctive structural pathway with channels and tubes. Rather, AH 
passes through, around and between tissues of the ciliary muscle, supraciliary space 
and suprachoroidal space. Compared to the conventional pathway, the uveoscleral 
pathway is less well understood. Nonetheless, new devices that can provide surgical 
access to these spaces have led to a renewed interest in this anatomical region.
The anterior portion of the ciliary body extends into the chamber angle and there 
is no epithelial barrier between the anterior chamber and the ciliary muscle [17]. 
Similarly, there is no continuous cellular layer on the anterior iris face, so aqueous 
has direct access from the anterior chamber to the interstitial spaces of the ciliary 
muscle, and then through to the supraciliary and suprachoroidal spaces [16].
The supraciliary space is a narrow area between the outer surface of the ciliary 
body and the internal surface of the sclera anteriorly. Posteriorly, the suprachoroidal 
space is located between the choroid and the internal surface of the sclera. This 
subspace is approximately 30 nm thick and is composed of layers of pigmented col-
lagenous processes derived from each tissue, forming a delicate collagen meshwork 
[18]. This space forms a transitional zone between the choroid and sclera and does 
not contain overt fluid under normal physiologic conditions.
The mechanism of how fluid from the supraciliary and suprachoroidal spaces 
exits the eye remains contested: Bill traced the route of radioactive-labelled proteins 
and other large molecules and proposed that the fluid seeps through sclera and epi-
sclera by diffusion into the orbit and then is absorbed by the orbital vasculature [16, 
19, 20]. In contrast, Barany and others have suggested that the fluid is osmotically 
absorbed by the choroid and passes into the vortex veins [21–23].
Evidence of the potential IOP-lowering effect of the suprachoroidal space is 
derived from the clinical observation that a cyclodialysis cleft from trauma often 
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leads to hypotony. However, harnessing a cyclodialysis cleft to control IOP has 
remained challenging due to uncontrolled low pressures and then conversely pres-
sure spikes on closure of the cleft. A number of new MIGS devices target this space 
with the view to obtaining a controlled IOP with appropriate pressure reduction and 
minimal hypotony.
2.6  Physiological Characteristics 
of Unconventional Outflow
Aqueous entry into the uveoscleral pathway begins through the interstitial spaces of 
the ciliary muscle, and ciliary muscle tone has an important influence on outflow. 
Administration of pilocarpine, which causes contraction of the ciliary muscle fibres 
and compression of extracellular space, causes uveoscleral outflow to decrease by 
90% in cynomolgus monkeys [24]. In contrast, administration of atropine has the 
opposite effect: it causes relaxation of the muscle fibres, expansion of the extracel-
lular space and thereby increases uveoscleral outflow [25]. Various prostaglandins 
also increase uveoscleral outflow by modifying the extracellular matrix between 
ciliary muscle bundles, thus reducing outflow resistance and allowing increased 
flow through these spaces [26].
Measuring outflow of the uveoscleral pathway is challenging because of intrinsic 
challenges in measuring the flow rate. Measurements can either be direct or indirect. 
Direct measurements involve injecting a tracer molecule into the anterior chamber 
and measuring its accumulation in ocular tissues and blood. While accurate, these 
tests are invasive and thus not generally suitable for human subjects. Only one study 
has reported direct measurements of uveoscleral outflow in the living human eye: 
Bill and Phillips [16] measured outflow in two normal eyes that were not receiving 
topical pilocarpine or atropine and found uveoscleral outflow accounted for 4–14% 
of total outflow.
Indirect techniques calculate uveoscleral outflow using a modified Goldmann 
equation, which requires the measurement of four other parameters, each with 
inherent variability. This method tends to yield large standard deviations with con-
siderable variability.
These limitations notwithstanding, the uveoscleral outflow pathway appears to 
be relatively insensitive to IOP differences, even over the range of 4 to 35 mmHg 
[19]. This observation in part has meant that the majority of surgical targets to 
lower IOP have focused on the pressure-dependent trabecular outflow system. 
However, once the ciliary muscle is bypassed (through a shunt or a cyclodialysis 
cleft), most of the resistance it offers is lost [27] and the uveoscleral pathway 
becomes pressure dependent, with outflow increasing fourfold [28]. When the 
uveoscleral pathway is turned into a pressure-dependent pathway, as noted above, 
its capability of lowering IOP is so significant that the postoperative IOP can reach 
the low teens or single digits [29–31].
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2.7  Conjunctival Lymphatic System
The human lymphatic system plays an important role in body fluid homeostasis, 
lipid absorption and immune function [31–33]. Fundamentally, the lymphatic sys-
tem removes excess arterial fluid that is unable to be absorbed by the venous system 
from the interstitial space and acts to enhance immune surveillance. Traditionally 
seen as passive channels for fluid and immune cells, recent discoveries have drasti-
cally changed our view of lymphatic vasculature, which lags far behind our knowl-
edge of the vascular system. Lymphatic vessels are now appearing to have diverse 
functions with remarkable specialization depending on tissue microenviron-
ment [34].
Despite this limited knowledge, it appears conjunctival lymphatics are particu-
larly important for the success of glaucoma surgical outcomes [35–37]. In the nor-
mal eye, conjunctival lymphatics are not involved in AH flow pathways, and 
lymphatics have no communication with conjunctival veins [38]. However, glau-
coma filtering surgery alters the normal pathways. Aqueous humour is diverted into 
the subconjunctival space, which is equivalent to interstitial tissue fluid, where con-
junctival lymphatic vessels exist. Animal studies confirm that the presence of lym-
phatic drainage pathways is associated with persistence of subconjunctival drainage 
pathways, which in turn play a key role in determining surgical outcomes of glau-
coma filtration surgery [39]. Thus, understanding conjunctival lymphatic drainage 
is critical to optimize glaucoma therapeutic interventions.
Conjunctival lymphatics remain difficult to study because of their transparent, 
colourless nature and very thin vessel walls with absent basement membrane or 
pericytes. The lymphatic system is a series of unidirectional, thin-walled vessels 
that transport lymph to the lymphatic nodes, which eventually empty into the blood 
veins via the thoracic duct.
Conjunctival lymphatics in monkeys start with blind-ended terminals located in 
the superficial conjunctiva between the epithelium and Tenon’s capsule [40]. These 
tubular vessels are of uneven calibre with numerous branch communications that 
are responsible for the initial drainage of interstitial fluid. The mechanism of fluid 
uptake appears to be transient fluid pressure gradients between the interstitial fluid 
and the initial lymphatic [41, 42]. The fluid then drains into valved precollectors, 
which are mostly located in the deep layer under Tenon’s capsule. These connect to 
larger collectors and eventually empty into the preauricular and submaxillary lymph 
nodes [43, 44]. The lymphatics appear to be relatively evenly distributed in the bul-
bar conjunctiva, with no difference between each quadrant or between the limbus or 
fornix regions.
Our knowledge of conjunctival lymphatics is still rudimentary, but an under-
standing of this system’s role in interstitial fluid drainage is crucial to optimizing 
and targeting aqueous drainage in glaucoma therapy. Understanding the lymphatic 
vessels structure and function, distribution in the conjunctiva and eventually their 
functional assessment prior to filtration surgery will have significant implications 
for surgical glaucoma treatments that create a conjunctival bleb.
K. Lam and M. Lawlor
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2.8  Conclusions
Lowering IOP has been central to glaucoma care for over a century. New surgical 
devices are able to exploit different aspects of aqueous outflow to reduce IOP. A 
complete understanding of outflow pathways is important to develop new treatment 
strategies, improve current ones, and to better target the right operation for particu-
lar glaucoma subtypes.
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3iStent: Trabecular Micro-Bypass Stent
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3.1  Device Design
The iStent (or  iStent Trabecular Micro-Bypass Stent) (Glaukos Corporation, San 
Clemente, USA) has become a popular device within the realm of minimally inva-
sive glaucoma surgery (MIGS). These procedures are known to have a higher safety 
profile and a more rapid recovery time in comparison to more invasive filtering 
surgery. MIGS procedures have demonstrated the ability to both reduce IOP and a 
patient’s need for medications, a significant benefit considering concerns regarding 
compliance rates among glaucoma patients [1]. Unlike many other surgical inter-
ventions for glaucoma, iStent implantation does not diminish the superlative visual 
and refractive outcomes inherent to modern phacoemulsification. As with many 
MIGS procedures, stent placement is minimally traumatic to the target tissue and 
spares the conjunctiva via an ab interno approach.
The iStent was developed by Glaukos (Glaukos Corporation, San Clemente, CA, 
USA) with the first implantation in the United States performed in 2005 [2]. The 
stent is designed to fit into and remain within Schlemm’s canal. Made from non- 
ferromagnetic titanium, it consists of an inlet (or “snorkel”) connected at a 40° 
angle to the implanted portion. The stent itself is then attached to the tip of a 
26-gauge disposable insertion instrument, which has been sterilized by gamma radi-
ation (Fig. 3.1a, b). The inserter tubing contains four-finger extensions which grasp 
the stent. A pointed end of the device facilitates entry into the canal and the direction 
of this point corresponds to the designation of a right or left-handed model 
(GTS100R and GTS100L, respectively). Depending on the preference of the sur-
geon, both “right” and “left” iStents have been developed to ease implantation. The 
segment residing within the canal includes a half cylinder opening, which combined 
with heparin coating, helps to prevent blockage or fibrosis. Three retention arches 
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help to ensure that the device will be held in place within the canal. The implant is 
1.0 mm in length, 0.33 mm in height, and with a weight of 60 μg. The snorkel has a 
length of 0.25 mm and bore diameter of 120 μm [3] (Fig. 3.2).
The iStent inject system (Glaukos Corporation, San Clemente,  CA, USA), a 
second-generation device or G2, consists of an apical head connected to a narrow 
thorax that is attached to a wider flange. Currently, the smallest medical implant 
approved for use in the human body, the implant is 360 μm in length and with a 
diameter of 230 μm (Fig. 3.3a, b). The central inlet and outlet lumen has a diameter 
of 80 μm. The head is inserted directly into the canal without the necessity to adjust 
the angle for implantation. It resides within the canal and contains four inlets for 
fluid passage, each with a diameter of 50 μm. The 23-gauge stainless steel injector 
contains two stents for implantation in the nasal angle, at a distance of approxi-
mately 30–60° (Fig. 3.4). The iStent inject was approved for use in Europe in 2006, 
and FDA approval in the United States was obtained in June 2018.
The iStent works at the level of the trabecular meshwork (TM). Research regard-
ing the physiology of primary open-angle glaucoma (POAG) has demonstrated that 
the diseased juxtacanalicular meshwork is the primary site of reduced outflow facil-
ity resulting from increased outflow resistance [4]. Implantation of the device allows 
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Fig. 3.3 (a, b) The iStent inject is the smallest known medical implant used in the human body. 
(c) The trochar of the injector system pierces the trabecular meshwork, allowing the distal portion 
of the stent to be injected into Schlemm’s canal. (Copyright Glaukos Corporation, San Clemente, 
CA, USA; reproduced with permission)
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for aqueous to bypass the increased TM resistance to outflow and provides a direct 
pathway into Schlemm’s canal and the subsequent collector channels. The postop-
erative IOP would not be expected to fall below the episcleral venous pressure 
(EVP), which has been reported in different studies to range between 7.6 and 
9.1 mmHg [5–7] and may be elevated in some glaucoma patients [8]. This is a limi-
tation in the treatment of patients with very low target IOP; however, a benefit in the 
avoidance of hypotonous sequelae.
Zhou et al. demonstrated the effectiveness of trabecular bypass on outflow facil-
ity and IOP [9]. A series of equations explored this relationship and demonstrated 
that in normal healthy eyes, the outflow facility increases by 13 and 26% in the 
presence of a unidirectional and bidirectional bypass, respectively. The IOP could 
be reduced to physiologic levels with outflow facility enhancement. Bahler et al. 
looked at the effect of a trabecular meshwork bypass on IOP in cultured human 
anterior segments [10]. A single stent placed into Schlemm’s canal provided the 
greatest change in pressure (21.4 ± 3.8 mmHg to 12.4 ± 4.2, P < 0.001) with the 
addition of more stents providing further lowering of pressure, but to a lesser degree.
Similarly, Bahler et al. also addressed the influences of the iStent inject on the 
outflow facility of cultured human anterior segments [11]. Outflow facility was 
shown to increase and IOP to decrease with a single stent placement. An additional 
increase in outflow facility was demonstrated with the placement of a second stent.
3.2  Patient Selection
In 2012, the FDA approved the iStent for use in combination with cataract extrac-
tion for patients with mild-to-moderate open-angle glaucoma who were using 
between 1 and 3 ocular hypotensive medications. The stent is currently approved in 
Europe as a stand-alone procedure or for use in combined cataract/MIGS procedures.
Ideal candidates are those with stable and well-controlled or modestly uncon-
trolled disease. Patients demonstrating rapid progression or extreme elevation of 
IOP on their current medication regimen may require more aggressive surgical 
Fig. 3.4 The iStent inject 
system allows for 
implantation of two 
preloaded trabecular 
micro- bypass stents with a 
single entry. (Copyright 
Thomas Samuelson, MD; 
reproduced with 
permission)
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intervention such as filtration surgery. Optimal patients typically need pressure low-
ering, but not to an extreme level. In addition to improving IOP, another goal is to 
reduce the dependency on topical medication, but not necessarily advance the 
aggressiveness of treatment.
Patients with a very shallow anterior chamber with peripheral anterior synechiae 
are typically avoided, as implantation requires access to Schlemm’s Canal. Although 
the angle will be deeper once the native lens has been removed, implantation in 
shallow anterior chambers can be more difficult with an increased risk of iris or 
endothelial damage. Secondary glaucomas related to elevated episcleral venous 
pressure are less ideal, as successful outcomes require an otherwise functional out-
flow system. Patients with neovascular glaucoma are contraindicated because of 
both the increased bleeding risk and reduced function of the outflow system [12].
As the surgeon is first developing their implantation skills and becoming more 
comfortable with the procedure, it may be of benefit to select patients who would do 
well with cataract surgery alone. These patients will still likely do well postopera-
tively should implantation be unsuccessful. Other favorable traits for initial cases 
might include highly cooperative individuals with at least moderate pigmentation of 
the TM and easily identifiable angle structures. If a surgeon favors right or left eyes 
for phacoemulsification, he or she is likely to favor such eyes for initial iStent cases 
as well.
3.3  Surgical Technique
Proficiency with intraoperative gonioscopy is imperative to success with iStent 
implantation. For surgeons who do not perform gonioscopy often, it is useful to 
examine patients in clinic to better familiarize oneself with the angle anatomy. 
Practicing intraoperative gonioscopy during routine cataract cases can also be of 
benefit prior to implanting the first stent. Gently touching the anterior meshwork 
with a viscoelastic cannula can help one become more comfortable with the hand 
positioning.
Upon completion of cataract surgery and implantation of the IOL, injection of a 
miotic helps to pull the iris away from the angle and insertion of viscoelastic mate-
rial will aid in maintaining the anterior chamber. For initial cases, it is desirable to 
remove all viscoelastic from the retropupillary space and capsular bag before the 
pupil is constricted. Once more experience is achieved, many surgeons will choose 
to wait until the iStent has been successfully implanted before the viscoelastic is 
removed and the miotic instilled. The patient’s head and the operating microscope 
are rotated 30–40° in opposite directions to facilitate a gonioscopic view of the 
angle. The surgical gonioprism is placed on the cornea with a coupling solution 
(goniosol, viscoelastic) and the angle is viewed under high magnification. Care to 
avoid pressure on the eye with the goniolens is important, as resultant corneal striae 
will impede the view. Likewise, the surgeon should not place pressure on the wound 
with the insertion trochar to avoid expressing viscoelastic from the eye. Once a clear 
view of the trabecular meshwork is achieved, the applicator is inserted into the 
3 iStent: Trabecular Micro-Bypass Stent
26
anterior chamber through the clear corneal incision and advanced across the anterior 
chamber toward the nasal angle. As mentioned previously, there are two different 
designs designating the direction of the pointed end. The intent of the unique iStent 
design is that after implantation, the body of the stent points toward the inferior 
angle such that right stents are used in right eyes and left stents are used in left eyes 
(Fig. 3.5). Evidence that right or left orientation makes any clinical difference, how-
ever, is lacking. As such, most surgeons believe that right- and left-hand models are 
interchangeable (i.e., right and left iStents can be used in both right and left eyes) 
depending on what feels more comfortable (forehand or backhand) in the dominant 
hand of the surgeon.
The anterior 1/3 of the trabecular meshwork is approached at a 15° angle and is 
perforated by the tip and advanced into the canal. By slightly adjusting the angle 
after perforation (lowering the heel and raising the toe), the stent will slide into the 
canal more easily. A “landing strip” technique has recently been described to help 
guide implantation. Zheng et  al. suggested using a 25-guage microvitreoretinal 
blade to bisect the trabecular meshwork for less than 1 clock hour, thus creating a 
guide for assistance stent placement [13]. Once securely positioned with the ridges 
of stent covered by meshwork tissue, the device is released by pushing the button 
on the applicator. Subtle posterior pressure and relaxing of the hand will ensure a 
stable release.
After release, the iStent should appear to be well seated within the canal. The 
device will be viewed running parallel to the iris plane (Fig. 3.6a, b). The applicator 
tip is used to gently push the inlet to verify it has memory (i.e., with minimal dis-
placement, it will return to the original position). After successful placement, visco-
elastic material should be thoroughly removed at the conclusion of the case.
RIGHT LEFT
Fig. 3.5 The intent of the unique iStent design is that after implantation, the body of the stent 
points toward the inferior angle such that right stents are used in right eyes and left stents are used 
in the left eyes. Evidence that right or left orientation makes any clinical difference is lacking and 
most surgeons now believe that right- and left-hand models are interchangeable. (Copyright 
Glaukos Corporation, San Clemente, CA, USA; reproduced with permission)
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3.3.1  Avoiding Complications and Surgical Pearls
Advantages of the iStent procedure include sparing of the conjunctiva and avoid-
ance of the long-term complications and short-term risks associated with trabecu-
lectomy and tube shunt surgery. More specifically, issues of hypotony are avoided 
because episcleral backpressure remains.
With any surgical procedure, however, adverse events can occur. The larger 
studies involving the iStent have not demonstrated any significant added risk in 
comparison to cataract surgery alone. Publications from the iStent Study User 
Group at both 12 and 24 months showed the overall incidence of adverse events 
and long- term safety profile was similar between cataract surgery alone and cata-
ract surgery with iStent implantation. Unanticipated adverse device effects were 
not seen [14, 15].
Now with several years of use and data, there have been a few case reports pub-
lished describing isolated complications. Sandhu et al. reported the first documented 
case of delayed-onset and recurrent hyphema after iStent placement [16]. Two epi-
sodes of spontaneous hyphema were seen within a 19-month postoperative period. 
There were no associations with anticoagulants, stent malposition, or angle abnor-
malities, and the episodes were thought to be related to ocular pressure from sleep-
ing position that was reduced upon waking. Regarding implantation, Mantravadi 
et al. reported a case of inadvertent implantation of an iStent into the supracilliary 
space [17]. An iridodialysis cleft was created at the time of attempted stent reposi-
tioning. The stent was no longer visible intraoperatively and was subsequently iden-
tified in the supracilliary space via ultrasound biomicroscopy. No adverse sequelae 
were identified related to the malposition.
Although the overall risks and adverse events seen postoperatively with iStent 
placement are similar to cataract surgery alone, there are some intraoperative 
a b
Fig. 3.6 (a) With successful implantion, the iStent is viewed running parallel to the iris plane with 
retention arches covered by trabecular meshwork tissue (Copyright Thomas Samuelson, MD; 
reproduced with permission). (b) Gonioscopy photograph of two iStents showing superficial 
placement of the left stent as evidenced by visible retention arches. The right stent is well placed 
in Schlemm’s canal and the retention arches are obscured by the pigmented trabecular meshwork. 
(Copyright Chelvin Sng, FRCSEd; reproduced with permission)
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complexities that may be encountered and steps that can be taken to ensure a suc-
cessful implantation.
When viewing the angle gonioscopically at the time of stent placement, 
Schlemm’s canal is often highlighted by blood within. This is a benefit in regard to 
canal identification, but can also impede the view as blood is released after perfora-
tion of the trabecular meshwork. If the angle anatomy becomes obscured, irriga-
tion and aspiration may be utilized to clear the blood or additional viscoelastic may 
push it out of the way. Blood visualized flowing out of the snorkel after insertion is 
a good but somewhat inconsistent sign, indicating correct positioning within the 
canal (Fig. 3.7) Quite often blood reflux is not seen until after viscoelastic removal 
prior to re-pressurization of the eye. Similarly, transient blanching of the episcleral 
vessels has been proposed as means to confirm accurate stent placement and may 
be a prognostic indicator (Fig. 3.8a, b). Fellman et al. first described this phenom-
enon in patients undergoing combined phacoemulsification–trabectome surgery 
and believed the episcleral venous fluid wave signifies intraoperative structural 
patency of the conventional outflow system [18]. They were subsequently able to 
demonstrate a diffuse venous wave resulted in lower IOP, fewer glaucoma 
Fig. 3.7 Blood visualized 
exiting the snorkel of the 
device can be an indicator 






Fig. 3.8 (a, b) Episcleral vasculature before and after successful iStent placement. The episcleral 
venous wave demonstrates a structurally intact collector channel system. (Copyright Christine 
Larsen, MD; reproduced with permission)
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medications, and lower requirement for additional surgery in 68 eyes of a similar 
patient population [19]. Similarly, trypan blue dye (Vision Blue, DORC 
International) can be used to confirm correct stent placement by allowing the delin-
eation of aqueous veins in blue (Fig. 3.9). This finding has led to the idea of tar-
geted placement. Identification of larger episcleral veins at the beginning of surgery 
may allow the surgeon to preferentially position the iStent at this location. The 
same idea is employed under gonioscopic view of the angle. Areas of increased 
pigmentation or blood within the canal may signify proximity to a collector chan-
nel [20] and would thus be an ideal target for iStent placement. Unfortunately, no 
method exists to evaluate the patency and capacity of collector channels before 
deciding to proceed with canal surgery. There is also no current mechanism to 
modulate wound healing in the canal, which can be a detriment to the surgical suc-
cess of MIGS procedures. The second- generation device, iStent inject obviates the 
need for intelligent placement to some extent by virtue of the fact that more than 
one stent is placed increasing the likelihood of reaching collector channels.
As discussed earlier, avoidance of patients with shallow anterior chambers can 
help prevent issues with endothelial damage or iris root tears. Should these occur, 
the stent can still be safely inserted, however, the patient may require more intensive 
postoperative care should transient corneal edema or hyphema result.
Another important precaution relates to the re-grasping maneuver should the 
iStent need repositioning. While the stent can be readily re-grasped by the inserter, 
care must be exercised to be certain that the re-grasping prongs do not accidentally 
grasp the iris along with the stent. Should this occur, an iridodialysis or iris trauma 
could result.
After intraocular lens placement, viscoelastic should be completely removed 
from both the anterior chamber and posterior to the iris and IOL. Successful evacu-
ation of all viscoelastic is the most important final step in preventing early postop-
erative IOP spikes. After the instillation of a miotic, the amount of viscoelastic 
Fig. 3.9 Injection of trypan blue dye in the anterior chamber clearly delineates the aqueous veins 
in an eye with two well-placed iStent Trabecular Micro-Bypass Stents. (Copyright Chelvin Sng, 
FRCSEd; reproduced with permission)
3 iStent: Trabecular Micro-Bypass Stent
30
reintroduced into the anterior chamber should be enough to provide stability and 
adequate visualization of the canal without resulting in pressure on the meshwork. 
After stent placement, the viscoelastic is again thoroughly removed. Some surgeons 
may elect to place the iStent prior to phacoemulsification. One advantage of this 
strategy is that viscoelastic management subsequently proceeds as per usual for 
standard cataract surgery. In addition, the view through the cornea may be clearer 
prior to cataract removal.
3.3.2  Postoperative Management
Open-angle glaucoma patients are more susceptible to intraocular pressure eleva-
tion after surgery regardless of whether cataract surgery is performed alone or in 
combination with iStent placement. In addition to an early postoperative pressure 
increase related to retained viscoelastic, these patients are also at increased risk of 
experiencing a steroid response. It may be beneficial to taper steroids more rapidly. 
The supplemental benefit of a nonsteroidal anti-inflammatory agent often allows 
earlier discontinuation of steroidal agents.
It will typically take about 6–8 weeks from the surgery date to reach a new 
steady state for intraocular pressure. Glaucoma medications may be discontin-
ued on a case-by-case basis. Lower risk eyes and those with a lower medication 
burden (i.e., 1–2 topical medications) may be able to have all glaucoma treat-
ment withdrawn. For those requiring two or more medications or a higher risk 
patient, medications should be discontinued more cautiously and in a stepwise 
fashion.
Other potentially encountered issues in the postoperative period include the pres-
ence of a hyphema, with possible occlusion of the stent with blood, or occlusion by 
iris tissue (Fig. 3.10). Treatment of a hyphema in this case is no different than the 
normal standard of care. Should the stent become blocked with iris tissue, 
neodymium:YAG laser or argon laser can be utilized to successfully clear the block-
age should IOP become uncontrolled [14, 21].
Fig. 3.10 Gonioscopy 
photograph showing 
complete iStent 
occlusion with iris in an 
eye with angle-closure 
disease. (Copyright 
Chelvin Sng, FRCSEd; 
reproduced with 
permission)
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3.4  Safety, Efficacy, and Clinical Results
3.4.1  iStent Trabecular Micro-Bypass Stent
The US iStent Study Group performed a large comparative study in POAG patients 
already undergoing planned cataract surgery to compare the effect between cataract 
removal alone and cataract removal in combination with iStent placement [14]. 
Prior to this study, several pilot studies had been performed demonstrating the effec-
tiveness of iStent implantation at lowering IOP.
The initial results of the iStent Study Group, the largest study to date, were pub-
lished in 2011 [14]. The study involved 239 patients with 116 patients receiving the 
stent. Patients involved in the study were those with mild–moderate glaucoma who 
had an unmedicated IOP between 22 and 36 mmHg. The primary efficacy measure 
was defined as unmedicated IOP ≤21 mmHg at 1 year and was seen in 72% of treat-
ment eyes versus 50% of controls. A secondary outcome was unmedicated IOP 
reduction ≥20% at 1 year and was seen in 66% of treatment eyes versus 48% of 
controls. Approximately half as many patients in the iStent group were using topical 
drops compared to the cataract only group at 1 year, suggesting that the iStent may 
delay or eliminate the need for drops after cataract surgery (a mean reduction in 
medications of 1.4 for iStent group and 1.0 for cataract only group).
The incidence of adverse events seen with cataract surgery plus iStent placement 
versus cataract surgery alone was similar in the iStent Study Group. No unantici-
pated adverse device effects were seen. The goal of improved vision was achieved 
in ≥95% of subjects for both groups.
A subsequent paper published by the iStent Study Group looked at the same end 
points at 24 months [15]. It found that the proportion of patients with an IOP of 
<21  mmHg without medication was significantly higher in the stent group. The 
mean IOP was stable between the 1 and 2 year end points in the stent group, how-
ever, was slightly increased in the control group (17.0 ± 3.1 vs. 17.8 ± 3.3). The total 
number of hypotensive medications was shown to be significantly less in the stent 
group at 12 months. This finding was additionally maintained at 24 months, how-
ever, was no longer statistically significant. It should be noted that the original study 
was only powered to detect a difference out to 1 year. Again, postoperative compli-
cations and adverse events were similar between groups at 24 months (Table 3.1).
Several publications have since demonstrated similar findings in terms of iStent 
efficacy and safety profile [22–24]. A summary of the randomized controlled trials 
and case series to date is provided in Table 3.2. The most common complication 
across all studies was stent obstruction or malposition, which in general did not 
result in any adverse sequelae.
3.4.2  iStent inject
Fea et al. conducted a randomized, prospective, multicenter evaluation which sug-
gested that treatment with two iStent  inject devices is comparable to medical 
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Table 3.1 Postoperative ocular complications reported in the iStent User Group at 24 months




Anticipated early postoperative eventa 20 (17.2%) 22 (18.8%)
Posterior capsule opacification 7 (6%) 12 (10.3%)
Elevated IOP 4 (3.4%) 5 (4.3%)
Elevated IOP requiring oral or IV medications or surgery 1 (0.9%) 3 (2.6%)
Stent obstruction 5 (4.3%) –
Blur or visual disturbance 4 (3.4%) 8 (6.8%)
Stent malposition 3 (2.6%) –
Iritis 1 (0.9%) 6 (5.1%)
Conjunctival irritation from hypotensive medication 1 (0.9%) 3 (2.6%)
Disk hemorrhage 1 (0.9%) 3 (2.6%)
Abbreviations: IOP intraocular pressure
Data from Craven et al. J Cataract Refract Surg. 2012;38:1339–1345
aCorneal edema, anterior chamber cell, corneal abrasion, discomfort, subconjunctival hemorrhage, 
blurred vision, floaters
Table 3.2 Clinical studies involving single iStent placement in combination with 
phacoemulsification
















Fea [38] RCT 12 15 3 (17%) 1 (9%) 1.6 (80%) 0.6 (32%)
Samuelson 
et al. [14]
RCT 111 12 8 (33%) 8 (33%) 1.4 (87%) 1.0 (73%)
Craven 
et al. [15]
RCT 116 24 8 (33%) 7 (28%) 1.3 (81%) 1.0 (67%)
Spiegel 
et al. [39]




NRS 19 60 3 (16%) – 0.5 (36%) –
Vandewalle 
et al. [41]
CS 10 12 4 (19%) – 1.0 (37%) –
Patel et al. 
[42]
CS 40 6 4 (21%) – 1.7 (74%) –
Neuhann 
[43]
NRS 62 36 9.2 (36%) – 1.5 (83%) –
Ferguson 
et al. [44]
CS 350 24 3.96 
(20.7%)
– 0.58 (49%) –
Seibold 
et al. [45]
CS 64 12 1.5 (10.2%) – 0.4 (22%) –
Note: The value under medication reduction refers to the decrease in the mean number of hypoten-
sive agents, followed by the mean percent reduction from baseline
Abbreviations: RCT randomized clinical trial, CS case series, NRS non-randomized study, IOP 
intraocular pressure
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therapy and may be of benefit in reducing the medication burden [25]. Similarly, 
the Synergy Trial was a multicenter prospective, post-market, unmasked study 
conducted in Europe consisting of 99 patients with OAG who underwent implan-
tation of two GTS400 stents as a stand-alone procedure [26]. Patients were on at 
least two topical ocular hypotensive medications and required additional IOP low-
ering. Eighty-one percent of subjects achieved IOP ≤ 18  mmHg with either a 
single medication or no medication. Reduction from preoperative medication bur-
den was seen in 86.9% of patients. A summary of completed studies to date is 
included within Table 3.3.
The iStent inject Study Group conducted a large prospective, randomized, single- 
masked, concurrently controlled, multicenter clinical trial to compare the effect 
between combined cataract surgery and iStent inject implantation with cataract sur-
gery alone [27]. After uncomplicated phacoemulsification, eyes with mild-to- 
moderate POAG and unmedicated IOP between 21 and 36 mmHg were randomized 
3:1 intraoperatively to iStent inject implantation (treatment group, n = 387) or no 
stent implantation (control group, n  =  118). The primary efficacy measure was 
defined as ≥20% reduction in unmedicated diurnal IOP at month 24 and was seen 
in 75.8% of treatment eyes versus 61.9% of control eyes (p = 0.005). The mean 
reduction in unmedicated diurnal IOP from baselines was greater in treatment eyes 
than in control eyes (7.0 ± 4.0 mmHg vs. 5.4 ± 3.7 mmHg, p < 0.001). Month 24 
medication- free diurnal IOP ≤ 18 mmHg was achieved by 63.2% of treatment eyes 
compared with 50.0% of control eyes (difference 13.2%, 95% confidence interval 
2.9–23.4). The safety profile of the treatment group was favorable and similar to that 
in the control group throughout the 2-year follow-up.
At this time, there have been no studies directly comparing the first- and second- 
generation iStent models. Glaukos has also launched the iStent inject W in Europe 
in 2020, which is a slight modification of the iStent inject with a wide flange at its 
base, allowing for enhanced visualization during implantation. In addition, the 
wider flange of the iStent inject W improves the predictability of the surgery, by 
minimizing the risk of “over-implanting” the device which results in the inlet being 
occluded by trabecular tissue. 
3.5  Off-Label Use
Currently, the iStent is approved for use in combination with cataract extraction in 
the United States, but is licensed for standalone use in Europe. As described previ-
ously, Bahler et al. found that the implantation of more than one stent into the canal 
of cultured human anterior segments provided additional pressure lowering to that 
achieved with a single stent, but to a lesser degree [10]. Several studies and case 
reports have since been published demonstrating the efficacy of implanting multiple 
stents [28–32]. Most notably, Katz et al. conducted a prospective, randomized study 
of one, two, or three trabecular bypass stents in patients with open-angle glaucoma 
on topical hypotensive medication [33]. Stent placement was performed as a stand- 
alone procedure in either phakic or pseudophakic eyes. The initial results were 
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reported in 2015 with a total of 38 subjects receiving 1 stent, 41 subjects with 2 
stents, and 40 with 3 stents. They were randomly assigned with a postmedication- 
washout baseline IOP ranging between 22 and 38. At 18 months, unmedicated mean 
IOP was 15.9 ± 0.9 with 1 stent, 14.1 ± 1.0 with 2 stents, and 12.2 ± 1.1 with 3 stents. 
Both the IOP reduction and decrease in medication use were found to be significantly 
greater with each additional stent. In 2018, the 42-month outcomes were reported 
[34]. By comparison, month 12 saw IOP reduction ≥ 20% without medication 
achieved in 89, 90, and 92% or one-, two-, and three-stent eyes, respectively; whereas 
month 42 showed the same reduction in 61, 91, and 91% of eyes. Based on the data 
available thus far, the additional reduction in both IOP and topical ocular hypotensive 
use seen with multiple stent implantation shows promise for iStent use in patients 
with more advanced disease and further prospective study is warranted. In addition, 
potential long-term health resource use may be reduced with the improved IOP con-
trol achieved with multiple stent placement versus more traditional treatment modal-
ities such as selective laser trabeculoplasty or topical medications [35].
iStent implantation in phakic patients and after previous filtering surgery has also 
been evaluated [30, 31]. A prospective study by Ahmed et al. involved 39 phakic 
patients with unmedicated baseline IOP between 22 and 38 mmHg. Patients received 
two stents placed through a clear corneal incision. The mean unmedicated IOP 
decreased from 25.3 ± 1.8 mmHg preoperatively to 17.1 ± 2.2 mmHg at 13 months 
postoperatively [31]. Ferguson et al. inserted a single iStent in a retrospective series 
of 42 pseudophakic eyes. Medication use was reduced or unchanged in 80% of 
patients at 1 year, although not of statistical significance. In addition, mean IOP at 
2 years was noted to improve from 20.26 ± 6.00 mmHg to 13.62 ± 4.55 (p < 0.01) [36].
Angle closure is currently a contraindication for iStent implantation. At present, 
only one prospective study has evaluated the safety and efficacy of iStent implanta-
tion in angle-closure eyes. Hernstadt et al. showed that the mean postoperative IOP 
decreased from 17.5 ± 3.8 mmHg to 14.8 ± 3.9 mmHg in 37 eyes with angle-closure 
disease 1 year after combined iStent trabecular micro-bypass device and phaco-
emulsification (p < 0.001). There were no sight-threatening intraoperative or post-
operative complications reported, but iStent occlusion with iris occurred in 27% of 
eyes [37]. However, it was not possible to determine the additional effect of iStent 
implantation in lowering the IOP compared with phacoemulsification alone. A ran-
domized study comparing phacoemulsification alone with the combined procedure 
in angle-closure eyes showed that the combined procedure was associated with a 
higher likelihood of complete success (87.5% [95% CI 58.6-96.7%] vs 43.8% [95% 
CI 19.8-65.6%]) [52]. 
A summary of additional trabecular micro-bypass clinical studies to date is dem-
onstrated in Table 3.3 and illustrates the efficacy of iStent alone, multiple stents, as 
well as the previously discussed iStent inject.
3.6  Conclusion
Treating glaucoma patients has traditionally consisted of medications, laser, or 
filtering surgery. The well-known complications that may accompany trabeculec-
tomy or tube shunt placement have led to the development of new therapeutic 
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approaches including the iStent and iStent inject implants. Although the reduction 
in intraocular pressure seen with these devices is not comparable to filtering sur-
gery, a majority of patients can expect additional improvement versus cataract 
surgery alone. Another added benefit is seen in the potential reduction of ocular 
hypotensive medication dependency. As new long-term data become available, 
indications may expand to certain types of secondary glaucoma, use without con-
comitant phacoemulsification, and more advanced disease. Among mini-
mally  invasive glaucoma surgeries, the iStent currently provides a promising 
benefit for mild–moderate open-angle glaucoma patients with a favorable safety 
profile and sparing of conjunctival tissue should more aggressive intervention be 
necessary in the future.
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Multiple experimental and morphological studies of primate and human eyes have 
demonstrated that the anatomical location of the greatest resistance to aqueous 
outflow is at the juxtacanalicular trabecular meshwork [1, 2]. To overcome this 
resistance, goniotomy was first introduced in 1936 as the first surgical procedure 
directed at the trabecular meshwork, with significant success in infants and young 
children with congenital glaucoma, but relatively poor outcomes in adults [3]. 
Opening Schlemm’s canal to direct aqueous outflow can be accomplished in 
adults from either an ab-externo or an ab-interno approach. In 1989, Rosenquist 
et al. studied the aqueous outflow resistance of enucleated human eyes and showed 
that complete (12 clock hours) internal trabeculotomy reduced 71% of the aque-
ous outflow resistance in eyes with 25  mmHg intraocular pressure. They also 
reported that with just one clock hour of trabeculotomy, 41% of the total effect 
was obtained [4].
Trabectome (NeoMedix Corporation, San Juan Capistrano, CA, USA) received 
approval by the US Food and Drug Administration in April 2004. The first pub-
lished trial of US patients was in January 2006 for the surgical treatment of open- 
angle glaucoma. The Trabectome removes a segment of the trabecular meshwork 
and the inner wall of the Schlemm’s canal using an ab-interno approach, enhanc-
ing aqueous outflow via increased access to the Schlemm’s canal and the collector 
channels (Fig. 4.1).
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4.2  Trabectome Device
The Trabectome device consists of a single-use, disposable handpiece that com-
bines electrocautery, irrigation, and aspiration. The handpiece is connected to a gen-
erator with a frequency of 550 kHz that allows adjustments in 0.1 W increments and 
is controlled via a three-stage foot pedal that initiates irrigation, aspiration, and 
electrocautery in sequence (Figs.  4.2 and 4.3). Irrigation and aspiration permit 
removal of debris and regulation of temperature. The tip of the Trabectome is angled 
at 90° to create a protective triangular-shaped footplate for easier insertion into 
Schlemm’s canal. The footplate is coated permitting smoother movement within the 


































Fig. 4.1 Upper panels: Histopathology images of the trabecular meshwork and Schlemm’s canal 
before and after Trabectome procedure. Lower panels: Electron microscopy images of the anterior 
chamber angle structures before and after Trabectome procedure. (Copyright NeoMedix 
Corporation, San Juan Capistrano, CA, USA; reproduced with permission)
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The electrode tip of the Trabectome creates plasma that ablates the trabecular 
meshwork, thereby creating a less traumatic procedure [5]. Continuous infusion 
minimizes thermal injury to surrounding structures and aspiration removes tissue 
debris to allow for more consistent action of the electrode. In studies by Minckler 
and Francis [6, 7], Trabectome-treated specimens showed less damage to surround-
ing structures compared to eyes treated by goniotomy blade (Fig. 4.1).
4.3  Trabectome Procedure
Some surgeons pretreat patients with topical apraclonidine 0.5% or brimonidine 
0.1% to reduce intraoperative reflux bleeding. Bleeding can also be reduced by 
adequate pressurization of the anterior chamber at the conclusion of the procedure. 
The patient’s head is tilted 30–45° away from the surgeon and the operating micro-
scope is tilted 30–45° toward the surgeon to create a near 90° viewing angle to the 
viewing axis of the eye (Fig. 4.3b, c).
When performing both Trabectome and phacoemulsification (phaco- 
Trabectome), we prefer to perform the Trabectome portion first to optimize corneal 
clarity. A 1.8 mm, two-step clear corneal incision is created using a keratome blade. 
The inner third of the incision can be flared to improve mobility of the handpiece 
and visualization of the surgery by eliminating corneal striae from torquing of the 















b. Power, IA Line
c. Irrigation/Aspiration Unit
d. High Frequency Generator
e. Clean Tray
f.  Main Stand
g. Foot Control
Fig. 4.2 Trabectome console and foot pedal. (Copyright NeoMedix Corporation, San Juan 















Fig. 4.3 (a) Trabectome handpiece distal end: Electrode, aspiration port, and irrigation port are 
visible. Footplate dimensions: heel to tip, 800 μm; footplate maximum width, 230 μm; footplate 
maximum thickness, 110 μm. Gap between electrocautery pole and footplate: 150 μm. (Copyright 
NeoMedix Corporation, San Juan Capistrano, CA, USA; reproduced with permission) (b) 
Microscope and head positioning: Operating room microscope is tilted between 35 and 45° (left 
panel) while the patient’s head is similarly turned 35–45° away from the surgeon. In this example, 
the patient’s position is shown in the typical faceup position for cataract surgery (right upper panel) 
and appropriate positioning for the right eye for the Trabectome procedure (right lower panel). (c) 
Intraoperative positioning of the operating room microscope and patient’s head as shown in b. (d) 
Schematic of the centripetal and lateral vectors of motion of the probe while in Schlemm’s canal 
in order to accommodate the circular shape of the canal
R. L. Rabin et al.
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button on the foot pedal and the probe is inserted into the anterior chamber under 
direct visualization. Cohesive viscoelastic (Healon) may be used to deepen the nasal 
anterior chamber angle and as a coupling agent for the gonioscopy lens. The active 
irrigation of the Trabectome system helps to keep the anterior chamber formed dur-
ing the procedure and is designed to reduce the need for viscoelastic in the anterior 
chamber.
After the probe’s irrigation port enters the anterior chamber, the direct view sur-
gical gonioscopy lens, e.g., Swan Jacob gonioprism, is applied on the cornea to 
view the nasal angle. After the trabecular meshwork is identified, the probe is 
inserted into Schlemm’s canal and the foot pedal is depressed fully to activate aspi-
ration and electrocautery. The foot pedal has three positions—“off” in which neither 
aspiration nor electrocautery is active, “first position” in which aspiration is active, 
but not electrocautery, and “second position” in which both aspiration and electro-
cautery are activated. Torquing of the eye and failure to advance the tip with gentle 
pressure may indicate that the tip is lodged in the back wall of the Schlemm’s canal. 
This can be corrected by backing the probe up toward the area of previously treated 
tissue and trying again. During the procedure, it is crucial to eliminate any outward 
push on Schlemm’s canal as this can damage the wall of Schlemm’s canal and the 
collector channel system. It is therefore important to apply a slight inward pull (i.e., 
toward the pupil) during ablation to offset any tendency to push or rub against the 
wall of Schlemm’s canal (Fig. 4.3d).
After successfully completing one direction of treatment, the Trabectome probe 
can be rotated 180° and advanced in the opposite direction. Following a successful 
Angle microscope
Temporal approach









procedure, the outer wall of Schlemm’s canal will appear opalescent  (Fig. 4.4). 
After the treatment, the probe is retracted so that the irrigation port is just inside the 
wound. The gonioscopy lens is then removed and the probe is removed from the eye 
under direct visualization. The microscope and patient’s head can then be reposi-
tioned if cataract surgery is to be performed. A properly constructed wound should 
seal with stromal hydration.
Most surgeons experienced in Trabectome procedures report treating 60–120° of 
angle. The length of the ablation arc has not been found to be significantly corre-
lated with the subsequent intraocular pressure (IOP) decrease [8]. Up to 800 mW of 
electrocautery power can be used. Coagulation necrosis can result if the energy used 
exceeds 1000 mW, which manifests as darkening along the edge of the ablated tissue.
To reduce intraocular bleeding, air–bubble tamponade in the anterior chamber 
can be considered or the eye can be pressurized to 20–25 mmHg, provided optic 
nerve/visual field damage is not advanced and other risk factors for complications 
associated with transiently elevated IOP are absent, e.g., post-cataract surgery ante-
rior ischaemic optic neuropathy or retinal vascular occlusion following previous eye 
surgery. Postoperative care generally includes the use of topical antibiotic and ste-
roid eye drops, with a tapering regimen according to the surgeon’s preference. In 
general, we recommend a rapid taper of corticosteroids. Some surgeons advocate 
prescribing pilocarpine 1–2% postoperatively to prevent the formation of peripheral 
anterior synechiae.
Fig. 4.4 Ablation of trabecular meshwork using the Trabectome probe. (Copyright NeoMedix 
Corporation, San Juan Capistrano, CA, USA; reproduced with permission)
R. L. Rabin et al.
47
4.4  Surgical Planning
In patients with mild cataract and glaucoma, many options exist—phacoemulsifica-
tion alone, minimally invasive glaucoma surgery (MIGS) alone, combined cataract 
surgery and MIGS, conventional glaucoma surgery, i.e., trabeculectomy and tube 
shunt implants. The surgery can be either a single operation with multiple proce-
dures performed at the same sitting or staged cataract and glaucoma surgery. 
Phacoemulsification alone reduces IOP, with the extent of IOP reduction varying 
between different studies, but is approximately 4  mmHg (16.5%) based on the 
Ocular Hypertension Treatment Study [9]. This IOP-lowering effect is directly pro-
portional to the IOP prior to surgery. If the patient has a component of angle closure, 
then cataract removal may be indicated even with 20/20 acuity.
4.4.1  Target IOP
In patients requiring a target IOP below 12 mmHg, Trabectome is not ideal. Devices 
that are designed to remove or bypass the trabecular meshwork by shunting fluid to 
Schlemm’s canal theoretically cannot achieve IOP below the episcleral venous pres-
sure, 8–10 mmHg [10]. In patients requiring an IOP of 12 mmHg or less, the proce-
dures that may have a higher chance of success create a communication between the 
anterior chamber and subconjunctival space, e.g., subconjunctival MIGS devices or 
conventional glaucoma surgery (trabeculectomy, tube shunt device [e.g., Baerveldt 
or Ahmed glaucoma implant]).
In patients with a target IOP of approximately 15–17 mmHg, Trabectome sur-
gery could be considered. Numerous studies have shown IOP decreases to the 
15–17 mmHg range with both phaco-Trabectome and with Trabectome-alone [11–
14]. Mizoguchi et al. reported that the Trabectome failure rate was higher in the eyes 
with a preoperative IOP <18 mmHg and lower in those with a preoperative IOP of 
18–22 mmHg [15]. Successful outcomes have been reported in studies with higher 
baseline IOP as well, such as 37.6 ± 6.6 mmHg in a study by Akil et al. [16] and 
31.6 ± 9.9 mmHg by Shoji et  al. [17]. These studies suggest that the higher the 
baseline IOP, the greater the percentage reduction in IOP.
4.4.2  Trabectome Can Be Performed in Patients 
with Narrow Angles
Trabectome has traditionally been reserved for patients with open angles (at least 
Shaffer grade 3) because it was thought that the failure rate would increase in 
patients with narrower angles and that the procedure would be difficult to perform 
safely. In Trabectome-alone cases and phaco-Trabectome combined cases, Bussel 
et al. found no significant difference in IOP reduction between eyes with Shaffer 
grade 3 or greater versus those with grade 2 or less. This would allow many patients 




In Chinese patients, Lee et al. reported that despite seeing an open-angle configu-
ration on gonioscopy, the small dimensions of the anterior segment make it difficult 
to maneuver the Trabectome handpiece in the eye without damaging ocular struc-
tures such as the iris. Therefore, they only performed Trabectome surgery on pseu-
dophakic Chinese eyes. Even in pseudophakic Chinese eyes, the view of the treated 
area of Schlemm’s canal was obscured by normal iris (not peripheral anterior syn-
echiae) in some eyes by 1 month after Trabectome surgery, as a consequence of the 
small anterior segment dimensions. However, this was not correlated with an IOP 
increase. [19].
4.4.3  Contraindications
Contraindications to trabectome surgery include neovascularization of the anterior 
chamber angle, glaucoma secondary to elevated episcleral venous pressure, chronic 
angle closure, and active uveitis [20]. Poor visualization of the trabecular meshwork 
or a very narrow anterior chamber angle increases the risk of damage to surrounding 
ocular structures.
4.5  Results of Trabectome
4.5.1  Quality of Evidence
While Trabectome surgery is widely performed, it is important to note the paucity 
of high-quality evidence. In 2016, Hu et  al. conducted a Cochrane review of all 
published Trabectome studies. They included only randomized controlled trials 
resulting in the exclusion of all 113 published reports on Trabectome. A single ran-
domized controlled trial was underway, NCT00901108, but has since been termi-
nated [21]. The current compendium of Trabectome literature suffers from a lack of 
prospective, randomized, controlled studies. Other issues include industry- 
sponsored studies with poor clinical trial procedures, e.g., enrollment, data collec-
tion and methods of patient selection. Variations in surgical techniques are likely to 
confound the surgical outcomes as each surgeon will ablate a different length of 
trabecular meshwork.
4.5.2  Clinical Efficacy
4.5.2.1  Trabectome-Alone
In 2005, the first clinical study by Minckler et al. reported results of Trabectome- 
alone in 15 patients with primary and secondary open-angle glaucoma, who were 
recruited from a clinical practice in Tijuana, Mexico. At 1 year, the IOP decreased 
from 22.6 ± 4.7 mmHg to 16.3 ± 2.0 mmHg, with a reduction in the mean number 
of medications from 1.2 to 0.1 [22].
R. L. Rabin et al.
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The largest data set comes from the global Trabectome study database sponsored 
by the device manufacturer, NeoMedix, which analyzes the first 20 cases of any 
Trabectome surgeon who voluntarily sends in de-identified clinical data as post- 
market surveillance. This database is stored by the company, and the most recent 
update was published in 2014, which included 5435 cases of Trabectome-alone and 
phaco-Trabectome procedures, with up to 90 months of follow-up. On average, the 
IOP was reduced from 23.0 ± 7.9 mmHg to 16.5 ± 3.8 mmHg (29% reduction) and 
the number of glaucoma medications was reduced from 2.6 ± 1.3 to 1.6 ± 1.3 (38%) 
[23]. However, a large number of patients were lost to follow-up with incomplete data 
from the first postoperative day, hence limiting the generalizability of these results.
In 2008, Minckler et al. published a follow-up study to update their results [13]. 
They adapted the success criteria from the Tube versus Trabeculectomy Study to 
evaluate Trabectome surgery (Table 4.1). This criteria has been adopted by most 
subsequent Trabectome studies. Although Minckler et al. noted the success rate of 
Trabectome after 12 months to be 50%, the 1-year success rates have varied signifi-
cantly in different studies, ranging from 36% [24] to 94% [25]. The study which 
reported a 1-year success rate of 36% found that this decreased to 22.4% by 2 years 
[24]. In many of the aforementioned studies, the high dropout rates are likely to 
introduce selection bias, limiting the generalizability of the study results.
These studies use Kaplan-Meier survival plots to display the success rate over 
time. The significance of the plots is difficult to interpret because most of the 
Kaplan-Meier survival plots only show the success rate, but do not indicate the 
number of patients at each follow-up visit [23]. Inter-study results may vary as a 
consequence of different study designs, surgical technique, population differences 
between study groups, or different patient evaluation protocols (e.g., masked vs. 
unmasked IOP readings) [6–8, 11, 15–17, 22–24, 26].
4.5.2.2  Trabectome-Alone Versus Trabeculectomy with Mitomycin C
In a retrospective cohort study, Jea et al. compared Trabectome to trabeculectomy 
with mitomycin C. This cohort study had a very low rate of participant dropout. 
After 24 months, IOP decreased from 28.1 ± 8.6 mmHg to 15.9 ± 4.5 mmHg in the 
Trabectome group versus 26.3 ± 10.9 mmHg to 10.2 ± 4.1 mmHg in the trabeculec-
tomy group; 43.5% of Trabectome eyes and 10.8% of trabeculectomy eyes required 
subsequent glaucoma surgery. Two-year success rates were 22.4% and 76.1% in the 
Trabectome and trabeculectomy groups respectively, demonstrating a lower success 
rate of Trabectome compared to trabeculectomy. Younger age and lower preopera-
tive IOP were risk factors for Trabectome failure [24]. The results were later cor-
roborated by Sit et al. [27].
Table 4.1 Commonly used Success and Failure criteria
Success criterion: postoperative IOP <21 mmHg and reduction of IOP ≥20% from baseline. 
Failure was determined if these criteria were not met on two consecutive visits after 
postoperative month 3
Failure: success criterion not met and/or need for additional glaucoma surgery
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4.5.2.3  Phaco-Trabectome Versus Trabectome-Alone
Neiweem et al. published an algorithm to calculate anticipated IOP after Trabectome. 
They found that phacoemulsification plays a minimal role in IOP reduction when per-
formed with Trabectome surgery. They calculated that adding phacoemulsification to 
Trabectome surgery lowers final IOP by only 0.73 ± 0.32 mmHg [28]. Similarly, stud-
ies have shown that there is no significant difference in the mean postoperative IOP and 
the mean number of hypotensive medications for phaco- Trabectome compared with 
Trabectome-alone [23, 25]. However, these findings are contradictory to the results of 
randomized control trials comparing cataract surgery alone to cataract surgery com-
bined with other MIGS procedures, including iStent, CyPass, and Hydrus implantation.
Other studies have reported that the success rate of phaco-Trabectome is higher 
than that of Trabectome-alone. In a meta-analysis by Kapowitz et  al., the mean 
1-year success rate of Trabectome-alone was 61 ± 17% (n = 5 studies) and that of 
phaco-Trabectome was 85 ± 17% (n = 6 studies) [29].
4.5.3  Phaco-Trabectome Versus Phaco-iStent
Three nonrandomized retrospective studies have compared phaco-Trabectome to 
phacoemulsification with two iStents [12–14]. In all three studies, there were no statis-
tical differences between the postoperative IOP and the number of medications between 
the two groups. Lavia et al. came to the same conclusion in a meta- analysis [30].
4.5.4  Preoperative Glaucoma Severity on Surgical Outcome
It is thought that MIGS is most effective for mild-to-moderate glaucoma. Roy et al. 
looked at the 1-year postoperative outcomes of 498 patients undergoing phaco- 
Trabectome, and stratified results based on a pre-operative glaucoma severity index 
which incorporated pre-operative IOP, the number of hypotensive medications and 
visual field status. Severity was designated on a scale of 1 through 4 with a higher 
number indicating more severe disease. Success rates after 1 year were noted to be 
98, 93, 96, and 88% in groups 1 to 4 respectively, with a 1.69 ± 0.2 mmHg larger 
IOP reduction with each increase in group number. This study suggests that phaco- 
Trabectome surgery can be successful for severe glaucoma in carefully selected 
patients  [31], though the efficacy of  conventional glaucoma surgery (trabeculec-
tomy and tube shunt implants) is certainly much more established in such patients.
4.5.5  Other Potential Factors Affecting Efficacy
4.5.5.1  Does Prior Ineffective Selective Laser Trabeculoplasty (SLT) 
Alter Trabectome Outcomes?
Vold et al. retrospectively compared the impact of Trabectome surgery on patients 
with and without prior SLT treatment [32]. No significant difference in IOP was 
found between the two groups. At 1 year, patients without prior SLT treatment 
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(n = 177) had mean IOP of 16.5 ± 4.0 mmHg, while those with prior SLT treatment 
(n = 58) had mean IOP of 15.7 ± 3.0 mmHg.
Klamann et  al. retrospectively compared the 6-month outcomes of eyes 
which underwent combined phaco-Trabectome 3 months after 360° SLT, com-
pared with eyes which did not undergo prior SLT.  In eyes with POAG, there 
was no significant difference in IOP between the two groups at 6 months. In 
eyes with pigment dispersion and pseudoexfoliation, those that underwent 
prior SLT had a greater IOP reduction compared with those without previous 
SLT, though this difference was significant only at the 6-month time point and 
the number of hypotensive medications was similar between the two groups. In 
view of the small sample size, the lack of masking and a significant difference 
between the two groups being detectable only at a single time point, these 
results must be verified in a larger study before extrapolation to clinical prac-
tice [33].
4.5.5.2  Trabectome for Patients with Secondary 
Open-Angle Glaucoma
Pseudoexfoliation glaucoma, pigmentary glaucoma, and steroid-induced glau-
coma have responded well to Trabectome surgery [26, 33–35]. Pahlitzsch et al. 
compared Trabectome-alone in POAG versus pseudoexfoliation glaucoma 
patients. They showed an IOP reduction from 19.10  ±  4.11  mmHg to 
14.27 ± 2.93 mmHg and glaucoma medication reduction from 2.40 ± 0.92 to 
1.77 ± 1.00 in the POAG group after 36 months. The pseudoexfoliation group 
had an IOP decrease from 22.49  ±  9.40  mmHg to 14.57  ±  5.05  mmHg and 
glaucoma medication reduction from 2.31 ± 1.02 to 1.75 ± 0.91 after 36 months 
[26]. Steroid-induced glaucoma has also responded well to Trabectome surgery 
[34, 35]. Dang et al. showed that the success rates were 86% and 85% respec-
tively for steroid-induced glaucoma and POAG at 1-year follow-up [34]. 
Trabectome surgery has been shown to be effective in uveitic glaucoma as 
well [36].
Some studies suggest that Trabectome surgery may be more successful in sec-
ondary open-angle glaucoma (SOAG) compared to POAG. In a Japanese study by 
Shoji et al., the success rate at 12 months for POAG patients (n = 80) and SOAG 
patients (n = 46) were 53.9 ± 7.5% and 77.2 ± 5.4%, respectively [17]. In the SOAG 
group, 11 patients had steroid-induced glaucoma, 22 patients had pseudoexfoliation 
glaucoma, and 13 patients had uveitic glaucoma. In a study by Ting et al., success 
rates at 12 months for POAG and pseudoexfoliation glaucoma patients were 62.9 
and 79.1% respectively (P = 0.004) [37]. Akil et al. found that Trabectome-alone 
success rates after 12 months were 86 and 92% for POAG and pigmentary glau-
coma patients, respectively [16].
It is believed that Trabectome works well for secondary open-angle glaucoma, in 
particular pseudoexfoliation glaucoma and pigmentary glaucoma, because the site 
of greatest aqueous outflow resistance is at the trabecular meshwork (due to occlu-
sion by pseudoexfoliative material or pigment), hence these eyes should respond 
well to trabecular meshwork removal.
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4.5.5.3  Trabectome Can Be Performed in Patients with Previous 
Failed Trabeculectomy
It was previously believed that following conventional glaucoma surgery, aqueous 
flow through the trabecular outflow pathway decreased significantly. Bussel et al. 
showed that Trabectome surgery can be beneficial with or without phacoemulsifica-
tion in eyes with failed trabeculectomy [38]. At 1 year postoperatively, the mean 
IOP of the Trabectome-only group decreased by 28% from a baseline of 23.7 mmHg 
while that of the phaco-Trabectome group decreased by 19% from a baseline of 
20 mmHg. The mean number of hypotensive medications decreased from 2.8 to 
2.0 in the Trabectome-only group and from 2.5 to 1.6 in the phaco-Trabectome group.
4.5.5.4  Intraoperative Prognosticator for Postoperative Outcome
Fellman et  al. suggested that a prominent post-Trabectome episcleral venous fluid 
wave may be a reliable biomarker for successful Trabectome surgery [39]. Immediately 
after the Trabectome procedure, the extent of episcleral venous blanching adjacent to 
the Trabectome site was noted in response to increased IOP, achieved by adjusting the 
irrigation level within the anterior chamber. Preoperatively, patients had mean IOP of 
19.3 ± 5.1 mmHg on 2.7 ± 0.9 medications. Patients with a prominent fluid wave had 
a post-Trabectome mean IOP of 13.3 ± 2.7 mmHg on 1.4 ± 1.2 medications while 
patients with a poor fluid wave had a post-Trabectome mean IOP of 18.4 ± 3.1 mmHg 
on 2.9 ± 0.9 medications at 12 months follow-up. However, the study did not report 
the preoperative IOP and number of medications separately for the two cohorts, hence 
it was possible that the difference in postoperative outcomes between the groups 
might be partly attributable to preoperative differences. A reliable method of assessing 
the preoperative episcleral venous flow has not been established and the magnitude of 
increase in episcleral venous flow secondary to Trabectome surgery is unclear. 
Furthermore, the value of this sign for preoperative prognostication is limited as it can 
only be observed after the procedure has been performed.
4.6  Complications of Trabectome
In 2008, Minckler et  al. reported the rate of complications associated with 
Trabectome surgery from a review of 1127 patients [40]. In this study, 17 patients 
(1.5%) had hypotony (IOP < 5 mmHg) at day 1, 65 patients (5.8%) had an IOP spike 
(IOP >10 mmHh above baseline), 874 patients (77.6%) had intraoperative blood 
reflux, and one patient had aqueous misdirection (0.09%). Infection, wound leak, 
bleb formation, choroidal effusion, choroidal hemorrhage, or visual acuity decrease 
of more than two lines did not occur in any of the patients [40] (Table 4.2).
In the study by Francis et al. which included 304 eyes that underwent phaco- 
Trabectome, an IOP spike of 10 mmHg or greater occurred in 26 eyes (8.6%) at day 
1 and in 6 eyes (2.0%) at week 1 after the surgery. Francis et al. also noted minor iris 
injury from the Trabectome tip in four cases (1.3%) [42].
Mizoguchi et  al. reported that the complications after Trabectome surgery 
included microhyphema (76.8%), hyphema (23.2%), IOP spike >10 mmHg (4.9%), 
decrease in VA greater than two lines (1.2%), and cataract progression (1.2%) [15].
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Serious complications are rare after Trabectome surgery, with the incidence sim-
ilar to that associated with cataract surgery [29]. Maeda et al. showed that there was 
no statistically significant difference in corneal endothelial cell count before and 
after Trabectome surgery [45].
The most common reasons for surgical failure are incomplete or improper 
removal of the trabecular meshwork, ablation of the wrong site hence damaging the 
ciliary body, and damage to Schlemm’s canal or surrounding tissue which results in 
scarring. While blood reflux from the collector channels is common, surgical inter-
vention for hyphema is rare [46]. Peripheral anterior synechiae have been observed 
in nearly a quarter of patients in some studies [6].
Berk et al. documented the first case of cyclodialysis cleft secondary to a com-
plicated Trabectome procedure which resulted in hypotony requiring direct 
suture cyclopexy [43]. While there have been a few reports on cyclodialysis cleft 
formation after Trabectome surgery, it may be an underreported complication. A 
cyclodialysis cleft may be difficult to identify in the clinic postoperatively, as the 
associated hypotony may narrow the anterior chamber angle and hinder visual-
ization of the ciliary body band. Ultrasound biomicroscopy may be helpful in 
identifying cyclodialysis clefts postoperatively [44]. The cleft is most easily 
visualized immediately after creation when the eye is still pressurized from the 
Trabectome infusion.
One should suspect a cleft intraoperatively when there is excessive bleeding or 
when the postoperative IOP reduction is more than expected. Closure of the cleft 
typically results in a transient IOP spike which usually lasts about 4–5 days.
4.7  After Trabectome Has Failed
4.7.1  Does Trabectome Surgery Impact Future Glaucoma 
Surgery Outcomes?
Trabectome surgery spares the conjunctiva and Jea et  al. showed that failed 
Trabectome surgery did not impact the success of subsequent trabeculectomy 
[47]. However, after failed Trabectome surgery, subsequent SLT has limited ben-
efit [48].
Table 4.2 Complications of 
Trabectome surgery
Intraoperative blood reflux (78% of 1127 cases) [40]; 92% 
of 557 [41]
Postoperative hyphema (23.2% of 82 cases) [15]
Peripheral anterior synechiae (14.0% of 101 cases) [6]
Transient IOP spike (5.8% of 1127 cases) [40]
IOP at 1 week >10 mmHg higher than preop (2.0% of 304 
cases) [42]
Hypotony (1.5% of 1127 cases) [40]
Cyclodialysis cleft, low incidence rate [43, 44]
Iris injury (1.3% of 304 cases) [42]
Cataract progression (1.2% of 82 cases) [15]
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4.7.2  Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) 
Procedure as a Potential Treatment Option After Failed 
Trabectome Surgery
GATT is adapted from ab-externo trabeculotomy to create a safer and easier 
approach to access Schlemm’s canal. A microcatheter is fed into Schlemm’s canal 
more than 360° using an ab-interno approach through a trabecular incision. GATT 
has been shown to be effective at decreasing medication reliance and improving 
IOP in both primary and secondary glaucoma [49, 50]. Hyphema is the most fre-
quent complication and is present in 34% of eyes 1 week after the surgery.
In patients who initially responded to Trabectome surgery but subsequently 
developed elevated IOP again, GATT may be beneficial as it allows aqueous to 
access a larger segment of Schlemm’s canal than Trabectome surgery. The GATT 
fiber optic probe may be inserted into the Schlemm’s canal through the previous 
Trabectome trabecular incision.
4.8  Conclusion
Trabectome surgery bypasses the trabecular meshwork and allows aqueous to flow 
directly from the anterior chamber to the Schlemm’s canal. This is a bleb-less pro-
cedure which spares the conjunctiva. Multiple studies have shown that Trabectome 
surgery results in a reduction in IOP and the number of ocular hypotensive agents, 
though the efficacy is significantly less than conventional glaucoma surgery. 
Trabectome surgery has a favorable safety profile compared with conventional fil-
tration surgery, with the most common complication being intraoperative and post-
operative bleeding. Disadvantages of Trabectome surgery include the modest 
efficacy, which is limited by episcleral venous pressure, and the difficulty in target-
ing treatment to the segment of Schlemm’s canal with the highest concentration of 
functional collector channels. Additional research is required to understand how the 
efficacy of Trabectome surgery can be maximized.
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The Hydrus Microstent (Ivantis Inc., Irvine, CA, USA) is an intracanalicular scaf-
fold which reduces the intraocular pressure (IOP) in order to treat glaucoma. The 
Microstent comes preloaded in a delivery system designed for ab-interno implanta-
tion under gonioscopic visualization. This is performed through the trabecular 
meshwork into Schlemm’s canal typically in conjunction with planned cataract sur-
gery. The implantation procedure is relatively intuitive and, if combined with cata-
ract surgery, is usually performed at the end of surgery through the same corneal 
incision [1].
5.2  Material/Design
The Hydrus Microstent has a length of 8 mm. A 7-mm scaffold segment resides 
within the lumen of Schlemm’s canal and a 1-mm inlet portion resides within the 
anterior chamber (Fig. 5.1) [1]. The Microstent is designed to fit the curvature of the 
canal without obstructing collector channel ostia located along the posterior wall 
(Fig. 5.2) [2]. The 8-mm Microstent is a modification of an earlier design that was 
15 mm in length with a larger, nearly circular profile [3].
The Hydrus Microstent is made of nitinol (nickel–titanium alloy), a material 
with unique shape memory properties, which has been used widely in vascular med-
icine and other medical applications [4, 5]. The biocompatibility of nitinol for ocu-
lar applications has been reported previously and the Hydrus Microstent was 
initially evaluated in rabbit and primate ocular models [6, 7].
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Fig. 5.1 After 
implantation into the 
Schlemm’s canal, the 
Hydrus® Microstent is 
visible through slit lamp 
gonioscopic examination. 
About 7 mm of the 
Microstent lies in 
Schlemm’s canal, 
scaffolding and dilating it. 
A smaller segment of the 
Microstent (about 1 mm) 
prolapses at the site of 
implantation through the 
trabecular meshwork back 
in the anterior chamber. 
(Copyright permission 
granted by Elsevier Inc. 
according to STM 
Guidelines [1])
Fig. 5.2 The 8-mm Hydrus® Microstent consists of a scaffold of three windows and three spines 
and an inlet region. The cross section of the Hydrus Microstent in the Schlemm’s canal of a donor 
eye shows the canal dilated, the trabecular meshwork stretched, and the access to collector channel 
ostia free. (Copyright permission granted by Elsevier Inc. according to STM Guidelines [2])
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5.2.1  Mechanism of Action
The Hydrus Microstent has a dual mode of action: First, this is a trabecular bypass 
minimally invasive glaucoma surgery (MIGS) device: the trabecular resistance, 
which plays a major role in the pathogenesis of open-angle glaucoma, is bypassed 
as aqueous gains direct access to the Schlemm’s canal through the small inlet por-
tion. Secondly, it dilates and scaffolds Schlemm’s canal in order to increase the 
circumferential flow and maintain or facilitate access to collector channels (Fig. 5.3). 
Surgical procedures, such as canaloplasty, are based on a similar principle [8]. It has 
been hypothesized following ex vivo studies that elevated IOP itself may lead to 
alterations in the anatomy of trabecular meshwork and Schlemm’s canal, which 
then becomes narrower or collapses [9]. The surgical dilation of Schlemm’s canal 
leads to increased aqueous outflow and a reduction in IOP [10]. While canaloplasty 
offers a 360° dilation, the Hydrus Microstent can dilate only part of the canal’s cir-
cumference. It creates a maximum Schlemm’s canal dilation of 241 μm or approxi-
mately four to five times the natural cross-sectional area of the canal across its 
length [3].
A mathematical model has demonstrated that bypassing the trabecular mesh-
work increases the pressure and circumferential flow rate within Schlemm’s canal, 
as well as the flow rate in collector channels adjacent to the bypass [11]. The same 
model showed that dilating Schlemm’s canal adjacent to the bypass further reduces 
the pressure in the dilated region, which increases the circumferential flow rate 
even more. Thus, the Hydrus Microstent is unique in its design, which allows aque-
ous to flow without significant resistance from the anterior chamber directly into 
the collector channels. The small proximal 1-mm inlet of the Microstent in the 
anterior chamber bypasses the trabecular meshwork and permits a direct pathway 
for aqueous flow from the anterior chamber to Schlemm’s canal, while the larger 




intracanalicular portion provides persistent dilation of Schlemm’s canal and access 
to the collector channel ostia.
5.3  Ex Vivo Testing
Grierson et al. reported the histological changes in primate and rabbit eyes after 
implantation of the Hydrus Microstent [7]. The host response to the Microstent 
within the ocular tissues at the anterior chamber angle was judged to be minimal: 
there was no evidence of tissue degeneration near the Microstent or elsewhere 
within the eyes. No histopathological signs of metallosis such as depigmentation, 
apoptosis, or tissue necrosis were present and there was no evidence of significant 
intraocular inflammation. A low-grade mononuclear immune response involving a 
few scattered macrophages was present in some tissues both close to and remote 
from the Microstent. An extremely thin capsule wall was found around the 
Microstent, consisting of one to two thin spindle-shaped fibroblasts without a sub-
stantial fibrous collagen component.
Johnstone et al. used scanning electron microscopy to assess the structure of the 
outer wall of Schlemm’s canal after Microstent implantation in human cadaveric 
eyes [2]. Particulate debris was found at the site of the Microstent but did not 
occlude Schlemm’s canal. Collector channels were regularly visible with intact 
margins and were not obstructed or compressed.
The mechanism of action of the device was tested in anterior segment perfusion 
models using human donor eyes [3, 12, 13]. Gulati et al. and Hays et al. performed 
experiments using the 8 mm version of the Microstent, while Camras et al. tested the 
effect of the previous 15 mm version. Overall, these studies confirmed an increase in 
outflow facility, compared with controls after sham treatment. This increase in out-
flow facility was more profound when the IOP was elevated. This implies that eyes 
with higher outflow resistance can be expected to have a greater improvement in 
outflow and therefore a greater decrease in IOP with the Hydrus Microstent. In addi-
tion, it is possible that the Microstent prevented Schlemm’s canal from closure and 
collapse when the IOP was elevated, a phenomenon which has been shown in studies 
of the anatomy of the angle tissues in eyes with raised IOP [9, 14]. The dilation of 
Schlemm’s canal by the Hydrus Microstent enabled the aqueous outflow to be mea-
surably higher in eyes with significant IOP elevation, even though only one-quarter 
of the entire Schlemm’s canal was stented. Another interesting finding in the study of 
Camras et al. [12] was that the improved outflow was attributable only to the pres-
ence of the Microstent itself and not by the implantation process or the subsequent 
histological changes in the trabecular meshwork or the Schlemm’s canal: the outflow 
was not improved in eyes in which the Microstent was first implanted and then 
removed again. Histological examination of the site of implantation offered a possi-
ble explanation. It showed that the Schlemm’s canal was widened by the Microstent, 
while the overlying trabecular meshwork appeared stretched but intact. Thus, dam-
age to the angle structures by Hydrus Microstent implantation or the Microstent itself 
was very mild and was not likely to reduce trabecular resistance.
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5.4  Surgical Technique
The Hydrus Microstent comes preloaded in a sterile delivery cannula (Fig. 5.4). The 
cannula is slightly curved so as to conform to the morphology of the angle and the 
Schlemm’s canal. During implantation, the Hydrus Microstent is fed along 3 clock 
hours of Schlemm’s canal. In order to facilitate this, the cannula can be rotated on 
the injector, permitting the surgeon to optimize his or her hand orientation for 
implantation. The device is inserted into the anterior chamber through a small clear- 
corneal paracentesis. Visualization of the angle via a goniolens is required for the 
precise implantation of the Hydrus Microstent. The cannula penetrates the trabecu-
lar meshwork at a very small angle almost tangential to its surface, so as to cannu-
late Schlemm’s canal. Subsequently, the tracking wheel on the delivery system is 
used to slowly advance and implant the Hydrus Microstent, while keeping the can-
nula tip firmly in place. When approximately 1  mm of the proximal Microstent 
protrudes as an inlet from the trabecular meshwork into the anterior chamber, the 
delivery system is fully released.
5.5  Site of Implantation
The most common site for the implantation of the Hydrus Microstent is the nasal 
quadrant due to its accessibility through a clear corneal temporal incision [15]. The 
nasal angle also has the highest concentration of collector channels [16]. However, 
bypassing the trabecular meshwork may not be sufficient for lowering the IOP in 
some eyes, as the distal conventional aqueous outflow pathway, such as the collector 
channels and aqueous veins, may be obstructed and may also confer significant 
resistance to aqueous outflow. Correct identification of the parts of the angle with 
functional collector channels and targeted implantation of the Hydrus Microstent 
could theoretically improve the efficacy of the stent in lowering IOP.
The intraoperative signs which indicate the success of ab-interno trabeculotomy 
can also be used to assess whether the Hydrus Microstent has been implanted cor-




Fig. 5.4 The trimodal 
mechanism of action of the 
Hydrus® Microstent. 
(Copyright Ivantis Inc., 





of the episcleral venous plexus when balanced salt solution is injected into the ante-
rior chamber) indicates that the trabecular bypass procedure is successful in access-
ing the downstream collector channels and aqueous veins. Fellman suggested that 
this wave can be induced with the aid of the irrigation and aspiration system: insert 
the irrigation and aspiration handpiece into the anterior chamber with the infusion 
turned off, then initiate maximal irrigation, creating a high-pressure gradient for 
balanced salt solution to surge from the anterior chamber through the Microstent 
into the canal and the venous collector system.
Another useful sign that Hydrus Microstent implantation is successful is the 
presence of blood reflux into the anterior chamber from the Microstent lumen 
under low-pressure conditions. When the IOP is lower than the pressure in the 
episcleral veins, retrograde blood flow through patent collector channels and 
Schlemm’s canal can occur. Implantation of the Hydrus Microstent into Schlemm’s 
canal further allows blood to flow from the Schlemm’s canal into the anterior 
chamber. Grieshaber et al. showed that the postoperative IOP correlated with the 
quantity of blood reflux into Schlemm’s canal in 28 eyes of African patients who 
underwent ab-externo canaloplasty [18]. In the same study, the patency of the col-
lector channels was also checked by injecting fluorescein dye into Schlemm’s 
canal using a flexible microcatheter. However, this technique required conjuncti-
val peritomy, which would defeat the objective of the ab-interno approach and 
compromise the success of subsequent glaucoma filtration surgery if indicated. 
Ab-interno procedures for assessing the conventional outflow system spare the 
conjunctiva and can provide valuable information regarding Hydrus Microstent 
placement and the likelihood of success for Schlemm’s canal surgery. For exam-
ple, Saheb et al. injected dye through the inlet of the Microstent after implantation 
in order to assess the anatomy and patency of the distal outflow pathway [15]. 
Furthermore, high-resolution imaging of the conventional outflow system can 
also help to determine the optimal site of implantation. Kagemann et  al. used 
spectral domain ocular coherence tomography (OCT) to noninvasively assess 
Schlemm’s canal, collector channels, and the intrascleral venous plexus [19, 20]. 
Further evolution of the imaging techniques and the introduction of OCT angiog-
raphy may aid in planning optimal Hydrus Microstent placement and for predict-
ing its probability of success.
5.6  Patients
Suitable patients for Hydrus Microstent implantation are those with primary open- 
angle glaucoma and pseudoexfoliative glaucoma. Contraindications include angle- 
closure glaucoma and secondary glaucoma, such as neovascular, uveitic, traumatic, 
steroid-induced, and lens-induced glaucoma. Furthermore, patients who previously 
underwent argon laser trabeculoplasty, cyclo-destructive procedures, trabeculec-
tomy, tube shunt implantation, or any incisional glaucoma surgical procedure are 
not ideal candidates for Hydrus Microstent implantation: possible changes in the 
Schlemm’s canal after such interventions can make implantation challenging or 
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impossible. Hence, the surgical outcomes of Hydrus Microstent implantation in 
such patients remain uncertain [1].
5.7  Efficacy
The performance of the Hydrus Microstent in reducing IOP was evaluated in the 
HYDRUS II study: a prospective, single-masked, randomized controlled clinical 
trial conducted in seven European centers [1]. Patients were randomized to either 
cataract surgery combined with Hydrus Microstent implantation or cataract sur-
gery alone and then followed up for 2 years. In order to accurately determine the 
efficacy of the surgery, patients underwent a washout of their hypotensive medi-
cations, similar to the protocol in the Ocular Hypertension Treatment Study [21] 
(Table 5.1).
One year after Hydrus Microstent implantation in combination with cataract sur-
gery, the mean washed-out IOP decreased significantly by 9.7  mmHg (from 
26.3 mmHg to 16.6 mmHg) compared with preoperative IOP. This effect persisted 
for 2 years after surgery, with the mean washed out diurnal IOP only 0.3 mmHg 
higher than that at 1 year at 16.9 mmHg. There was also a significant decrease in 
IOP at 1 year for eyes which underwent cataract surgery alone, with a mean reduc-
tion of 9.2 mmHg (from 26.6 mmHg to 17.4 mmHg). However, at 2 years, there was 
an increase in IOP to 19.2 mmHg in eyes which underwent cataract surgery alone, 
and this was significantly higher than the 2-year IOP in eyes which underwent 
Hydrus Microstent implantation in combination with cataract surgery.
Combined Hydrus Microstent implantation and cataract surgery were also asso-
ciated with a reduction in glaucoma medications, with 77.1% and 72.3% of patients 
requiring no medications to achieve target IOP at 1 year and 2 years after surgery, 
respectively. Amongst patients who underwent cataract surgery alone, the propor-
tion of patients who were medication-free at 1 year and 2 years after surgery was 
significantly lower compared with those who underwent combined Hydrus 
Microstent implantation and cataract surgery, at 49% and 36.4%, respectively. 
Moreover, patients who underwent combined Hydrus Microstent implantation and 
Table 5.1 The efficacy of Hydrus® Microstent either as a standalone procedure or in combination 
with cataract surgery as reported in a number of studies [1, 8, 15, 22–24]
Group Procedure Follow-up Pre-OP IOP Post-OP IOP
Pfeiffer et al. [1] Hydrus + Cataract Surgery 2 years 26.3 mmHg* 16.9 mmHg*
Ahmed et al. [15] Hydrus + Cataract Surgery 6 months 17.9 mmHg 15.3 mmHg
Fea et al. [22] Hydrus + Cataract Surgery 2 years 19.4 mmHg 15.7 mmHg
Al-Mugheiry et al. 
[23]
Hydrus 2 years 18.1 mmHg 15.3 mmHg
Fea et al. [24] Hydrus 1 years 23.1 mmHg 16.5 mmHg
Gandolfi et al. [8] Hydrus 2 years 24.0 mmHg 15.0 mmHg
*In the study by Pfeiffer et al., washout of glaucoma medication was performed in order to accu-
rately determine the efficacy of Hydrus® Microstent implantation
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cataract surgery required only half the mean number of glaucoma medications at 2 
years compared with those who underwent cataract surgery alone.
The results of the Hydrus II study are similar to that of other smaller case series. 
Ahmed et  al. reported the 6-month outcomes of 28 eyes with mild-to-moderate 
primary open-angle glaucoma after combined phacoemulsification and Hydrus 
implantation [15]. Baseline IOP was 17.9 ± 4.1 mmHg with 2.4 ± 1.0 glaucoma 
medications, and washed-out IOP was 29.9 ± 5.8 mmHg before surgery. The IOP 
and the mean number of glaucoma medications at 6  months were significantly 
reduced to 15.3 ± 2.3 mmHg and 0.1 ± 0.4, respectively. Fea et  al. reported the 
2-year results of 92 eyes that underwent combined cataract surgery and Hydrus 
Microstent implantation [22]. This was a retrospective study with no washout of 
glaucoma medications. Nevertheless, a 20% reduction in the mean IOP from 
19.4 mmHg preoperatively to 15.7 mmHg at 2 years after surgery was observed. In 
a single-center and single-surgeon observational study, Al-Mugheiry et al. reported 
the 2-year results of 25 eyes which underwent combined Hydrus Microstent implan-
tation and cataract surgery. At the end of 2 years, the mean medicated IOP was 
reduced from 18.1 (±3.6) mmHg to 15.3 (±2.2) mmHg [23].
The HORIZON study was a 24-month prospective, multicenter, single-masked 
randomized controlled trial which compared the reduction in IOP and medication 
use in subjects who underwent combined cataract surgery and Hydrus Microstent 
implantation (HMS, n  =  369) with those who underwent cataract surgery alone 
(NMS, n = 187). At 24 months, 77.3% of the HMS group eyes achieved ≥20% 
reduction in unmedicated modified diurnal IOP (MDIOP) compared with 57.8% of 
NMS group eyes (difference = 19.5%, 95% confidence interval [CI] 11.2%–27.8%, 
p < 0.001). The mean ± standard deviation decrease in unmedicated MDIOP was 
−7.6 ± 4.1 mmHg in the HMS group and −5.3 ± 3.9 mmHg in the NMS group at 
24 months (difference = 2.3 mmHg, 95% CI −3.0 to −1.6, p < 0.001). The safety 
profile was similar in both groups with no serious ocular adverse events related to 
the microstent [24]. These results confirmed the findings of the HYDRUS II study, 
that the efficacy of combined phacoemulsification and Hydrus Microstent implanta-
tion in lowering the IOP and glaucoma medications was superior to phacoemulsifi-
cation alone.
Although Hydrus Microstent implantation is typically performed in combination 
with cataract surgery, the device can also be implanted as a solo procedure. Fea 
et  al. reported the 1-year outcomes of Hydrus Microstent implantation as a solo 
procedure in 31 eyes (20 phakic, 11 pseudophakic) with primary open-angle glau-
coma [25]. One year after surgery, the mean IOP decreased by 6.6 ± 5.6 mmHg 
(from 23.1  mmHg to 16.5  mmHg) and 47% of eyes were medication-free. This 
nonrandomized prospective study also compared the results of Microstent implanta-
tion with selective laser trabeculoplasty. At 1 year, IOP reduction was similar 
between Hydrus Microstent implantation and selective laser trabeculoplasty. 
However, eyes that underwent Hydrus Microstent implantation required signifi-
cantly fewer medications to achieve target IOP compared with those which under-
went selective laser trabeculoplasty, even though the eyes which underwent Hydrus 
Microstent implantation had more severe glaucoma. Gandolfi et  al. reported the 
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2-year results of stand-alone Hydrus Microstent implantation compared with 
canaloplasty [8]. There was a significant and similar IOP decrease in both groups, 
from 24 ± 6 mmHg to 15 ± 3 mmHg in eyes that underwent Hydrus Microstent 
implantation and from 26 ± 4 mmHg to 16 ± 2 mmHg in eyes which underwent 
canaloplasty. In the COMPARE study, Ahmed et al. randomized 152 eyes from 152 
patients with open-angle glaucoma to standalone MIGS consisting of either one 
Hydrus Microstent or two iStent Trabecular Micro-Bypass devices in a prospective, 
multicenter, randomized clinical trial. At 12 months, the Hydrus group had a higher 
rate of complete success (39.7% vs. 13.3%, p < 0.001) and reduced medication use 
(difference = −0.6 medications, p = 0.004), with more patients in the Hydrus group 
being medication-free (difference = 22.6%, p = 0.0057) [26].
5.8  Safety
Hydrus Microstent implantation is associated with a favorable safety profile [24, 
27]. In the Hydrus II and HORIZON studies, the visual acuity of eyes that under-
went combined cataract surgery with Hydrus Microstent implantation was similar 
to that of eyes after cataract surgery alone [1, 24]. Adverse events, such as cornea 
punctate staining, erosion of the corneal epithelium, stromal edema, endothelial 
folds, anterior chamber cells, and flare, were generally mild. All these were observed 
in the early postoperative period, with resolution within 4 weeks. In the course of 
the follow-up in the Hydrus II study, the formation of peripheral anterior synechiae 
(Fig. 5.5) was observed in six eyes at 1 year and nine eyes at 2 years after Hydrus 
Microstent implantation. Serious ocular adverse events were rare and not attributed 
to the procedure in the opinion of the investigators (acute vitreomacular traction, 
anterior ischaemic optic neuropathy, retinal detachment, and macular edema) [1]. A 
study by Ahmed et al. reported a low incidence of corneal edema, hyphema, and 
peripheral anterior synechiae [15]. The presence of peripheral anterior synechiae 
was not related to an increase in IOP in the HORIZON study [24].
Fig. 5.5 Gonioscopy 
photograph showing 
peripheral anterior 
synechiae formation at the 
inlet of the Hydrus® 
Microstent. (Copyright 





In a retrospective study by Fea et al., which included 92 eyes with combined 
Hydrus Microstent implantation and cataract surgery, one patient developed 
hyphema exceeding 2.0 mm in the early postoperative period and this resolved 
spontaneously without any sequelae [25]. The placement of the Hydrus Microstent 
was not satisfactory in two eyes and intraoperative repositioning was performed. 
Peripheral anterior synechiae without Microstent obstruction was observed in 
eight eyes, and iris occlusion of the device inlet occurred in one eye, which was 
treated with argon laser 8 months after the surgery. In one eye, the Microstent was 
malpositioned (outside Schlemm’s canal) and the IOP was above target. This 
patient subsequently required trabeculectomy at 18 months. Al-Mugheiry et al. 
reported the outcomes of Hydrus Microstent implantation in 25 eyes by a surgeon 
with no prior surgical experience with the Microstent [23]. Despite the surgical 
inexperience, there were very few intraoperative complications. Hyphema 
occurred in two eyes during Microstent insertion. In one eye, the Microstent could 
not be fully inserted at the first attempt, but it was successfully inserted in another 
position at the second attempt. The postoperative adverse events on day 1 were 
mild-to-moderate anterior uveitis (12 eyes), mild corneal edema (7 eyes), micro-
hyphema (7 eyes), or hyphema >1.5 mm (2 eyes). In one eye with microhyphema, 
there was an associated IOP spike (28  mmHg) and in one eye with a 2-mm 
hyphema, there was a blood clot seen at the opening of the Microstent, but this 
resolved spontaneously after a week. There was no correlation between day 1 
complications and outcome.
Stand-alone Hydrus Microstent implantation was also found to be safe for phakic 
eyes, with a low incidence of adverse events being reported. In the prospective study 
by Fea et al., IOP spikes occurred in 2 out of 31 eyes (6.45%) on the first postopera-
tive day [25]. After temporary treatment with systemic acetazolamide, the IOP was 
normalized in all eyes by the third postoperative day. There was a transient decrease 
in visual acuity in three eyes (9.68%) on the first postoperative day, which was due 
to corneal edema secondary to an IOP spike in one eye and hyphema in two eyes. 
Visual acuity returned to baseline by 1 week after the surgery in all three cases. 
Gandolfi et al. reported that hyphema was the most common post-operative adverse 
event (4 out of 21 eyes) [8]. The hyphema cleared completely over a few days in all 
cases. An early postoperative IOP spike (≥30 mmHg within the first 48 h) occurred 
in one eye after Hydrus Microstent implantation. Peripheral anterior synechiae 
developed in four eyes during follow-up, which was treated with a YAG laser proce-
dure. Ahmed et al. reported that there was no significant difference in adverse events 
at one year between study eyes which underwent standalone Hydrus Microstent 
implantation compared with those which underwent implantation of two iStent 
Trabecular Micro- Bypass devices in the COMPARE study. Two subjects in the two 
iStent group required subsequent glaucoma surgery due to uncontrolled IOP despite 
maximum medical therapy, while none of the subjects in the Hydrus group required 
additional incisional glaucoma surgery. Ocular adverse events in both groups were 
mostly mild and transient [26].
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In summary, Hydrus Microstent implantation may be associated with transient 
IOP spikes, hyphema, stent malposition or obstruction and the development of 
peripheral anterior synechiae. IOP spikes occur mostly in the early postoperative 
period and can be easily managed with glaucoma medications. Bleeding in the 
anterior chamber can vary from a circulating or micro-hyphema to a large 
hyphema. This is typically transient and self-resolving within a few days or weeks. 
Microstent malposition is associated with impaired stent function and surgical 
intervention may be required in these cases. Development of peripheral anterior 
synechiae is relatively common postoperatively, but is without clinical signifi-
cance in most of the cases. However, synechial formation at the Hydrus Microstent 
inlet can result in stent obstruction, and this may be relieved by laser treatment in 
some cases. Clinically significant and long-standing hypotony or other potentially 
sight- threatening complications have not been described so far with Hydrus 
Microstent implantation, as its capacity to reduce IOP is limited by episcleral 
venous pressure.
5.9  Conclusion
Hydrus Microstent implantation in combination with cataract surgery or as a solo 
procedure is safe and effective for the treatment of primary open-angle glau-
coma. This Schlemm’s canal scaffold lowers IOP to the mid-teens and reduces 
glaucoma medication use for up to 2 years. Hence, it is promising as a long-term 
treatment modality for patients with mild to moderate primary open-angle 
glaucoma.
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6.1  Device Design and Evolution
The concept of the XEN Glaucoma Treatment System was initially developed at the 
Lions Eye Institute in Perth, Australia. It was commercialized by the company 
AqueSys, Inc. (Fort Worth, Texas, USA) which later was acquired by Allergan plc 
(Dublin, Ireland) in 2015. The concept was to create a subconjunctival aqueous 
drainage pathway similar to trabeculectomy, but via an ab-interno approach. The 
XEN Gel Implant is a 6-mm hydrophilic collagen cylindrical implant comprising of 
cross-linked porcine gelatin. It has an external diameter of 150 μm and an internal 
lumen of 45 μm. It aims to provide a direct permanent communication between the 
anterior chamber and the subconjunctival space (Fig. 6.1). It is rigid when dry, but 
softens and swells externally after immersion in aqueous. The soft gelatinous prop-
erty was thought to improve biocompatibility in the subconjunctival space and 
reduce the risk of erosion, while the small amount of external expansion aids device 
anchorage and minimizes migration. The XEN Glaucoma Treatment System 
received the CE mark in 2013 and was approved by the FDA in 2016. The lumen 
size of the XEN Gel Implant has changed from the initial 140 μm and later, 63 μm 
diameter versions, to the current, commercially available, 45 μm (also known as the 
XEN-45 implant), which is claimed to provide approximately 6–8 mmHg internal 
pressure resistance according to the Hagen–Poiseuille law and protect against post-
operative hypotony [1].
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The XEN Gel Implant is preloaded in the XEN injector that is sterile and for 
single use only (Fig. 6.2). The injector comprises a straight 27-gauge double bev-
eled needle with the XEN Gel Implant preloaded, a white surgical handle and a blue 
slider that deploys the implant. The injector advances across the anterior chamber 
through an inferotemporal clear corneal incision and delivers the XEN Gel Implant 
into the superonasal quadrant of the subconjunctival or sub-Tenon’s space (Fig. 6.3). 
On completion of the deployment, the XEN Gel Implant should be placed 1 mm in 
the anterior chamber and 2 mm within the sclera, leaving a 3-mm extraocular por-
tion under the conjunctiva. The implant should exit the sclera 3-mm posterior to the 
limbus, ideally creating a posterior filtration bleb. This is augmented by the use of 
Fig. 6.1 The XEN Glaucoma Treatment System. (Copyright Allergan plc, Dublin, Ireland; repro-
duced with permission)
a b
Fig. 6.2 The XEN Injector. (a) The XEN Gel Implant is preloaded in a disposable single-use 
injector. When the blue slider is moved forward, the XEN Gel Implant is injected into the subcon-
junctival space. (b) The tip of the injector comprises of a 27-gauge double beveled needle. 
(Copyright Allergan plc, Dublin, Ireland; reproduced with permission)
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the antimetabolite, Mitomycin-C (MMC), which is typically given as a subconjunc-
tival injection prior to device implantation.
6.2  Patient Selection
According to the CE mark, the XEN Gel Implant is intended to reduce intraocular 
pressure (IOP) in patients with primary open-angle glaucoma where previous medi-
cal treatments have failed. The Xen Glaucoma Treatment System was approved in 
the United States for the management of refractory glaucoma, where previous surgi-
cal treatment has failed, or in patients with primary open-angle glaucoma, pseudo- 
exfoliative or pigmentary glaucoma that is unresponsive to maximum tolerated 
medical therapy.
This procedure is suitable for patients with an open drainage angle, typically 
Shaffer grade 3 or above. The main advantages of the XEN Gel Implant over other 
filtering procedures include its less invasive surgical procedure which does not 
require conjunctival peritomy, the favorable safety profile, fast visual recovery, and 
short surgical duration, rendering this implant especially appropriate for patients 
who are unable to tolerate long surgical procedures or those who cannot accept pro-
longed visual recovery. Although designed as a stand-alone procedure, XEN implan-
tation can be combined with phacoemulsification in patients with concurrent cataract. 
Since the implant is placed in the superonasal quadrant, other surgical options involv-
ing the supero-temporal quadrant are still an option in case of filtration failure.
The outcome after XEN implantation is dependent on the formation and mainte-
nance of a filtering bleb. In contrast to conventional trabeculectomy where the out-
flow can be manipulated postoperatively via suture removal, the XEN Gel Implant 
is a fixed-flow device. As a result, its success is greatly dependent on the postopera-
tive subconjunctival resistance. Therefore, patients at risk of bleb fibrosis are likely 
to have a less favorable surgical outcome, and careful patient selection is crucial for 
achieving success with this procedure. Known risk factors for fibrosis after filtering 
Fig. 6.3 Supero-nasal 
XEN Gel Implant 
associated with a diffuse 
bleb. (Copyright Leon Au, 
FRCOphth; reproduced 
with permission)
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surgery include younger age, darker skin color, multiple topical glaucoma medica-
tions, diabetes, systemic autoimmune diseases, and a history of previous ocular 
surgery, especially procedures involving the conjunctiva. Moreover, preexisting 
intraocular and ocular surface inflammation increases the risk of postoperative 
fibrosis. Therefore, careful preoperative slit-lamp examination, including assess-
ment of the inflammatory status, integrity, and mobility of the (superonasal) con-
junctiva, as well as goniocopy to assess the angle, is mandatory for appropriate 
patient selection. Preoperative ocular surface disease and inflammation should be 
treated for ideally at least 1 month prior to surgery. Surgeons can consider altering 
or reducing the topical glaucoma medications before the surgery to reduce inflam-
mation and decrease the preservative load, prescribing topical steroids or even 
switching from topical glaucoma medications to oral acetazolamide if there are no 
contraindications. Lid disease, blepharitis, and chronic dry eyes should be treated 
appropriately before the surgery.
It is important to achieve good surgical exposure for this procedure, especially 
because the procedure is performed with the eye in the primary position, as com-
pared to conventional filtration surgery in which a corneal traction suture is used to 
rotate the eye downward. Hence patients need to be assessed preoperatively to 
ascertain whether the palpebral aperture is sufficiently wide and to identify factors 
which may cause surgical difficulties, including tight eyelids (e.g., history of con-
tact dermatitis), a deep sunken sulcus or high cheekbones (Fig. 6.4). A comprehen-
sive medical and surgical history should also be documented. Uncontrolled systemic 
hypertension or the use of oral anticoagulants for valvular heart disease increases 
the risk of intraocular and subconjunctival hemorrhage, the latter of which contrib-
utes to bleb fibrosis and surgical failure. Lastly, MMC is required for this procedure; 
hence, limbal stem cell failure and pregnancy are contraindications.
6.3  Surgical Technique
To indicate the intended implantation site, the conjunctiva is marked 3 mm from the 
limbus in the superonasal quadrant, close to the 12 o’clock position. Hydro- 
expansion of the tenon’s capsule is performed by injecting MMC subconjunctivally 
in the target quadrant, at least 5 mm posterior to the limbus. An inferotemporal clear 
Fig. 6.4 A patient with 
deep and sunken superior 
sulcus which could result 
in difficulties in access 
during XEN surgery. 
(Copyright Ingeborg 
Stalmans, MD; reproduced 
with permission)
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corneal incision is made at approximately 1 mm anterior to the limbus and an addi-
tional small incision is made nasally at the limbus. The anterior chamber is filled 
completely with a cohesive viscoelastic. The preloaded Xen injector is introduced 
across the anterior chamber through the main incision. The needle tip is aimed at the 
superonasal angle on the opposite side, ideally anterior to the pigmented trabecular 
meshwork and Schlemm’s canal. Intraoperative gonioscopy can be used to position 
the injector needle precisely, before perforating the sclera to enter the subconjuncti-
val space 2.5–3 mm behind the limbus. After ensuring that the entire bevel of the 
needle has exited the sclera and is within the subconjunctival space, the slider on the 
injector is moved forward. During the first half of the slider movement, the distal 
part of the implant is ejected from the needle tip into the subconjunctival space. 
Further movement of the slider forward results in the retraction of the needle into 
the injector while releasing the remainder of the implant in the sclera and anterior 
chamber. After the needle has fully retracted into the injector, it is removed from the 
anterior chamber. The position and the mobility of the subconjunctival segment of 
the implant are assessed and the correct length and position of the internal segment 
are confirmed by gonioscopy. Viscoelastic is removed from the anterior chamber 
and the incisions are hydrated (suturing is optional). The anterior chamber is irri-
gated and slightly pressurized to ensure that a filtration bleb is formed.
When XEN implantation is combined with phacoemulsification, cataract surgery 
is usually performed first. At the end of the cataract surgery, the anterior chamber is 
refilled with cohesive viscoelastic. XEN implantation can be performed through the 
main corneal incision used for phacoemulsification (if temporal) or an additional 
corneal incision can be made. The subsequent steps are similar to the solo procedure.
6.3.1  Avoiding Complications and Surgical Pearls
This section provides a step-by-step approach to the surgical procedure details, with 
practical recommendations on how to refine the surgical technique and to avoid and 
correct implant placement imperfections.
The surgeon can be seated superiorly or temporally. It is recommended that sur-
geons starting off with XEN implantation sit in their normal position for phacoemul-
sification, but also, as they gain confidence, try the alternative position. Similarly, 
there are several ways to hold the injector. The most comfortable hand position is 
also surgeon-dependent and is determined by a number of factors such as the hand 
size, the position of the surgeon relative to the patient, etc. However, holding the 
injector in the right hand when operating on a right eye and the left hand when oper-
ating on a left eye is advisable. Surgeons in training should try different seating and 
hand positions in the dry lab first, in order to find the most comfortable configuration. 
For the initial few cases, one should consider implanting pseudophakic patient with 
good surgical exposure and the right eye for the right-handed surgeon and vice versa. 
One should avoid implanting phakic patients until experienced with the technique.
The choice of anesthesia is also at the discretion of the surgeon. The majority of 
the procedures are performed under topical anesthesia, using anesthetic drops in 
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combination with an intracameral supplement (separately injected in the anterior 
chamber or as a combo-product with the viscoelastic) and/or subconjunctival anes-
thesia (either in combination with the hydro-expansive fluid or separately). When 
used subconjunctivally, the anesthetic can be complemented with adrenaline as a 
vasoconstrictor. Some surgeons prefer a sub-tenon, peribulbar, or retrobulbar anes-
thesia. The advantage of the latter is deeper anesthesia, ensuring a painless proce-
dure. In addition, for the novice, these provide akinesia, making the procedure 
easier. On the other hand, hydro-expansion may be more difficult because the 
patient cannot be instructed to look down to expose the posterior superior bulbar 
conjunctiva. We would encourage surgeons to move toward topical anesthesia when 
their techniques mature, because of the advantage of better access especially for 
hydro-expansion of the conjunctiva and delivery of MMC posteriorly into the fornix 
rather than at the limbus (Fig. 6.5).
To avoid excessive sub-conjunctival hemorrhage during hydro-expansion (which 
may obscure the implantation site and make the implantation procedure more chal-
lenging), a vasoconstrictor, such as topical apraclonidine (Iopidine®, Alcon, Fort 
Worth, Texas, USA) may be administered immediately prior to the surgery. This can 
counteract the hyperemia which is often caused by chronic glaucoma medication or 
pilocarpine administered preoperatively to constrict the pupil and protect the lens 
during standalone procedures. Alternatively, one can add adrenaline to the hydro- 
expansion fluid, as mentioned above or apply topical adrenaline. This has the poten-
tial disadvantage of pupil dilation, which can be prevented by preoperative topical 
pilocarpine. Ideally, one should use a fine (30G) needle for the hydro-expansion and 
carefully place the needle to avoid perforating conjunctival blood vessels. If sub- 
conjunctival hemorrhage does occur, one can immediately inject some fluid at the 
intended implantation site to prevent the blood from spreading to that area or com-
press the conjunctiva with a cotton tip and massage the blood away.
The use of antimetabolites in the hydro-expansion fluid is highly recommended. 
Although off-label, MMC is widely used in filtering surgery and accepted as com-
mon practice to prevent scarring and improve surgical outcomes. The concentration 
of the MMC can be titrated according to the patient profile which determines the 
anticipated scarring tendency (e.g., age, race, previous surgical history, etc.). The 
Fig. 6.5 Posterior 
injection of mitomycin-C 
used for intra-tenon’s 
hydroexpansion. 
(Copyright Ingeborg 
Stalmans, MD; reproduced 
with permission)
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dose typically used is 0.02 mg in a volume of 0.1 mL, although it can vary between 
0.01 and 0.05 mg. It is important to stress that the usage of MMC dosage greater 
than 0.02 mg is uncommon with the Xen and should be seen as exception rather 
than the rule, because of the higher risk of bleb avascularity and associated compli-
cations. To avoid an avascular bleb at the limbus and the risk of postoperative blebi-
tis or endophthalmitis in rare cases [2, 3], MMC is injected as far posteriorly as 
possible and massaged backward with a cotton tip if it spreads close to the limbus.
After hydro-expansion, the fluid ideally lifts the conjunctiva slightly at the 
intended implantation site, to reduce the risk of conjunctival perforation with the 
injector needle as it comes out of the sclera, without obscuring the implantation site 
due to excessive chemosis.
The inferotemporal incision is made 1 mm from the limbus in order to approach 
the implantation site at the appropriate angle. In a patient with a prominent cheek-
bone, the surgeon may want to rotate the eye slightly between the injector and the 
side instrument, such that the injector is rotated away from the patient’s cheek to a 
more temporal position. Alternatively, a more temporal incision may be considered, 
in combination with a more tangential approach to the superonasal angle rather than 
crossing the pupil axis (Fig. 6.6). A gentle face turn toward the temporal direction 
would also help to lower the cheekbone while the eye is brought slightly nasal to 
maintain a primary gaze during implantation. A nasal placement of the implant, 
however, is not recommended because of a higher incidence of dysesthesia from 
nasally placed blebs and potentially greater risk of implant erosion through the con-
junctiva in nasally placed implants (presumably because of rubbing of the eyelid 
over the implant) (Fig. 6.7).
A cohesive viscoelastic material is used to fill the anterior chamber, providing a 
stable anterior chamber during implantation. This can also be removed more easily 
and more completely than a dispersive viscoelastic. We would recommend filling up 
the anterior chamber firmly during implantation, as it is more difficult to pierce 
Fig. 6.6 Mild cyclo-
rotation of the eye during 
XEN Gel Implant surgery, 
associated with a tangential 
approach of the injector 
which does not cross the 
pupil axis, so as to 
facilitate access to the 
superior-nasal quadrant of 
the eye in a patient with 
prominent cheekbones. 
(Copyright Leon Au, 
FRCOphth; reproduced 
with permission)
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sclera with the injector needle when the eye is soft. Similarly, avoid an excessively 
large corneal incision which allows viscoelastic to escape. The incision site needs to 
be marginally larger than 20 gauge to accommodate the injector. While small phaco 
wounds may be satisfactory, larger wounds can result in significant viscoelastic 
loss. A combined viscoelastic with anesthetic may also be used to complement the 
topical anesthesia and prevent pain during the procedure.
While entering the eye with the injector through the main port, small sidewise 
movements may facilitate smooth entry through the incision with the needle. A side 
instrument is used to stabilize the eye during the needle placement and injection. 
Various instruments can be used for this purpose, e.g., the Vera hook (Katena, USA), 
an iris spatula or a Bonn toothed forceps to grasp the cornea in the side point. As 
mentioned above, it is advisable to place the implant close to the 12 o’clock posi-
tion, as nasal placement has been associated with bleb dysesthesia. Ideally, the 
implant is inserted between the pigmented trabeculum and Schwalbe’s line. More 
posterior placement is associated with a higher risk of blood reflux from Schlemm’s 
canal and ostium occlusion by the iris. More anterior placement can result in a very 
short intrascleral portion, instability of the implant and, occasionally, intracorneal 
placement. During the learning curve, it may be advisable to use an intraoperative 
indirect gonioscope to guide the injector needle while approaching the angle. 
However, with practice, the use of the gonioscope at this stage could later be omitted.
As the needle traverses the sclera, some forward pressure is required and the side 
instrument can serve to exert counterpressure. To reduce scleral resistance, and 
hence the amount of forward pressure on the injector required for placement, the 
injector can be gently rolled back and forth between the fingers creating a rotational 
movement of the needle. The needle should exit the sclera at 2.5–3 mm from the 
limbus. If necessary, the inserter can be tilted up- or downwards slightly during the 
insertion process to make the intrascleral portion longer or shorter. A longer intra-
scleral portion can reduce para-implant leakage and subsequent early hypotony, 
which may be more frequent in highly myopic eyes or those with thin sclera. A slow 
and controlled exit from the sclera is important to avoid puncturing the conjunctiva. 
There is a continuous debate about the ideal position of the implant in relation to the 
conjunctiva/tenon layers. Some surgeons prefer to aim the injector needle upwards, 
placing the implant in the superficial layers of the subconjunctival space, and 
increasing the chance of a freely mobile implant with easier drainage. In an ideal 
a b
Fig. 6.7 Nasal placement of the XEN Gel Implant could result in a large nasal bleb. (a) A large 
nasal bleb which results in significant bleb dysesthesia. (b) Anterior segment optical coherence 
tomography image of the nasal bleb in (a), showing a large bleb cavity. (Copyright Chelvin Sng, 
FRCSEd; reproduced with permission)
L. Au and I. Stalmans
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world, one would have the implant exit in the sub-Tenon’s space behind Tenons 
insertion to avoid a thin bleb and implant erosion and maximize the use of the 
potential space available. The counterargument is that visualization of the patency 
of the XEN in the sub-Tenon’s space is more difficult. Once the needle is fully 
advanced and the bevel has emerged completely from the sclera, the injector should 
be rotated 90° with the bevel facing the 12 o’clock position, before advancing the 
slider. During the first half of this manoeuver, the implant is ejected and during the 
second half, the needle is retracted. When the slider reaches the point of transition, 
a slight resistance can be felt in the finger moving the slider. At that point, one 
should pause, zoom out to get an overview of the cornea, and relax the hands to 
release any tension on either the injector or the side instrument. This is extremely 
important to avoid the so-called flicks, which are caused by tension on the injector 
during the retraction phase. At the point where the needle is retracted into the injec-
tor, the tip is released from the angle disengaging the anchorage. Any tension at that 
time can result in a flicking movement of the injector to one side or the other. This 
can drag the implant back into the anterior chamber causing an excessively long 
intraocular portion. The sudden movement can also result in a hemorrhage, an 
enlargement of the implantation canal or, in the case of a downward flick, iris 
trauma, and even cyclodialysis cleft formation in extreme cases.
When the injector is being retracted, the attention of the surgeon should therefore 
shift from the subconjunctival needle tip to the corneoscleral limbus. One should 
keep a forward bias on the injector to ensure constant contact between the injector 
and the angle. Only when the slider has reached the forward end of its travel (and 
therefore the needle is completely retracted), can the injector be removed safely 
from the anterior chamber. Premature removal can result in damage to the angle or 
dislocation of the implant. Common causes of suboptimal implant placement, most 
commonly implants that are too long in the anterior chamber, are incomplete needle 
advancement into the subconjunctival or sub-Tenon’s space, incomplete slider 
advancement, early injector retraction, and flicks.
After implantation, it is important to check the position and mobility of the 
implant by gently moving the implant sidewise in both directions using a blunt 
instrument. Ideally, the implant should be 1 mm in the anterior chamber, 2 mm in the 
sclera, and 3 mm in the subconjunctival space (the so-called 1–2–3 configuration, see 
Fig. 6.8). The subconjunctival part of the implant should be straight and freely mobile 
sidewise. If the implant is not freely mobile or is curled, because it is stuck in Tenon’s 
capsule (Fig. 6.9), the risk of occlusion by Tenon’s, postoperative fibrosis and bleb 
failure is higher, even if the implant functions initially. Many surgeons will perform 
a primary needling in this situation. A 30G needle is inserted under the conjunctiva 
at a distance from the implant, and the tip of the implant is approached carefully 
avoiding the blood vessels. The Tenon’s capsule is moved away from the implant by 
gently swiping over and under the implant with the needle, paying attention not to cut 
or pull out the implant. This maneuver should result in a straight and mobile implant. 
An alternative is to gently tease the implant using a pair of tying forceps. It is some-
times possible to free an implant from Tenon’s by this method.
If no bleb is visible after removal of the viscoelastic, the internal position of the 
implant should be checked by performing gonioscopy. The ideal position of the 
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Courtesy of Luís Abegão Pinto
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Fig. 6.8 The 1–2–3 configuration of the XEN Gel Implant. (a) The ideal placement of the 
XEN Gel Implant is 1 mm in the anterior chamber, 2 mm in the sclera, and 3 mm in the sub-
conjunctival space. (Copyright Allergan plc, reproduced with permission) (b) Gonioscopic 
photograph focused on the entry site of the XEN Gel Implant, which is ideally between the 
pigmented trabeculum and the Schwalbe’s line. (c) Gonioscopic photograph focused on the 
XEN Gel Implant which has an ideal intraocular segment of 1 mm. (d) Gonioscopic photo-
graph showing a XEN Gel Implant which has an intraocular segment which is too short. 
(Copyright Luís Abegão Pinto, MD; reproduced with permission)
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implant is between trabeculum and Schwalbe’s line as mentioned previously. The 
iris is often pushed backward by the viscoelastic and the implant may appear free. 
However, if the implant is more posterior than the trabeculum, particularly if it is in 
contact with iris root at the scleral entry site, there is a risk of iris incarceration after 
viscoelastic washout. In which case, one might consider removing and reinserting 
the implant. An internal length of 0.5–1.5 mm, ideally 1 mm, is acceptable. If neces-
sary, the length can be adjusted by gently grasping the extraocular portion of the 
implant through the conjunctiva with plain forceps and pushing it in or pulling it 
out. If the position of the implant is not satisfactory even after correction, removal, 
and reinsertion should be considered. To remove an implant, it may be convenient 
to first push the implant maximally into the anterior chamber using plain forceps 
e.g., Tying forceps. The implant can easily be removed from the anterior chamber 
using vitreoretinal forceps or aspirated using bimanual irrigation/aspiration. The 
injector needle is brought forward by moving the slider backward, the implant is 
placed in the needle again, and the insertion procedure is repeated. Care needs to be 
taken when handling the implant as it is now soft and can be fractured easily if 
excessive force is used. If there is any suspicion that the implant has been damaged, 
it would be more prudent to replace it with a new implant.
The final important point is the complete removal of the viscoelastic in the ante-
rior chamber, which may otherwise block the implant in the early postoperative 
period and induce pressure spikes and meticulous hydration of the corneal incision. 
If the incisions are not watertight, they should be sutured. Thorough irrigation of the 
anterior chamber should result in a filtering bleb at the end of the surgery. If a filter-
ing bleb is not visualized at the end of surgery, the implant and its position should 
be carefully examined and the procedure repeated if necessary. Intracameral antibi-
otics and subconjunctival steroids are recommended.
6.3.2  Postoperative Management
All pressure-lowering medications are discontinued immediately after the surgery. 
The typical postoperative regimen consists of a broad-spectrum topical antibiotic 
and intensive topical steroid (e.g., 2 hourly dexamethasone 0.1% or prednisolone 
Fig. 6.9 A curled and 
immobile XEN Gel 
Implant which is impeded 
by Tenon’s capsule. 
(Copyright Ingeborg 
Stalmans, MD; reproduced 
with permission)
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acetate 1%). After 2 weeks, the antibiotic eyedrop can be discontinued while topical 
steroids can be gradually tapered over a course of 8–10 weeks. A longer duration of 
topical steroid may be required in eyes with significant or persistent conjunctival 
hyperemia or in pigmented eyes, which are at risk of more significant conjunctival 
scarring.
Typically, the IOP is low over the initial postoperative days. Based on the Hagen–
Poiseuille’s law and the dimensions of the XEN Gel Implant, the IOP should theo-
retically be 6–8  mmHg if the fluid passes solely through the implant without 
resistance in the subconjunctival space. In reality, day one IOP is often lower than 
6  mmHg, presumably because the intrascleral canal produced by the injector is 
wider than the XEN Gel Implant, therefore allowing a small amount of para-tube 
leakage. In the days after the implantation, the outer diameter of the hydrophilic 
implant swells and its position in the sclera becomes tighter. Therefore the pressure 
after 1 week increases to typically around 10 mmHg.
Early hypotony usually resolves spontaneously in the first few postoperative 
days, requiring no additional treatment. If shallowing of the anterior chamber is a 
concern, a short-acting cycloplegic may be considered. Long-acting cycloplegics, 
such as atropine, are better avoided if the implant is posteriorly placed, because of 
the risk of obstructing the internal ostium of the implant with iris. In cases of signifi-
cant anterior chamber shallowing or rarely when hypotony lasts 1–2 weeks after 
surgery, if accompanied by significant visual disturbance, corneal–lenticular touch, 
choroidal effusion, or maculopathy, slit-lamp injection of a small amount of disper-
sive visco-elastic can be used to temporize. Cohesive viscoelastics should be 
avoided as they may induce spikes in pressure.
A high IOP level on the first postoperative days is rare, assuming that the steps 
outlined above have been followed during the implantation procedure. A high- 
pressure spike is very suggestive of a mechanical cause. Gonioscopy should be 
performed to confirm correct implant placement and to rule out any mechanical 
blockage, e.g., by iris, blood, or fibrin. The most frequent cause of an early high- 
pressure spike is incomplete removal of the viscoelastic, in which case the pressure 
usually recovers in the first postoperative week. In cases of pronounced pressure 
spikes, anterior chamber washout should be considered. A limited hyphema gener-
ally resolves spontaneously, but if persistent or associated with an elevated pressure, 
a washout may rarely be required, ideally after a few days delay in order to reduce 
the risk of a rebleed.
If high pressure develops after the first postoperative week(s), again blockage of 
the internal ostium of the implant should be excluded gonioscopically. Other causes 
to be considered at this stage are a steroid response in combination with bleb encap-
sulation, especially if the bleb appears elevated. If the internal ostium is patent and 
there is no visible bleb elevation, then fibrosis around the implant is the more likely 
cause of the high pressure and needling or bleb revision may be considered. Needling 
is really only feasible if the implant is visible, revision can be carried out in either 
scenario. Encapsulation and fibrosis tend to develop after 3–4 postoperative weeks. 
If IOP elevation develops after 1–2 weeks, reversible mechanical obstruction of the 
XEN, with Tenon’s rather actual fibrosis should be considered.
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Bleb revision is often performed under local anesthesia. A small fornix-based 
conjunctival peritomy is performed and the subconjunctival fibrosis is carefully dis-
sected off to expose the XEN implant. The implant is often wrapped in a “sock” of 
tenon’s tissue and a slow meticulous technique is required to free the implant with-
out damaging it (Fig. 6.10). Once the XEN implant is mobile, one should be able to 
detect a slow dripping of aqueous from its distal end. Visualization may be enhanced 
using fluorescein drops and/or Vision Blue. If not, the implant itself might be 
blocked and one should consider flushing the device using a lacrimal cannula on a 
syringe containing BSS. If the device appears patent externally and internally but no 
aqueous is seen egressing from the distal end, then a fresh device should be 
implanted. Removal of the original non-functioning implant is unnecessary but is 
easy to perform at the same time. If MMC is to be used during a revision, ideally it 
should be applied after opening the conjunctiva but before freeing the XEN, in order 
to avoid any chance of MMC reflux into the anterior chamber. After the revision is 
complete, conjunctiva is closed in a similar fashion as conventional trabeculectomy. 
The postoperative eyedrop regime is similar to standard XEN Gel Implant surgery.
6.4  Safety, Efficacy, and Clinical Results
The APEX study group reported the 2-year results of a multicenter, prospective, 
nonrandomized open-label study of the XEN Gel Implant surgery in medically 
uncontrolled open-angle glaucoma [4]. In 202 eyes with a mean preoperative medi-
cated IOP of 21.4 ± 3.6 mmHg, the IOP was significantly reduced to 14.9 ± 4.5 mmHg 
at 1  year and 15.2  ±  4.2  mmHg at 2  years (both p  <  0.001). Medications were 
reduced from 2.7 ± 0.9 preoperatively to 0.9 ± 1.1 at 1 year and 1.1 ± 1.2 at 2 years. 
Overall, 51.1% and 47.7% of eyes were medication-free at 1  year and 2  years, 
respectively. There was no difference in outcome between eyes which underwent 
XEN implantation as a stand-alone procedure and those that underwent combined 
phacoemulsification with XEN implantation. Success was defined as ≥20% IOP 
reduction with the same or fewer glaucoma medications and 65.8% of eyes achieved 
a b c
Fig. 6.10 XEN Gel Implant bleb revision. (a) A small fornix-based conjunctival peritomy is per-
formed. (b) Subconjunctival fibrosis is carefully dissected off to expose and free up the XEN Gel 
Implant. (c) Once the XEN Gel Implant is mobile and free, slow aqueous flow is visible from its 
distal end. (Copyright Ingeborg Stalmans, MD; reproduced with permission)
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that at 2 years. These findings are consistent with other published retrospective and 
prospective studies reporting the outcome at 1 year [5–10] (Table 6.1).
In the US pivotal trial, Grover et al. reported the 12-month outcome of XEN surgery 
in refractory glaucoma where 84.6% of patients had a previously failed glaucoma pro-
cedure and 56.9% required ≥4 IOP lowering agents [10]. The average visual field 
mean deviation was −15.0 ± 7.7 dB and the mean cup-to-disk ratio was 0.82 ± 0.13. 
Despite the advanced nature of this group, 75.4% of patients achieved ≥20% IOP 
reduction with same or fewer medications at 12 months, resulting in a mean postopera-
tive IOP of 15.9 ± 5.2 mmHg. Nine out of the 65 eyes (13.8%) did require a secondary 
glaucoma procedure during the 12 months period. It is worth noting that in this study, 
conjunctival peritomy was performed in all cases in order to apply the licensed MMC 
sponges (Mitosol, Mobius Therapeutics LLC, USA), which was different from our 
current implantation technique and could theoretically affect the outcome.
The postoperative needling rate of XEN surgery varies greatly. In the APEX 
study, the mean needling rate was 41.1% but it varied greatly between sites, ranging 
from 0% to ≥80% [4]. Over two-thirds of the needled eyes required only one epi-
sode and there was no difference between XEN alone and combined phaco-XEN 
surgeries. Similar needling rates were reported by others, supporting the importance 
of postoperative bleb management. [5–10]
The reported incidence of both intraoperative and postoperative complications 
was low. Numerical hypotony (IOP <6 mmHg) occurred in up to 20% of patients in 
the initial postoperative period but mostly resolved without interventions [4–10]. 
Other complications, including device obstruction by iris, conjunctival erosion 
resulting in implant exposure, endophthalmitis, and significant visual loss, were rare.
In a retrospective study, Schlenker and colleagues evaluated the outcome of XEN 
surgery versus trabeculectomy in uncontrolled glaucoma with no prior incisional 
surgery [11]. The results demonstrated no difference in efficacy, safety, and risk of 
failure between the two groups, with the XEN group favoring a quicker visual 
recovery but a higher needling rate.




















13 XEN and 
phaco-XEN
16 ± 4 12 ± 3 41.7% 30.7
Hengerer 
et al. [7]
242 XEN and 
phaco-XEN
32.2 ± 9.1 14.2 ± 4.0 55.4% 27.7
Mansouri 
et al. [8]
149 XEN and 
phaco-XEN
20.0 ± 7.1 13.9 ± 4.3 57.7% 37
Tan et al. 
[9]









L. Au and I. Stalmans
87
6.5  Off-Label Use
Although the XEN Gel Implant was licensed for use in open-angle glaucoma and 
refractory glaucoma uncontrolled with medications or prior glaucoma surgery, 
its filtering property resembles that of trabeculectomy hence could potentially be 
adopted in other subtypes of glaucoma. Sng and colleagues reported good effi-
cacy with the XEN Gel Implant as a treatment for uncontrolled uveitic glaucoma 
[2]. In their cohort of 24 consecutive patients, XEN Gel Implant surgery achieved 
a remarkable 60.2% IOP reduction from a high baseline IOP of 30.5 ± 9.8 mmHg 
typically found in uveitic patients; 83.3% of patients avoided further surgery at 
1 year. Nevertheless, caution should be exercised when considering the XEN Gel 
Implant for uveitic eyes due to the significantly higher risk of postoperative 
hypotony. In Sng’s series, 20.8% of patients required anterior chamber reforma-
tion for hypotony. In addition, the implant could be occluded by inflammatory 
debris in uveitic eyes or by hypotonic/atrophic iris tissue if the position is too 
posterior. Angle closure is currently considered a contraindication for XEN 
implantation. In a case series of 19 angle-closure eyes, Sng et al. reported that 
combined XEN implantation with cataract surgery significantly reduced the IOP 
(11.7 ± 3.0 vs. 21.7 ± 3.7 mmHg, p < 0.001) and the number of glaucoma medi-
cations (0.2  ±  0.5 vs. 1.4  ±  0.7, p  <  0.001) compared to baseline. The safety 
profile of XEN implantation in their small case series was similar to that reported 
for POAG eyes, though implant occlusion with iris occurred postoperatively in 
one angle closure eye [12]. However, they could not determine the additional 
effect of XEN implantation in lowering the IOP compared with phacoemulsifica-
tion alone, and a randomized study comparing phacoemulsification alone with 
the combined procedure in angle-closure eyes is warranted. Successful XEN sur-
gery has also been reported in patients with ICE syndrome and endothelial trans-
plant as well as refractory glaucoma with previously failed trabeculectomy and 
two Ahmed valves [13, 14]. D’Alessandro and colleagues reported a novel com-
bination of the XEN Gel Implant and the Baerveldt tube in the treatment of dif-
ficult refractory glaucoma [15]. It offers the potential advantage of immediate 
drainage of the XEN Gel Implant and the posterior diversion of aqueous over a 
large plate of Baerveldt implant. The smaller XEN implant in the anterior cham-
ber is potentially more endothelial friendly than the larger glaucoma drainage 
implant. However, constant friction between the XEN Gel Implant and the much 
large Baerveldt tube may risk longer term implant fracture at this junction, 
thereby disconnecting the Baerveldt from the anterior chamber. There are also 
concerns that the XEN may slip out of the tube unless it is sutured securely, as 
the external diameter of the XEN is significantly less than the internal diameter 
of the Baerveldt. In addition, connecting the Baerveldt tube with the XEN Gel 
Implant does not necessarily prevent early postoperative hypotony, which can be 
a consequence of peri- implant aqueous flow [16]. Notably, most of these novel 
applications of XEN were performed in small numbers and their longer term 
results are yet to be determined.
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6.6  Conclusion
The XEN Glaucoma Treatment System is currently the only procedure that targets 
the subconjunctival filtering space through an ab-interno approach. It offers a more 
significant reduction in IOP and medications than other ab-interno MIGS proce-
dures. However, it is also arguably more technically demanding and a meticulous 
surgical approach is paramount. The creation of a filtering bleb requires careful 
pre- and postoperative management in order to secure success.
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7.1  Introduction
Reducing intraocular pressure (IOP) remains the only proven treatment to prevent 
vision loss from glaucoma [1–3]. Under-treatment of glaucoma remains a signifi-
cant issue and inadequate IOP reduction can increase the risk of vision loss [4]. 
Traditionally, trabeculectomy has been regarded as the gold standard in glaucoma 
surgery since it was described in the 1960s [5]. However, while one of the most 
effective IOP-lowering treatments, severe adverse events can occur, recovery can be 
prolonged and intense post-operative management is required.
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Trabeculectomy is well-recognized to achieve significant and sustained reductions 
in IOP. In the tube versus trabeculectomy (TVT) study the mean IOP following trab-
eculectomy was 12.6 mmHg at 5 years. However, 37% of patients in this study devel-
oped complications in the early perioperative period and 18% required re-operation 
[6]. Furthermore, there is a significant surgical learning curve associated with trabecu-
lectomy and a high level of surgical skill is required [7]. Intensive postoperative fol-
low-up is mandatory to achieve optimum outcomes and perioperative interventions 
are frequent, with up to 78% of cases requiring some form of bleb manipulation and/
or suture removal [8]. Although rare, sight- threatening complications following trab-
eculectomy can occur and include hypotony, choroidal effusions and suprachoroidal 
haemorrhage among others [6]. For these reasons, trabeculectomy is often reserved 
for late in the disease process when other treatments have failed [9].
The PRESERFLO® MicroShunt (Santen Pharmaceutical Co. Ltd., Osaka, 
Japan)  is a new glaucoma drainage microtube that has been developed with the 
intention to provide significant and long-term IOP and glaucoma medication reduc-
tion similar to that of trabeculectomy but in a simpler, safer and less-invasive opera-
tion with faster recovery than conventional surgery. This chapter summarizes the 
development, lab testing, pre-clinical studies and human clinical trials for the 
MicroShunt.
7.2  Device Design and Development
There have been three major iterations in the design of the shunt to enhance ease of 
insertion, minimize complications and improve success rates. The final design, the 
PRESERFLO MicroShunt, is 8.5 mm long with an internal lumen of 70 μm and an 
outer diameter of 350 μm (Fig. 7.1). It received a CE mark in 2012. The length of 
the device was designed to achieve 1–2 mm in the anterior chamber, 3 mm within 
the sclera and 3 mm posterior to the needle tract wound. These dimensions summed 
to 8.5 mm in length. The lumen diameter was then approximated with the Hagen–
Poiseuille equation to provide sufficient resistance to limit hypotony given pub-
lished aqueous humour flow rates and viscosities [11]. The shunt is made of 
poly(styrene-block-isobutylene-block-styrene) or ‘SIBS’ material. The anterior end 
is bevelled to facilitate entry into the scleral tunnel and anterior chamber and is 
8.5 mm long
3 mm distal length
4.5 mm tip connects the anterior







Tail allows aqueous to
drain to the bleb
Fig. 7.1 PRESERFLO® MicroShunt. (Copyright Santen Pharmaceutical Co. Ltd., Osaka, Japan; 
reproduced with permission)
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faced towards the cornea to enable visualization and clearing of the lumen if 
obstructed. Fixation fins are located approximately half-way down the shunt and 
serve three important functions. The fins fit snugly within the scleral tunnel and are 
designed to prevent leakage of aqueous around the tube, stop migration of the tube 
into the anterior chamber and orientate the shunt so that the bevel faces the cornea. 
The final design does not have a plate, reducing the complexity of insertion and 
minimizing the risk of diplopia.
The initial design, called the MIDI-Tube (an acronym for Miami InnFocus 
Drainage Implant), was trimmed in situ by the surgeon to approximately 11 mm 
long with an internal lumen of 70 μm and an outer diameter of 250 μm (Fig. 7.2). 
Early animal studies assessed the effect of lumen size on IOP lowering and found 
fewer complications and comparable IOP levels with a 70 μm lumen compared to 
larger 100 μm and 150 μm lumens [10]. A single fixation tab was located on one 
side to prevent migration into the anterior chamber and to enable insertion through 
a slotted needle with the fin protruding through the slot. The device was inserted 
through the scleral tunnel using this slotted needle inserter, however, due to the soft 
and flexible characteristics of the tube it would frequently jam in the inserter, and 
the surgeon would instead simply thread the MicroShunt through the scleral tunnel 
with forceps. The initial success rate, defined as an IOP ≤ 21 mmHg with a reduc-
tion from baseline of ≥20%, was low at 42% at 1 year in early human clinical trials 
[11]. However, it should be noted that in the first human trial (Bordeaux I), antime-
tabolites were not used and more than half of the patient population had failed previ-
ous glaucoma surgeries. In a subsequent clinical trial of 16 patients with previous 
failed incisional surgery (Bordeaux II), mitomycin-C (MMC) 0.2  mg/mL was 
applied for 2–3 min to only the sclera in the vicinity of the tube, and the success rate 
increased to 67% at 1 year [11].
A second-generation device, called the MIDI-Ray as it resembled a sting ray, 
was developed comprising a larger tube measuring 12 mm in length with an outer 
diameter of 350 μm, internal lumen of 100 μm connected to a plate 7 mm in diam-
eter (Fig. 7.2) [11]. It was hypothesized that the plate would prevent encapsulation 
and eliminate the need for anti-metabolites [11]. However, the device had a high 
rate of hypotony due to the larger diameter tube and undesirable cystic bleb mor-

















The MIDI-Tube The MIDI-Ray The PRESERFLO
® MicroShunt
(AKA InnFocus MicroShunt® and 
MIDI-Arrow)
a b c
Fig. 7.2 The three major iterations in the design of the glaucoma shunt: (a) the MIDI-Tube; (b) 
the MIDI-Ray and (c) the PRESERFLO® MicroShunt, which is the final design. (Copyright Santen 
Pharmaceutical Co. Ltd., Osaka, Japan; reproduced with permission)
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The third-generation device, called the MIDI-Arrow, comprised of symmetrical 
planar fins with a wingspan of 1.1  mm located midway along the length of an 
8.5 mm SIBS tube with a 350 μm outer diameter and a 70 μm lumen. The MIDI- 
Arrow name was dropped due to concerns about patients believing an arrow would 
be placed in their eye. At that time, many of the implanting surgeons simply called 
the device the ‘InnFocus device’ or the ‘InnFocus procedure’, therefore the device 
was called the InnFocus MicroShunt®, often referred to as simply the ‘IMS’. 
Santen Pharmaceutical Co. Ltd. acquired InnFocus Inc. in May 2016 and 3 years 
later renamed the device the PRESERFLO MicroShunt (Fig. 7.3).
7.3  Development of SIBS
Inflammation and fibrosis in the subconjunctival space may lead to surgical failure. 
Therefore, the selection of a biocompatible material that produces minimal inflam-
mation is important to increase success. Traditional glaucoma drainage devices 
such as the Molteno (Molteno Ophthalmic Limited, Dunedin, New Zealand) or 
Baerveldt (Abbott Medical Optics, Santa Ana, CA) have been shown to elicit intense 
a
b
Fig. 7.3 Anterior 
segment photograph 
showing (a) the 
PRESERFLO® 
MicroShunt in the 
anterior chamber and (b) 
a diffuse bleb associated 
with the PRESERFLO® 
MicroShunt. (Copyright 
Chelvin Sng, FRCSEd; 
reproduced with 
permission)
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inflammatory reactions with multinucleated giant cells and the deposition of dense 
fibrous tissue surrounding the implants [12, 13].
Conventional implant materials such as polyether urethane slowly degrade in the 
body due to hydrolysis and oxidation [14]. This degradation attracts granulocytes 
(e.g. polymorphonuclear leukocytes) and macrophages leading to a foreign body 
reaction and capsule formation; features undesirable for a subconjunctival filtration 
device [15]. Silicones are more biostable than the polyurethanes but are often con-
taminated with unreacted starting materials as well as fillers and elicit a foreign 
body reaction [14]. The PRESERFLO MicroShunt is made of ultrapurified medical- 
grade poly(styrene-block-isobutylene-block-styrene) or SIBS, a novel biostable and 
biocompatible synthetic polymer devoid of cleavable group such as amides, esters, 
ureas, carbamates, etc. on both its backbone and side groups. First approved for 
medical use in 2004, SIBS has been widely used in cardiac stents due to its lack of 
biodegradation, absence of platelet activation, minimal tissue reaction and ability to 
be used as a drug-eluting system [16, 17].
Poly(styrene-block-isobutylene-block-styrene) is a synthetic polymer devoid of 
any sites prone to degradation by mechanisms such as oxidation, hydrolysis or 
enzymatic degradation (Fig. 7.4) [16]. Consisting of stable alternating secondary- 
and- quaternary carbons, SIBS is not prone to double bond formation that could lead 
to embrittlement or stress cracking [16]. Synthesized by cationic polymerization, 
SIBS can be injection and compression moulded and is stable under harsh condi-
tions [18]. The SIBS material is soft and flexible and will conform to various shapes 
without surface cracking [19]. In addition, SIBS is a thermoformable material and 
will assume the shape it is placed in without a tendency to straighten as do the sili-
cones tubes which are thermoset materials that tend to straighten over time. Silicones 
need to be secured in place, usually covered with a patch graft, in contrast to SIBS 
tubes which assume the shape of the globe. SIBS is sterilizable with ethylene oxide 
but not gamma-ray irradiation [19].
The biocompatibility of SIBS has been established in both animal and human 









Fig. 7.4 Simplified structure of poly(styrene-block-isobutylene-block-styrene), or ‘SIBS’. (Copy
right Santen Pharmaceutical Co. Ltd., Osaka, Japan; reproduced with permission)
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of normal rabbit eyes and compared against discs of silicone rubber [20]. The sili-
cone discs showed angiogenesis, myofibroblasts and capsule formations, whereas 
there was no angiogenesis, myofibroblasts, nor intact capsules surrounding the 
SIBS material [20]. Further studies investigated the biocompatibility of a glaucoma 
drainage device made from SIBS in normal New Zealand white rabbits [21]. 
Glaucoma drainage devices made of SIBS were implanted into the anterior chamber 
while the distal tip was placed in the subconjunctival space [21]. Control animals 
underwent insertion of a similarly designed silicone tube [21]. At 3 months, haema-
toxylin–eosin staining revealed abundant collagen IV deposition around the silicone 
tubes with expression of alpha-smooth muscle actin [21]. In comparison, eyes 
implanted with the SIBS device showed a distinct absence of myofibroblasts, 
inflammatory cells and fibrosis [21]. In addition, encapsulation and neovascularisa-
tion were not observed in the SIBS group.
Glaucoma device patency was assessed by injection of fluorescein into the ante-
rior chamber. All SIBS tubes remained patent out to 6 months while only two of the 
six silicone tubes were patent at 3 months [21].
7.4  Clinical Data
The safety and efficacy of the PRESERFLO MicroShunt have been evaluated in a 
number of clinical trials. In a multicentre, retrospective clinical trial, Beckers et al. 
reported the results of 91 patients with open-angle glaucoma who underwent either 
stand-alone MicroShunt insertion (n  =  73) or combined cataract surgery and 
MicroShunt insertion (n = 18) [22]. All cases received MMC, but a varying concen-
tration (0.2–0.4 mg/mL on sponges for 2–3 min). At 12 months, the mean IOP had 
reduced from a baseline of 24.3 mmHg on 2.4 medications to 13.3 mmHg on 0.4 
medications with 83% of patients off all glaucoma medications [22]. The most com-
mon adverse event was transient numerical hypotony, occurring in 11% of patients 
[22]. All cases of hypotony resolved without intervention [22].
A second clinical trial examined the effect of MMC concentration on surgical 
outcomes [23]. In this retrospective two-centre study, patients with open-angle glau-
coma were implanted with either the MicroShunt alone (n = 66) or in combination 
with cataract surgery (n = 21) [24]. Patients received either MMC 0.2 mg/mL near 
the limbus, MMC 0.4 mg/mL near the limbus or MMC 0.4 mg/mL deep in the sub-
conjunctival conjunctival space [23]. For all patients, the duration of MMC expo-
sure was 2–3 min. Overall there was a reduction in IOP and glaucoma medication 
requirements in all groups with the lowest IOP being in patients treated with MMC 
0.4 mg/mL near the limbus [23]. In these patients, IOP reduced from a mean of 
23.8 ± 5.3 mmHg on 2.4 ± 0.9 medications at baseline to 10.7 ± 2.8 mmHg on 
0.3 ± 0.8 medications at 12 months [23]. There were no sight-threatening events in 
any group [23].
The patients who received MMC 0.4 mg/mL near the limbus were followed pro-
spectively and the results presented at 2 and 3  years [16, 24]. All patients had 
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primary open-angle glaucoma and had failed maximum tolerated medical therapy 
[16]. Patients with failed subconjunctival filtration surgery were excluded [16]. 
From a baseline IOP of 23.8 ± 5.3 mmHg on maximum tolerated medication ther-
apy, 100% of patients achieved an IOP of 18 mmHg or lower at both 1 and 2 years 
[16]. The most common adverse events were mild and consisted of transient shallow 
anterior chamber and IOP < 5 mmHg (3/23, 13%) [16].
At 3 years, 100% of the patients continued to achieve an IOP ≤ 18 mmHg and 18 
(82%) had an IOP of ≤14 mmHg [24]. The mean IOP at 3 years was 10.7 ± 3.5 mmHg, 
representing a 50% reduction in IOP [24]. Mean medication usage reduced from a 
baseline of 2.4 ± 0.9 medications to 0.7 ± 1.1 and 80% of patients were off glau-
coma medications [24]. There were no sight-threatening complications and no 
patient lost >1 line of visual acuity [24]. The most common adverse events were 
transient hypotony (3/23, 13%) and transient choroidal effusions (2/23, 8.7%) [24]. 
All resolved spontaneously [24]. There were no cases of bleb leak, infection, tube 
exposure or persistent corneal oedema [24].
In August 2019, Santen Pharmaceutical announced the results of the US premar-
ket approval (PMA), head-to-head study of the PRESERFLO MicroShunt versus 
trabeculectomy [25]. This prospective, randomized, controlled, single-masked, 
multicentre study compared standalone MicroShunt implantation with intraopera-
tive 0.2 mg/mL MMC against stand-alone trabeculectomy with the same concentra-
tion of MMC. At 12 months, mean (± standard deviation) diurnal IOP was reduced 
from 21.1 ± 4.9 mmHg to 14.2 ± 4.4 mmHg in the MicroShunt group and from 
21.1 ± 5.0 mmHg to 11.2 ± 4.2 mmHg in the trabeculectomy group. The mean num-
ber of glaucoma medications at month 12 was reduced in both groups, from 3.0 
medications at baseline to 0.6 in the MicroShunt group and 0.3 in the trabeculec-
tomy group, with 71.6% of subjects in the MicroShunt group being medication-free 
compared with 84.8% of subjects in the trabeculectomy group. Although the 
12-month IOP was statistically lower in the trabeculectomy group compared with 
the MicroShunt group, trabeculectomy was associated with a greater incidence of 
hypotony at any time (51.1% vs. 30.6%), bleb leaks and lens opacity.
7.5  Patient Selection
The PRESERFLO MicroShunt is indicated for patients with open-angle glaucoma 
refractory to medical therapy. The MicroShunt can be performed alone or in combi-
nation with cataract surgery for patients with both refractory glaucoma and visually 
significant cataract. The MicroShunt provides a simple and fast alternative to pri-
mary trabeculectomy and eliminates the need for scleral flap dissection, iridectomy 
and post-operative suture lysis. Once efficacy and safety are fully established, the 
MicroShunt may allow for an earlier transition to surgical management. Because a 
significant proportion of patients are medication-free following the MicroShunt 
procedure compared to other MIGS procedures, it may be especially suited for 
patients with intolerance to topical glaucoma medications or adherence problems. 
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Due to its ability to achieve IOP in the low to mid-teens, the MicroShunt may be 
appropriate for patients with more advanced disease, unlike some other minimally 
invasive procedures. The MicroShunt can theoretically be placed in any quadrant, 
however as with trabeculectomy, prior failed subconjunctival filtration surgery may 
reduce surgical success rates. Inferior placement may increase the risk of bleb- 
related infection and is not recommended.
The PRESERFLO MicroShunt may be useful in the treatment of angle-closure 
glaucoma when combined with cataract surgery or in pseudophakic patients. 
Because the PRESERFLO MicroShunt shares features of both trabeculectomy and 
a glaucoma drainage device, it may potentially have a role in conditions such as 
iridocorneal endothelial cell syndrome, uveitic glaucoma and neovascular glau-
coma. However, at the present time, there is limited data on the efficacy and safety 
of the device for these off-label indications.
7.6  Surgical Technique
The PRESERFLO MicroShunt comes in a sterile pre-packaged kit containing a 
3 mm marking ruler, marking pen, sponges to apply MMC, a 1 × 1 mm triangular 
slit keratome knife to create a scleral pocket, and either a 25G or 27G needle.
The procedure is most commonly performed under a local anaesthetic block and 
the preferred site for implantation is superiorly at 11 or 1 o’clock (Fig. 7.5). Initially, 
a 6- to 8-mm wide peritomy is made at the limbus before Westcott scissors are used 
to dissect posteriorly for 8–10  mm, ensuring to dissect under Tenon’s capsule. 
Bipolar diathermy is then used to achieve haemostasis before MMC application. 
Three sponges soaked in MMC, typically between 0.2 and 0.4 mg/mL, are placed 
under Tenon’s for 3 min before irrigation with >20 mL of normal saline. Care should 
be taken to apply the sponges close to the limbus as well as deep in the flap. The 
1 2 3 4
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Fig. 7.5 PRESERFLO® MicroShunt implantation. (Copyright Santen Pharmaceutical Co. Ltd., 
Osaka, Japan; reproduced with permission)
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ruler is used to mark 3 mm and a scleral tunnel fashioned with a slit keratome for 
2 mm. A 25G needle is passed within the scleral tunnel to the apex before entering 
the anterior chamber in the plane of the iris and away from the corneal endothelium. 
The MicroShunt is inserted into the scleral tunnel with forceps and the wings 
secured within the tunnel (Fig. 7.6). The distal end is observed for flow (Fig. 7.7). If 
there is no flow, gentle pressure can be applied to the globe or the shunt can be 
flushed with a thin-walled 23G cannula if required. The distal end is tucked under 
Tenon’s, which is advanced with the conjunctiva back to the limbus prior to con-
junctival closure. The distal end should be checked to ensure it is not occluded with 
Tenon’s and lastly it should be verified that there is no leak.
a b
c d
Fig. 7.6 Insertion of the PRESERFLO® MicroShunt. (a) A mark is made 3 mm from the surgical 
limbus. (b) A 2-mm shallow tunnel is formed in the sclera using a slit knife. (c) A 25-guage needle 
is passed through the tunnel to enter the anterior chamber. (d) The MicroShunt is inserted through 
the needle tract with the bevel up until the wedges are locked in the scleral incision. 
(Copyright Moorfields Eye Hospital and Keith Barton; reproduced with permission)
a b
Fig. 7.7 The PRESERFLO® MicroShunt drains aqueous from the anterior chamber to the subcon-
junctival/subtenon space. (a) The proximal tip of the MicroShunt positioned in the anterior cham-
ber. (b) Egress of aqueous from the distal end of the MicroShunt. (Copyright  Moorfields Eye 




7.7.1  Intraoperative Complications
Intraoperative complications are uncommon with the PRESERFLO MicroShunt. 
Potential complications include hyphaema or malposition of the shunt with occlusion 
by iris or placement of the tip of the device close to the endothelium with risk of endo-
thelial cell damage. These are theoretical risks with any glaucoma drainage device 
inserted into the anterior chamber and can be avoided with careful surgical technique. 
Observation of the device directly through the cornea or with the aid of a goniolens 
can confirm safe placement of the device and in the event the surgeon is not pleased 
with the placement, the device can simply be pulled out of the scleral tunnel and repo-
sitioned in a new tunnel. Confirmation of flow through the device is indicative of no 
periannular leakage as well as non-obstruction of the tube lumen by iris or cornea.
7.7.2  Early Postoperative Complications
Extreme IOP fluctuations within the first week post-operatively with the MicroShunt 
are rare. Conventional drainage devices such as the Molteno or Baerveldt valves 
require tying off of the tube lumen to prevent hypotony as well as fenestration of the 
tube to allow some flow of aqueous humour to maintain the bleb. Similarly, trabecu-
lectomy requires suture tension on the scleral flap to prevent immediate hypotony. 
These subjective procedures provide a myriad of pressure excursions within the first 
week post-operatively. The MicroShunt is a fixed flow resistor and the pressure 
excursions are reduced to a standard deviation of ±4–5 mmHg which can be half 
that of the aforementioned filtering devices.
Potential early post-operative complications include hyphaema (Fig.  7.8), 
obstruction of the tube (Fig. 7.9), wound leak and hypotony. Transient numerical 
hypotony is the most common complication and can be managed with observation. 
If there is shallowing of the anterior chamber or large choroidal effusions, 
Fig. 7.8 Hyphaema 
associated with the 
PRESERFLO® 
MicroShunt. (Copyright 
Chelvin Sng, FRCSEd; 
reproduced with 
permission)
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cycloplegics can be commenced and if necessary, injection of viscoelastic into the 
anterior chamber can be performed. The patient should be observed closely for 
intraocular pressure spikes if viscoelastic is injected into the anterior chamber. Tube 
obstruction from iris is a concern if the internal end of the Microshunt is posteriorly 
located and close to the iris (Fig. 7.9b), and YAG laser or a needle can be used to 
remove iris from the tip if required. Obstruction of the tube with fibrin or inflamma-
tory debris is usually transient and self-resolving with topical steroids. Wound leaks 
may be present if conjunctival closure was inadequate. Leaks will usually settle 
with conservative management, such as bandage contact lenses for anterior leaks. 
Aqueous misdirection is rare with this device. Similarly, decompression retinopathy 
has not been observed but is a theoretical concern if there is hypotony.
7.7.3  Late Complications
As with trabeculectomy, bleb encystment can occur and may require needling and/
or bleb revision. Both needling and bleb revision are typically performed with anti-
metabolites to modulate would healing. Erosion or migration of the shunt is 
a
b
Fig. 7.9 Obstruction of 
the PRESERFLO® 
MicroShunt with (a) a 
blood clot and (b) iris. 
(Copyright Chelvin Sng, 




fortunately rare and can be managed with revision of the shunt and bleb. Blebitis 
and endophthalmitis have not been reported following MicroShunt implantation but 
are potential complications of any glaucoma filtration procedure which creates a 
bleb. Persistent hypotony on two consecutive visits beyond 90 days has not been 
reported. Lastly, corneal decompensation is a potential complication but this risk 
can be reduced by preventing the shunt or MMC from coming into contact with the 
endothelium.
7.8  Conclusion
The PRESERFLO MicroShunt is a promising new device that offers substantial 
reductions in IOP, rivalling those seen with trabeculectomy, in a less invasive and 
safer procedure. Its improved safety profile may permit earlier surgical intervention 
in glaucoma management.
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The suprachoroidal outflow pathway has the potential to reduce the intraocular pres-
sure (IOP) dramatically, as the pressure gradient between the anterior chamber and 
the suprachoroidal space/uveal capillaries (colloidal osmotic pressure) permits flow 
even when IOP is very low. Compared with trabecular bypass minimally invasive 
glaucoma surgery (MIGS) devices, suprachoroidal MIGS harnesses a pathway that 
has a much greater IOP-lowering potential as suprachoroidal aqueous drainage is 
not dependent on the episcleral venous pressure. However, this pathway has a higher 
risk of severe and prolonged hypotony, because of the greater pressure gradient. The 
reason that most patients do not develop severe hypotony is because of fibrosis in 
the suprachoroidal space which restricts aqueous draining from the anterior cham-
ber through the device from exiting the device into the suprachoroidal space. This 
may limit the long-term success of suprachoroidal devices [1].
8.2  Physiology of the Suprachoroidal Outflow Pathway
The natural suprachoroidal outflow pathway drains aqueous from the anterior cham-
ber to the suprachoroidal space via the ciliary muscle [2]. Though the existence of 
this drainage pathway was proposed more than a century ago, it was poorly under-
stood until monkey studies by Bill et al. in the 1960s allowed its physiology to be 
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better defined [3, 4]. Aqueous permeates through ciliary muscle, the principal site of 
outflow resistance [3, 5], to the supraciliary and suprachoroidal spaces which exert 
a negative pressure. This outflow is IOP-independent over a wide range of IOP 
(4–35 mmHg) [3, 6, 7]. Aqueous exits the eye from the suprachoroidal space via 
two distinct drainage routes: the uveoscleral route (larger molecules: from the 
suprachoroidal space through the sclera to the orbit) and the uveovortex route 
(smaller molecules: from the suprachoroidal space to the uveal capillaries and the 
vortex veins). Of the two drainage routes, the uveovortex drainage pathway is the 
predominant pathway and is dependent on the difference in the colloid osmotic 
pressure between the uveal interstitial fluid (low) and the uveal capillaries (high) as 
well as the intraocular hydrostatic pressure [3, 8].
8.3  Early Surgical Approaches
It is surgically possible to bypass the ciliary muscle pathway, described above, by 
disrupting the attachment of the ciliary body to the scleral spur, hence allowing 
aqueous to flow directly between the anterior chamber and the suprachoroidal space. 
In 1905, Heine described a technique of cyclodialysis performed ab externo through 
the sclera using a spatula [9, 10]. Modifications of the technique were proposed in 
the twentieth century to prevent closure of the cleft, including the implantation of 
tissue or other material [11–13].
Unfortunately, these techniques caused significant ocular trauma and their effi-
cacy in lowering the IOP was unpredictable with a high proportion of eyes develop-
ing prolonged hypotony followed by significant IOP spikes after spontaneous cleft 
closure, hence they were abandoned. Moreover, complications including supracho-
roidal haemorrhage, hyphaema and secondary cataract were frequent. Nevertheless, 
this pathway is still unique in its impressive IOP-lowering potential, hence various 
modifications in the surgical technique of trabeculectomy [14, 15], non-penetrating 
glaucoma surgery [16] and glaucoma drainage devices [17] have been proposed 
over the years in vain attempts to utilize suprachoroidal drainage in addition to 
external filtration. Although these modifications did not result in higher complica-
tion rates compared with the conventional surgical techniques, neither did they 
improve efficacy.
8.4  Ab-Externo Suprachoroidal Devices
To avoid the complications associated with excessive filtration, some means of con-
trolling the rate of aqueous outflow to the suprachoroidal space is required. Hence, 
several ab-externo suprachoroidal devices have been introduced, pioneered by the 
Gold Glaucoma Shunt (GGS, SOLX Ltd., Waltham, MA, USA) and followed by the 
STARflo Glaucoma Implant (iSTAR Medical, Isnes, Belgium) and the Aquashunt 
(OPKO Health Inc., Miami, FL, USA). Despite a sophisticated design incorporating 
flow control to prevent early hypotony with the GGS, long-term efficacy was poor 
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as fibrosis and encapsulation developed around the device [18, 19]. Conjunctival 
peritomy and scleral flap dissection are also required in order to implant such ab- 
externo suprachoroidal devices, which added to the risk of scarring and, addition-
ally, there was a concern that the GGS might also result in significant corneal 
endothelial cell loss because of its positioning. Hence, this has led to the develop-
ment of ab-interno suprachoroidal MIGS devices, which are conjunctiva-sparing 
and less invasive.
8.5  Ab-Interno Suprachoroidal MIGS Devices
The emergence of MIGS has revolutionized glaucoma surgery [20]. The high safety 
profile of MIGS permits earlier use of surgery in the glaucoma treatment algorithm. 
Ab interno suprachoroidal MIGS devices are implanted through a corneal incision, 
hence spare the conjunctiva. Compared with ab-externo suprachoroidal devices, the 
potential advantages of accessing the suprachoroidal space with an ab-interno 
MIGS device are obvious, including less trauma, better safety profile  and less 
inflammation and scarring. However, as with ab-externo suprachoroidal devices, 
the long-term efficacy of ab-interno devices may also be limited by scarring in the 
suprachoroidal space.
8.5.1  CyPass Micro-Stent
The CyPass Micro-Stent (Alcon Laboratories, Inc., Fort Worth, Texas, USA) was 
the first commercially available suprachoroidal MIGS device (Fig. 8.1). Originally 
developed by Transcend Medical, the CyPass Micro-Stent was a 6.35-mm polyam-
ide tube with a 430-μm external diameter and a 300-μm lumen. After implantation 
into the suprachoidal space, it permitted unrestricted flow between the anterior 
chamber and the suprachoroidal space. The CyPass Micro-Stent had fenestrations 
(76-μm pores) along its length, to facilitate additional lateral flow and three reten-
tion rings at the proximal end, which acted as reference points for device position 
during implantation.
8.5.1.1  Surgical Technique
The CyPass Micro-Stent was inserted ab interno into the suprachoroidal space via 
a clear corneal incision. First, the device was loaded onto the retractable guidewire 
of the applier, assuming the same curvature as the applier guidewire, thereby facili-
tating insertion into the suprachoroidal space along the scleral contour. To obtain a 
good view of the anterior chamber angle, the patient’s head was tilted away from the 
surgeon and the microscope tilted towards the surgeon. The device was inserted via 
a 20-gauge corneal incision diametrically opposite to the implantation site after 
pharmacological miosis and filling the target area with cohesive viscoelastic. The 
goniolens was placed on the cornea and the applier inserted through the corneal 
incision (Fig.  8.2). The blunt tip of the applier guidewire was slowly advanced 
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between scleral spur and ciliary body, ensuring no iris movement when entering the 
angle. If the guidewire was inserted into the correct tissue plane and, if the insertion 
angle were correct, very little resistance would be encountered when inserting the 
device between ciliary body and sclera. The curvature of the applier guidewire per-
mitted the CyPass Micro-Stent to advance along the scleral curvature. Once the 
CyPass Micro-Stent was at the correct depth, depression of the release button 
allowed the guidewire to retract. Ideally, the device was positioned so that the rim 
of the collar was at the upper border of the trabecular meshwork. After implantation 
of the CyPass Micro-stent, the viscoelastic was removed completely and the corneal 
incision sealed by hydration. A demonstration of the technique is available online 
(www.youtube.com/watch?v=_WXNL0CoJws&list=UUnkpnhwaQCC4Ary7gIyX
RIw&index=2, accessed 2nd November 2019).
Poor Visualization of the Anterior Chamber Angle
Good visualization of the anterior chamber angle during implantation was impor-
tant, though less critical than with trabecular meshwork stents as the target 
a
b
Fig. 8.1 (a) A CyPass Micro-Stent in a good position on gonioscopy in the operating theatre at the 
end of surgery. Note the blood outlining Schlemm’s canal demonstrating that the collar of the 
CyPass Micro-Stent is sitting at the level of trabecular meshwork, well away from cornea and the 
entry of the CyPass Micro-Stent into the ciliary body band, peripheral to iris root (copyright 
Moorfields Eye Hospital and Keith Barton, reproduced with permission). (b) A well-positioned 
and patent CyPass Micro-Stent visible on gonioscopy a number of weeks after surgery (Copyright 
Moorfields Eye Hospital and Keith Barton; reproduced with permission)
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implantation site, the ciliary body band is, on account of its position as the most 
posterior structure in the angle before the iris root, harder to miss. The CyPass was 
approved for implantation in eyes with open-angle glaucoma (Shaffer grade 3 or 4).
Resistance Encountered During Implantation
If resistance was encountered when advancing the device, this was either due to 
failure of the device to follow the scleral curvature or positioning of the tip of the 
guidewire in iris or ciliary body rather than between ciliary body and sclera. If the 
angulation and position of the applier were corrected, the device could be implanted 
in the suprachoroidal space with very little resistance.
Position of Device Too Anterior
If the proximal end of the CyPass Micro-Stent was positioned more anterior than 
the ideal position (rim of the collar at the level of the trabecular meshwork) (Fig. 8.3), 
the guidewide tube of the applier could be used to gently push the device deeper into 
the suprachoroidal space.
Position of Device Too Posterior
If the CyPass Micro-Stent was pushed too far into the suprachoroidal space, then 
there was a higher risk of post-operative device occlusion by iris. Sometimes the 
a
b
Fig. 8.2 (a, b) Insertion of the CyPass Micro-Stent in Fig. 8.1 (Copyright Moorfields Eye Hospital 
and Keith Barton; reproduced with permission)
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device could then be grasped carefully with retinal micro-forceps and pulled gently 
forwards into the anterior chamber. If the CyPass Micro-Stent were implanted so 
posteriorly that the tip of its collar could not be visualized, the device would have to 
be abandoned and left in the supra-choroidal space as attempted removal would 
cause excessive trauma. Implantation of a second CyPass Micro-Stent in the same 
eye would then generally be performed at least 2 clock-hours away from the first, in 
order to avoid the creation of a cyclodialysis cleft between the devices.
8.5.1.2  Mechanism of Action
Ultrasound biomicroscopy [21] and optical coherence tomography (OCT) [22] 
studies have shown that aqueous accumulated in the suprachoroidal space around 
and posterior to the CyPass Micro-Stent. In addition, as the device resumed a 
straight configuration after guidewire retraction, this created a fluid-filled space 
between the device and the sclera (tenting). Ultrasound biomicroscopy imaging of 
the suprachoroidal lake has shown that it could extend 360° circumferentially 
around the eye after CyPass Micro-Stent implantation. However, the fluid around 
and posterior to the device, as well as the space between the device and the sclera 
reduced with time, due to fibrosis in the suprachoroidal space. Given the ease with 
which choroidal effusions resorb with pressure elevation, it is most likely that aque-




Fig. 8.3 (a) Improperly 
positioned CyPass 
Micro-Stent protruding 
anteriorly and abutting 
cornea 2 years after 
surgery (copyright 
Moorfields Eye Hospital 
and Keith Barton, 
reproduced with 
permission). (b) The same 
CyPass Micro-Stent as (a), 
demonstrating that three 
rings are visible and the 
collar is very close to the 
cornea on gonioscopy, with 
a consequent high risk of 
corneal endothelial cell 
loss (Copyright Moorfields 
Eye Hospital and Keith 
Barton; reproduced with 
permission)
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8.5.1.3  Efficacy
The safety and efficacy of the CyPass Micro-Stent have been investigated in several 
clinical studies, including one large randomized controlled trial.
Hoeh et al. [23] reported the 6-month outcomes of combined cataract surgery 
and CyPass Micro-Stent implantation in an exploratory multi-centre case series of 
98 patients. The patients were divided into two groups based on whether their base-
line IOP was uncontrolled (IOP  ≥  21  mmHg, Cohort 1) or controlled 
(IOP < 21 mmHg, Cohort 2). In uncontrolled patients (n = 57), the mean IOP was 
decreased by 37% (p < 0.001) and the mean number of glaucoma medications was 
reduced by more than 50% (p < 0.001) at 6 months. Patients whose IOP was con-
trolled at baseline (n  =  41) had a 71% reduction in the number of glaucoma 
medications.
A similar study by Höh et al. [24] reported the 2-year outcomes of combined 
cataract surgery and CyPass Micro-Stent implantation, with the patients again 
divided into those with uncontrolled baseline IOP (n = 23, IOP ≥ 21 mmHg, Cohort 
1) and those with controlled baseline IOP (n = 59, IOP < 21 mmHg, Cohort 2). The 
IOP at 24 months was 15.8 ± 3.8 mmHg (37 ± 19% decrease from baseline IOP) and 
16.1 ± 3.2 mmHg (0 ± 28% decrease from baseline IOP) in Cohort 1 and Cohort 2, 
respectively. The mean number of glaucoma medications at 24  months was 
1.0 ± 1.1 in Cohort 1 and 1.1 ± 1.1 in Cohort 2. Fifteen subjects (11%) required 
additional incisional glaucoma surgery.
Garcia-Feijoo et al. [25] reported the results of the DUETTE study, a single-arm 
multi-centre study which examined the efficacy and safety of CyPass Micro-Stent 
implantation as a solo procedure in patients with medically uncontrolled POAG. Of the 
65 patients recruited, 12-month data were available for 55 patients. At 12 months, there 
was a significant decrease in the mean IOP (16.4 ± 5.5 mmHg vs. 24.5 ± 2.8 mmHg, 
p < 0.001) and the mean number of glaucoma medications (1.4 ± 1.3 vs. 2.2 ± 1.1, 
p  =  0.002). Nine patients required secondary incisional glaucoma surgery and two 
patients underwent implantation of a second Cypass Micro-Stent.
Vold et al. [26] reported the 2-year results of the COMPASS study (n = 505), a 
randomized comparative trial comparing stand-alone cataract surgery (control group, 
n = 131) with combined cataract surgery and CyPass Micro-Stent implantation (mic-
rostent group, n = 374). At baseline, both groups had similar mean IOP (24.5 ± 3.0 in 
the control group and 24.4 ± 2.8 mmHg in the microstent group, p > 0.05) and mean 
number of medications (1.3 ± 1.0 in the control group and 1.4 ± 0.9 in the microstent 
group, p > 0.05). At 2 years, a greater percentage of patients in the microstent group 
achieved ≥20% reduction in unmedicated IOP compared with the control group 
(77% vs. 60%, p < 0.001). The mean IOP reduction was 7.4 mmHg when combined 
surgery was performed and 5.4 mmHg when cataract surgery was performed as a 
standalone procedure (p < 0.001). At 2 years, 59% of the patients in the control group 
did not require any glaucoma medications compared to 85% of the patients in the 
microstent group. Three patients from the microstent group and four patients from 
the control group required further glaucoma surgery.
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8.5.1.4  Complications
As a minimally invasive and blebless glaucoma surgical procedure, the CyPass 
Micro-Stent had a better safety profile than conventional glaucoma procedures such 
as trabeculectomy and tube shunts. The post-operative care was also less intense 
than that after the above procedures [27]. However, compared with trabecular 
bypass MIGS procedures, the CyPass Micro-Stent was associated with potentially 
more severe complications.
Intra-operative Complications
Serious intraoperative complications were rare with the CyPass. Typically a minor 
amount of bleeding might occur if the tip of the guidewire engaged the anterior 
chamber angle in an insufficiently peripheral position, catching the iris root. It was 
rare for bleeding to impede visualization for implantation but, when it did, injection 
of additional viscoelastic into the anterior chamber was usually sufficient to improve 
the view. There was also the possibility of inadvertent lens or corneal damage dur-
ing implantation.
Significant lateral movement of the applier or an excessively traumatic implanta-




The incidence of early post-operative inflammation (within the first month) after 
CyPass Micro-Stent implantation has been reported to be around 4.2–8.6% and 
resolved in all cases without any sequelae [25, 26]. Hoeh et al. observed late-onset 
inflammation in 3.7% (n = 5) of his patients [28], whereas Kerr et al. reported 10% 
(n  =  2), in theirs [29]. Notably, the two patients with late-onset inflammation 
reported by Kerr et al. had a history of uveitis.
Eyes with early or late-onset post-operative inflammation require an increased 
frequency of topical steroids, which can be titrated according to the severity of 
inflammation and may be necessary for several months. The IOP should be moni-
tored closely in these eyes to identify and treat steroid responsiveness.
Hypotony
When post-operative hypotony occurred with the Cypass, it was the result of aque-
ous flow into the suprachoroidal space through the CyPass Micro-Stent or around 
the device (cyclodialysis cleft).
In the COMPASS study, hypotony occurred in 11 subjects (2.9%) undergoing 
combined CyPass Micro-Stent implantation with cataract surgery, with three cases 
considered clinically significant (i.e. associated with early maculopathy). Hypotony 
was transient in all 11 subjects and resolved spontaneously. Seven subjects in the 
microstent group developed a cyclodialysis cleft exceeding 2 mm, but none developed 
hypotony and did not require re-operation, so clearly were not functional clefts [26].
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Hoeh et al. observed transient early hypotony in 13.8% of patients undergoing 
combined CyPass Micro-Stent implantation and cataract surgery. With the excep-
tion of one patient who took 6 months to resolve, the hypotony resolved spontane-
ously by 1 month [23]. Hoeh et al. also reported early hypotony in 14% of subjects 
undergoing combined CyPass Micro-Stent implantation and cataract surgery in 
another series, with all cases resolving spontaneously without visual sequelae or 
further surgical intervention [28]. A study reporting 2-year outcomes for CyPass 
Micro-Stent implantation in conjunction with cataract surgery found a similar inci-
dence of early transient hypotony (15.4% of eyes), also resolving spontaneously in 
all cases [24].
When post-operative hypotony occurred after CyPass Micro-Stent implantation, 
the frequency of topical steroids would be reduced to encourage suprachoroidal 
fibrosis around the device. Rarely, hypotony persisted or was associated with hypot-
ony maculopathy or choroidal detachment. In such cases, surgical intervention was 
occasionally required to occlude the Cypass Micro-Stent. Sii et  al. [30] have 
reported two cases of persistent hypotony which were successfully treated by 
occluding the device’s lumen ab interno with a 4-0 Nylon suture (www.youtube.
com/watch?v=5zZnrSyB5vM&list=UUnkpnhwaQCC4Ary7gIyXRIw&index=11
&t=0s, accessed 2nd November 2019).
The risk of hypotony was believed to be higher in highly myopic eyes.
IOP Spikes
IOP elevation in the immediate post-operative period (up to 48 h after the surgery) 
was most often due to retained viscoelastic and could be remedied by posterior lip 
pressure on the corneal incision using a hypodermic needle at the slit-lamp or medi-
cation. Less commonly, IOP elevation in the immediate post-operative period may 
have been due to occlusion with blood or iris. An IOP spike after the second or third 
postoperative week could be due to steroid responsiveness or occlusion of the 
implant or surrounding cleft with fibrosis (or both).
In the COMPASS study, 16 subjects in the microstent group (4.3%) developed 
transient IOP spikes, defined as IOP ≥ 10 mmHg above baseline values. All cases 
resolved, although three subjects required additional glaucoma surgical intervention 
for IOP control [26]. The frequency of transient IOP spikes was 10.5% in a study by 
Hoeh et  al. [23] and 10.8% in a study by García-Feijoó et  al. (defined as 
IOP > 30 mmHg that resolved either on its own or by adding glaucoma medications) 
[25]. Kerr et al. reported a higher rate of transient post-operative IOP spikes, occur-
ring in 20% of subjects. Fortunately, none of these subjects required further glau-
coma surgery or experienced a deterioration in best-corrected visual acuity 
(BCVA) [29].
Hyphaema
The frequency of post-operative hyphaema was reported at between 1.5% and 15%, 
with all cases resolving spontaneously within the first month [24–26, 28, 29].
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Deterioration in Vision (Loss of ≥2 Lines of BCVA)
After CyPass Micro-Stent implantation, 1.1–3.1% of patients lost ≥2 lines of BCVA 
[25, 26, 28]. The causes of the vision loss included cystoid macular oedema, cata-
ract progression (in phakic patients who underwent CyPass Micro-Stent implanta-
tion as a solo procedure), corneal oedema or posterior capsular opacification, with 
the management directed at each cause (e.g. cataract surgery, YAG laser 
capsulotomy).
Device Occlusion
Occlusion of the CyPass Micro-Stent with peripheral anterior synechiae (PAS) 
occurred in 2.1% of subjects in the COMPASS study [26]. García-Feijoó et  al. 
reported that the device was occluded by PAS in two subjects (3.1%), and Nd:YAG 
laser was successfully used to clear the occlusion in one subject [25]. Hoeh et al. 
reported partial or complete device obstruction in nine subjects (5.4%), of which the 
device was occluded by PAS in two [28]. They also reported that occlusion occurred 
within the first 3 months in 80% of the 12 subjects (8.8%) in whom the CyPass 
Micro-Stent was occluded and was usually due to excessively posterior implanta-
tion of the device [24].
Device Malposition
Device malposition occurred in two patients and device migration/dislodgement 
occurred in two patients in the COMPASS study [26]. Hoeh et al. reported that one 
subject with an anteriorly positioned CyPass Micro-Stent required additional sur-
gery to push the device further into the suprachoroidal space [23]. Kerr et  al. 
reported that, in the hands of an experienced surgeon, device re-positioning can 
easily be performed at the slit lamp with a 30-gauge needle [29]. If the position of 
the CyPass Micro-Stent was too anterior after the surgery, it should be re-positioned 
as soon as possible before fibrosis and encapsulation develops.
Conversely, if the CyPass Micro-Stent was implanted too posteriorly in the 
suprachoroidal space, there was a higher risk of device occlusion by iris or PAS [28].
Additional Glaucoma Surgery
In the COMPASS study, three subjects (0.8%) in the microstent group required 
additional glaucoma surgery to control the IOP [26]. A higher glaucoma re- operation 
rate was reported by García-Feijoó et al., with 11 subjects (16.9%) requiring addi-
tional glaucoma surgery, mostly within the first 6 months. A second CyPass Micro- 
Stent was implanted in two subjects and the remaining nine subjects required 
subsequent trabeculectomy [25]. Hoeh et al. also reported that additional glaucoma 
surgery was required in 11.0% [15] subjects [28]. The COMPASS study included 
subjects with mild to moderate POAG on 1.4 ± 0.9 glaucoma medications at base-
line, many of whom were medically controlled prior to medication washout [26]. 
On the other hand, in the study by Garcia-Feijoo et al., the mean number of glau-
coma medicines at baseline was 2.2 ± 1.1, and all subjects were medically uncon-
trolled [25].
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Corneal Endothelial Cell Loss and Corneal Decompensation
The COMPASS-XT study (a post-approval extension of the randomized clinical 
COMPASS trial) showed that patients who had undergone combined CyPass Micro- 
Stent implantation with phacoemulsification had a significantly greater reduction in 
endothelial cell counts than patients who had phacoemulsification alone, 5 years 
after surgery. Based on these findings, Alcon, the manufacturer, voluntarily with-
drew the CyPass Micro-Stent from the global market in August 2018 (www.alcon.
com/cypass-recall-information). The extent of endothelial cell loss in the 
COMPASS-XT study correlated with the number of retention rings visible on goni-
oscopy, hence the associated corneal damage was almost certainly a consequence of 
the device position in the angle. Endothelial cell loss was more prominent when two 
or more retention rings were visible in the anterior chamber. Though none of the 
patients developed clinically evident corneal decompensation, this was of concern 
because the US Food and Drug Administration (FDA) restricts the use of the CyPass 
Micro-Stent to adult patients with mild-to-moderate open-angle glaucoma in con-
junction with cataract surgery. The safety of the device is particularly important in 
this group of patients who are conventionally treated with glaucoma medication. If 
the CyPass Micro-Stent should become available again in the future, it is likely that 
the manufacturer’s directions on the surgical implantation technique would be 
amended to recommend a more posterior positioning, specifying that the device 
should not protrude, ideally above the trabecular meshwork or at worst, the 
Schwalbe’s line. It would be less likely for significant endothelial cell loss to occur 
in these circumstances. Alcon may also consider extending the indication for the 
CyPass Micro-Stent to more refractory cases of glaucoma.
In an earlier study, Hoeh H et al. reported that the incidence of contact between 
the CyPass Micro-Stent and corneal endothelium was 1.2%, as a consequence of 
anterior device placement. None of these subjects experienced visual loss or 
required additional surgery, albeit with a short follow-up of 294 ± 121 days [28]. In 
another study by Höh H et al., device–corneal endothelial contact occurred in 3.7% 
of subjects [24].
If the CyPass Micro-Stent was positioned too anteriorly or if contact is detected 
between the device and the corneal endothelium, it was advisable to re-position the 
device in the early postoperative period. Within a few weeks, fibrosis develops 
around the device, preventing it from being easily re-positioned or removed. In such 
circumstances, the CyPass Micro-Stent could be trimmed using 23 gauge vitrec-
tomy scissors, so that it does not protrude beyond the Schwalbe’s line (www.you-
tube.com/watch?v=mRHdplofoBM&list=UUnkpnhwaQCC4Ary7gIyXRIw&inde
x=5&t=0s, accessed 2nd November 2019).
Cataract Progression
In a multicentre, single-arm interventional study by Garcia-Feijoo et al., cataract 
progression occurred in 12.2% of phakic eyes 1 year after stand-alone CyPass 
Micro-Stent implantation [25]. Höh et al. reported that CyPass Micro-Stent implan-
tation was associated with cataract progression in 2% of phakic eyes [24].
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8.5.2  iStent Supra
The iStent Supra (Glaukos Corporation, San Clemente, CA, USA) is another ab- 
interno suprachoroidal MIGS device which has the Conformité Européene Mark 
(Fig. 8.4). It is a ridged curved tube made of heparin-coated polyethersulfone and 
titanium. The length of the iStent Supra is 4 mm, with an interior lumen diameter of 
165 μm. The mechanism of action of the iStent Supra is very similar to that of the 
CyPass Micro-Stent.
8.5.2.1  Implantation Technique
The implantation technique of the iStent Supra is similar to that described above for 
the CyPass Micro-Stent. A 1.5-mm clear corneal incision is sufficient for the inser-
tion of the iStent Supra.
8.5.2.2  Efficacy and Safety
Myers et al. [31] reported the efficacy of iStent Supra implantation combined with 
the implantation of two iStent Trabecular Micro-Bypass Stents and post-operative 
travoprost in patients with refractory open-angle glaucoma and previously failed 
glaucoma filtration surgeries. This case series reported the 4-year outcomes although 
it was originally designed to be a 5-year study. The mean unmedicated IOP at all 
visits was ≤13.7  mmHg (≥37% reduction from baseline). Among eyes without 
additional medication or surgery, ≥91% of eyes had ≥20% decrease in IOP on one 
medication compared with pre-operative medicated IOP at all post-operative visits. 
At 4 years, 97% and 98% of the eyes achieved IOP ≤15 and ≤18 mmHg respec-
tively on one medication. Additional medication was required in six eyes, and none 
of the patients required additional glaucoma surgery. The most frequent adverse 
event was cataract progression (16% of the subjects) [31].
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8.5.3  MINIject
The MINIject (iSTAR Medical, Isnes, Belgium) is the latest suprachoroidal MIGS 
device to be introduced (Fig.  8.5). Like its predecessor, the STARflo Glaucoma 
Implant (iSTAR Medical, Isnes, Belgium), the MINIject is made from STAR® mate-
rial, which comprises of soft and flexible medical-grade silicone that conforms to 
the curvature of the eye. The STAR® material is composed of an organized network 
of hollow spheres with a micro-porous, multi-channel matrix which promotes bio- 
integration of surrounding tissues into the material, with the intention of reducing 
fibrosis and scarring, hence increasing the efficacy of the device. The MINIject is 
5 mm in length and the green ring at the anterior segment of the device is used as a 
reference point for device position during implantation.
8.5.3.1  Implantation Technique
The implantation technique of the MINIject is similar to that described above for 
the CyPass Micro-Stent. The MINIject implant is preloaded in a transparent sheath 
attached to an applier handle, and sliding a wheel on the applier handle retracts the 
sheath back into the handle, leaving the device in place in the suprachoroidal space. 
Correct placement depth is achieved when the green ring is at the level of the 
scleral spur.
8.5.3.2  Efficacy and Safety
The first-in-human STAR-I trial for stand-alone MINIject implantation (Clinical- 
Trials.gov Identifier: NCT03193736) included 25 patients with mild-to-moderate 
POAG uncontrolled by topical glaucoma medications. Six-month data from the 
STAR-I trial showed a reduction in the mean ± standard error IOP (23.2 ± 0.6 vs. 
14.2 ± 0.9, p < 0.0001) and the mean ± standard deviation number of glaucoma 
medications (2.0 ± 1.1 versus 0.3 ± 0.7), with 21 patients (87.5%) being medication- 
free and 23 patients (95.8%) achieving a minimum 20% IOP reduction from base-
line. There were no serious adverse events related to the device or procedure and no 
additional glaucoma surgery was required. The mean central or peripheral corneal 
endothelial cell density was not significantly different from baseline [32]. At the 
time of writing, the 1-year data from the STAR-I trial have not been published.
Fig. 8.5 MINIject 
(Copyright iSTAR 
Medical, Isnes, Belgium; 
reproduced with 
permission)
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9New Modalities of Cycloablation and High-Intensity-Focused Ultrasound
Natasha Nayak Kolomeyer and Marlene R. Moster
9.1  Introduction
Cycloablative or cyclodestructive procedures aim to lower intraocular pressure (IOP) 
by decreasing the function of the ciliary body and thereby decreasing the rate of 
aqueous production. Cycloablative procedures were typically used in refractory 
glaucoma in eyes with poor visual potential; however, more focused energy and tar-
geted destruction of the ciliary body has led to an increase in cyclodestructive treat-
ment options that are now an important adjunct to our surgical armamentarium.
9.2  Transscleral Diode Cyclophotocoagulation (TSCPC)
Cyclodestructive procedures have evolved since the 1920s, progressing from cyclec-
tomy, cyclodiathermy, cyclocryotherapy, and eventually to cyclophotocoagulation 
[1–3]. Cyclophotocoagulation was initially performed in 1961 by using light from 
xenon arc photocoagulation [4] and subsequently using a ruby laser in 1969 [5]. 
Cyclophotocoagulation established a more widespread application once Nd:YAG 
(neodymium–yttrium–aluminum garnet) and eventually semiconductor diode lasers 
were developed. Nd:YAG cyclophotocoagulation (1064 nm wavelength) can be per-
formed with or without ocular surface contact; however, noncontact methods were 
relinquished due to their higher complication rates. Currently, semiconductor diode 
lasers are the mainstay of transscleral diode cyclophotocoagulation (TSCPC). They 
have several advantages including greater uveal melanin absorption, compact size, 
and minimal maintenance requirements compared to prior lasers. Human cadaveric 
studies demonstrate epithelial coagulative necrosis and thermal coagulation of the 
ciliary stroma and vasculature in eyes receiving diode TSCPC [6].
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9.2.1  Procedure
• Typically, local anesthesia or sedation is administered along with regional (retro-
bulbar/peribulbar/subtenon’s) anesthesia.
• Common diode laser settings: Duration is often set at 2–3  s. Power starts at 
1250–2500  mW.  The power is titrated in 250  mW increments (maximum 
~4000 mW) until an audible “pop” is heard; the power is then titrated to 250 mW 
below the “pop” threshold [3].
• The number of spot treatments varies between 14 and 20, sparing the 3 and 9 
o’clock in order to avoid the long posterior ciliary nerves and vessels.
• The G-Probe is placed just posterior to the limbus, perpendicular to the limbus. 
This places the fiberoptic 1.2 mm posterior to the limbus. Maintain gentle pres-
sure on the G-Probe throughout the treatment duration.
• Some physicians choose to administer a subconjunctival injection of steroids 
after TSCPC. The eye is patched and a shield is placed over the eye.
• Patients are placed on steroid drops after the laser, with the frequency of topical 
steroids titrated according to the severity of inflammation. All preoperative glau-
coma medications are continued in the immediate postoperative period and can be 
selectively stopped depending on the IOP response. Patients are typically seen 
1 day and 1 week postoperatively and subsequently depending on patient response.
9.2.2  Indications
TSCPC is indicated in patients with refractory glaucoma or a blind painful eye. It is 
typically used in patients with poor visual acuity (VA). It can also be used earlier in 
patients where incisional surgery is less ideal, such as those with significant medical 
conditions, bleeding diathesis, or scarred conjunctiva. The laser power for TSCPC 
may be reduced when treating eyes with good vision to reduce the risk of sight- 
threatening complications.
9.2.3  Results
A thorough compilation of the results and complications of TSCPC can be referred 
to in a recent review article; we have highlighted the most relevant findings below 
[7]. The treatment effect is often seen around 1 month after TSCPC; it is advisable 
to wait at least 1  month for retreatment if possible. TSCPC has demonstrated a 
range of effect on IOP (12.3–66% IOP reduction); post-laser IOP of ≤21 mmHg has 
been reported in 54–92.7% of eyes. Various studies suggest a correlation between 
IOP reduction and the amount of energy per treatment session or the number of laser 
burns. However, there are several studies that could not find a direct correlation. 
Other factors that influence treatment success include pre-laser IOP and the subtype 
of glaucoma. Lower success rates have been reported in aphakic, traumatic, and 
juvenile glaucoma. TSCPC success rates also increase with age and decrease with a 
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history of prior surgery. More pigmented eyes usually require less energy, but there 
is no clear relationship with TSCPC success rates.
9.2.4  Complications
Adverse effects associated with treatment include vision loss (8.8–47%), hypotony 
(0–26%), hyphema (0–2%), anterior uveitis (9–28%), pupillary changes (0.8–50%), 
phthisis (0–10%), retinal detachment (1%), IOP spike, cataract progression, vitre-
ous hemorrhage, lens subluxation, necrotizing scleritis, and rarely sympathetic oph-
thalmia [1].
The literature suggests a relationship between the amount of energy delivered 
and the risk of hypotony and phthisis [8]. It is unclear if this is a nonlinear relation-
ship, but treatment sessions utilizing more than 80 J of energy tend to have higher 
rates of these complications. Glaucoma subtype (including neovascular glaucoma 
[NVG]) and high pretreatment IOP are also considered risk factors for hypotony 
and phthisis. This suggests that lower energy settings in a high-risk patient may be 
important in minimizing these complications.
Loss of more than two Snellen lines of VA was reported on average in 22.5% of 
eyes (0–55% range) [7]. Rotchford et  al. evaluated the outcomes of TSCPC in 
patients with VA of at least 20/60. After 5 years, 73.5% of patients had an IOP of 
16 mmHg or less and 30.6% had lost two or more Snellen lines of VA [9]. The pro-
portion of patients who lost vision is consistent with that reported after incisional 
surgery, suggesting that TSCPC can be considered as an option in selected eyes with 
good visual potential.
Concerns regarding postoperative complications must be balanced against over-
all efficacy for each individual patient, as studies suggest a relationship between the 
amount of laser energy delivered and IOP reduction, as well as the risk of hypotony 
and phthisis.
9.3  Micropulse Transscleral Cyclophotocoagulation 
(MP-TSCPC)
The micropulse delivery mode of diode laser (MP-TSCPC, MicroPulse P3, IRIDEX 
IQ810 Laser System, Mountain View, CA, USA) is a more recent form of 
TSCPC. MP-TSCPC operates in an “on” and “off” cycle mode, delivering 810 nm 
infrared radiation from a diode source. During the “on” cycle, multiple bursts of 
laser are emitted by the device resulting in an increase in thermal energy absorption 
in pigmented tissues and induction of coagulative necrosis. Theoretically, the non-
pigmented tissues do not cross the coagulative threshold because they have a lower 
rate of thermal energy absorption and are able to cool off during the “off” cycle. The 
MP-TSCPC also employs a novel probe that: (a) allows sweeping, continuous appli-
cations compared to individual spot treatments and (b) targets the pars plana rather 
than the pars plicata.
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9.3.1  Procedure
• MP-TSCPC can be performed under topical, regional (peribulbar/subtenon’s/ret-
robulbar), or general anesthesia. Some physicians find that topical or local anes-
thesia with a short burst of heavy sedation can be used without a need for 
retrobulbar anesthesia when in the operating room. However, if done in an office 
setting, regional (retrobulbar/peribulbar/subtenon’s) anesthesia is commonly 
employed.
• Default laser settings are: micropulse mode, 2000  mW power, duty cycle of 
31.33%, micropulse “on” time of 0.5 ms, and micropulse “off” time of 1.1 ms. 
At the surgeon’s discretion, the laser is delivered over 360° for 100–360 s, while 
sparing the 3 and 9 o’clock positions as above for TSCPC. The duration of treat-
ment is often titrated based on the patient’s history. While the default laser set-
tings are 2000 mW, more recently surgeons have titrated the power settings in the 
2000–2500 mW range based on the patient’s history as well.
• The MP-TSCPC probe is placed along the limbus perpendicular to the sclera. 
The probe is then moved in a continuous, sliding, slow motion around the lim-
bus, sparing 3 and 9 o’clock, while applying firm pressure. The rate of movement 
is encouraged to be around 10–20 s per quadrant. The probe tip is designed to 
position the fiberoptic tip 3 mm posterior to the limbus (Fig. 9.1).
• Some physicians choose to administer a subconjunctival injection of steroids 
after MP-TSCPC.
• Topical steroid drops are typically applied four times daily post-surgery to con-
trol the inflammation and subsequently tapered as inflammatory response 
decreases.
a b
Fig. 9.1 Micropulse transscleral cyclophotocoagulation (MP-TSCPC). (a) The notch on the 
probe is to be placed toward the limbus. The notch is located on the rounder half of the probe and 
can be marked for easier visibility with a marker. (b) The probe is then placed with the marked 
notch perpendicular to the limbus. (Copyright Marlene Moster, MD; Bill Romano; and Natasha 
Nayak Kolomeyer, MD; reproduced with permission)
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9.3.2  Indications
Indications for MP-TSCPC are broad, spanning noninvasive early interventions as 
well as refractory primary and secondary glaucomas. We recommend reviewing 
possible complications with the patient if using MP-TSCPC as an earlier intervention.
9.3.3  MP-TSCPC vs. TSCPC
MP-TSCPC versus TSCPC: A randomized exploratory study compared results of 
MP-TSCPC (with 100 s treatment duration) and continuous TSCPC in 48 patients 
with refractory end-stage glaucoma [10]. A successful primary outcome measure 
(IOP 6–21 mmHg and at least a 30% reduction with or without antiglaucoma medi-
cations after 18 months) was achieved after MP-TSCPC and continuous TSCPC in 
52% and 30% (p = 0.13), respectively. There was a significant difference at 1 year 
(75% vs. 29%) that reached statistical significance (p  <  0.01). Mean IOP was 
reduced by 45% in both groups from a baseline of 36.5 and 35  mmHg after 
17.5 ± 1.6 months of follow-up. There was no significant difference in the number 
of IOP-lowering medications, while the complication rate was higher in the con-
tinuous TSCPC (p  =  0.01) group including prolonged anterior chamber (A/C) 
inflammation, hypotony, and phthisis bulbi. There was a greater degree of IOP vari-
ance in the continuous TSCPC group, but the treatment settings were also more 
variable.
9.3.4  Results
Tan et al. [11] conducted a prospective case series of 40 eyes with refractory glau-
coma that received a mean of 1.4 treatments of 100 s of MP-TSCPC. Eighty percent 
of eyes achieved relative success (IOP < 21 mmHg or reduction of 30% from base-
line) with or without supplemental glaucoma medication, with 65% of eyes achiev-
ing successful IOP after one treatment. The average follow-up period of 
17.3 ± 2.0 months was significantly longer than most other studies.
A retrospective review of 79 refractory glaucoma patients who received 
120–360 s of MP-TSCPC demonstrated a treatment success rate of 75% at 3 months 
(IOP of 6–21 mmHg or a reduction of IOP by 20%), with an additional 10% of 
patients meeting the success criteria after the addition of IOP-lowering medications 
[12]. At 6 months, the treatment success rates dropped to 66% and were stable until 
the last follow-up for patients with at least 6 months of follow-up.
Emanuel et al. conducted a retrospective review of 84 eyes with a mean follow 
up of 4.3  months. There was a 41% and 53% reduction in IOP at 1  month and 
3 months postoperatively, respectively [13].
Another retrospective review compared 320 s of MP-TSCPC results in nine pedi-
atric (age 1–17 years) and 37 adult glaucoma patients [14]. At the 12-month follow-
 up period, success was achieved in 72% (26/36) of adult patients but only in 22% 
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(2/9) of pediatric patients (p = 0.02). Success was defined as IOP between 5 and 
21 mmHg and ≥20% reduction from baseline at 12 months of follow-up without the 
use of oral carbonic anhydrase inhibitors, loss of light perception vision, or reopera-
tion for glaucoma within the 12-month follow-up period. The mean IOP at postop-
erative months 1 and 6 was significantly decreased from baseline in the pediatric 
group, but the effect lost significance at 12 months. A majority (7/9) of pediatric 
eyes required reoperation to control IOP during the follow-up period.
9.3.5  Complications
The complications of MP-TSCPC in the retrospective review of 79 eyes by Williams 
et  al. [12] included 7 patients with hypotony (9%), 21 (26%) patients with pro-
longed A/C inflammation, 13 (16%) patients with loss of two or more lines of best- 
corrected VA for ≥3 months, 4 (5%) patients with macular edema, 2 (2.5%) patients 
with corneal edema, and 2 (2.5%) patients with phthisis bulbi. There were no 
reported cases of mydriasis or loss of accommodation; however, given the retro-
spective nature of the study, this information was not directly elicited from the 
patients. The ten patients who underwent re-treatment did not seem to be more 
inclined to complications.
Tan et  al. [11] did not observe any cases of hypotony or loss of vision after 
MP-TSCPC. All eyes had mild postoperative inflammation that resolved by 2 weeks in 
90% of eyes and by 4 weeks in the remainder of eyes. Seven (17.5%) eyes with NVG 
developed hyphema. This study employed shorter treatment duration (100 s) compared 
to Williams et al. (120–360 s). Further studies would be required to ascertain whether 
there is a treatment duration related effect on outcomes and complications.
Emanuel et al. [13] observed 5 (6%) cases of persistent hypotony, 3 (4%) cases 
of IOP spikes, as well as hyphema (4%) and choroidals (1%). Persistent inflamma-
tion at postoperative month 3 was found in 74% of eyes. At postoperative month 1, 
35% of eyes lost two more lines of vision. Three patients lost light-perception vision 
but were light perception at baseline. Tan et al. also found that MP-TSCPC caused 
significantly greater conjunctival inflammation and scarring compared to controls in 
Dutch Belted Rabbits, similar to continuous wave TSCPC [25]. Hence, further stud-
ies are required to investigate the effect of post-TSCPC conjunctival changes on 
future bleb morphology and survival. 
9.4  High-Intensity Focused Ultrasound (HIFU)
High-Intensity Focused Ultrasound (HIFU) (Therapeutic Ultrasound System; Sonocare 
Inc., Ridgewood, NJ, USA) was evaluated as an alternative to ciliary body destruction 
in the 1980s [15]. Interest in HIFU initially faded due to the duration and complexity 
of treatment as well as significant complications (scleral staphyloma, phthisis, persis-
tent hypotony, corneal thinning, and vision loss). However, modifications of the HIFU 
technology have resulted in recent renewed interest in this treatment modality. A min-
iaturized HIFU technique, ultrasonic circular cyclophotocoagulation (UC3, EyeOP1 
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HIFU, EyeTechCare, Rillieux-la-Pape, France), employs a circular operator-indepen-
dent probe that focuses the ultrasound energy circumferentially on the ciliary body 
without operator movement. Unlike diode laser, focused ultrasound technology can 
treat a defined tissue volume at any depth or location within the eye, without being 
affected by pigmentation. The complex transducers and higher operating frequency 
allow for more selective treatment areas.
9.4.1  Procedure
• UC3 can be performed under topical, regional (peribulbar/subtenon’s/retrobul-
bar), or general anesthesia.
• The coupling cone is placed in direct contact with the ocular surface and cen-
tered around the limbus. The coupling cone is then connected to a suction ring 
that establishes a low-level vacuum (70 mmHg) to maintain the cone in contact 
with the ocular surface to achieve alignment and control distance during the pro-
cedure. The probe is inserted into a coupling cone; probes are available in 11, 12, 
and 13 mm ring diameters (ring diameter size is determined preoperatively based 
on biometric data). The space between the ocular surface, the coupling cone, and 
the probe is filled with about 4 mL of room-temperature balanced salted solution. 
The probe (30 mm diameter, 15 mm height) is divided into six cylindrical piezo-
ceramic transducers that generate ultrasound beams that allow treatment of up to 
45% of the ciliary body. The ultrasound beam is focused at the depth of the cili-
ary body (2 mm below the sclera) [1] (Fig. 9.2).
• Each of the six transducers is activated for 4, 6, or 8 s (depending on treatment 
protocol), with a 20 s gap between each transducer, allowing cool down between 
each partial treatment. The entire treatment, which automatically proceeds with 
the activated foot pedal, is about 2.5 min.
• The settings specifically aim to avoid treatment of the retina, cornea, lens, as well 
as nasal and temporal zones.
a b c d e
Fig. 9.2 Ultrasonic circular cyclophotocoagulation (UC3) procedure comprises two elements: the 
probe with the six piezoelectric transducers generating the ultrasound beam and the coupling cone 
(a). The correctly positioned cone must show a homogeneous ring of visible sclera; when this ring 
is regular, the cone is then maintained by a mild vacuum system (b). After verification of the effec-
tive suction, the probe is inserted and stabilized into the cone (c). During the procedure, the cone 
is continuously filled with saline solution (d), in order to allow the ultrasound transmission. The 
treatment starts in the superior sectors with a progressive activation of each transducer (e). (This 
figure and description have been reproduced from an open-access article by Mastropasqua et al. [1])
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9.4.2  Mechanism
Ultrasound can cause thermal increase of up to 80 °C. The primary mechanism of 
action is reduction of aqueous production due to thermal necrosis of the ciliary epi-
thelium. Histopathology studies in rabbits by Aptel et  al. demonstrated focal 
necrotic changes in distal and intermediate ciliary processes, while sparing the basal 
and remaining parts of the ciliary body [15]. Untreated adjacent areas lacked signs 
of inflammation and had preserved architecture and vasculature. Additionally, there 
appears to be a correlation of treatment dosage and extent of ciliary process destruc-
tion [1]. Additional mechanisms of action could include modification of the scleral 
and conjunctival anatomy [16] and an increase in suprachoroidal and transscleral 
outflow [17–19].
9.4.3  Results
Giannacare et  al. conducted a prospective multicenter interventional study of 30 
eyes on maximum medical therapy with a 6-month follow-up [20]. Qualified and 
complete success (IOP reduction ≥20% and IOP ≥ 5 mmHg) was achieved in 70% 
and 46.7% of patients, respectively, while treatment failure was recorded in 6.6%. 
Eyes that were randomized to receive greater ultrasound exposure time (8  s per 
transducer) had greater IOP reduction compared to eyes with shorter ultrasound 
exposure time (4 or 6 s). There was significant IOP reduction on postoperative day 
1 (39%) despite study protocol requiring discontinuation of ocular hypotensive 
medications in the immediate postoperative period unless IOP was above 21 mmHg.
The EyeMUST1 study was a prospective multicenter interventional study of 52 
patients with refractory glaucoma [18]. Patients received either 4 s (group 1) or 6 s 
(group 2) exposure time per transducer (non-randomized). Success was defined as 
at least a 20% IOP reduction and IOP > 5 mmHg without additional hypotensive 
medications but with possible HIFU retreatment. Success was achieved at 6 months 
in 61.9% of group 1 patients and 65.4% of group 2 patients, while at 12 months the 
proportion was 57.1% and 48.0%, respectively (no significance at either time point). 
This difference was not statistically significant. Eight (15%) patients received HIFU 
retreatment. Twelve (22%) patients required a secondary glaucoma surgical inter-
vention between 6 and 12 months post-HIFU.
Melamed et al. performed a prospective interventional study of 20 patients who 
received HIFU treatment (using 6 s exposure time per transducer), with 4 (20%) 
requiring retreatment [21]. Complete (IOP reduction ≥20% and IOP >5 mmHg) and 
qualified (allowance of additional medication and/or retreatment) surgical success 
was achieved in 45% and 65%, respectively.
Aptel et  al. conducted a multicenter prospective clinical trial of 30 glaucoma 
patients without prior history of filtering surgery with a 6 s exposure time per trans-
ducer and 12-month follow up [22]. Complete success (IOP reduction ≥20%, IOP 
>5 mmHg and IOP < 21 mmHg with possible re-intervention and without additional 
hypotensive medication) was achieved in 47% of eyes and qualified success (allow-
ance of retreatment without additional medications) was found in 63% of eyes.
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De Gregorio et al. completed a prospective interventional study of 40 patients 
with an 8 s exposure time per transducer [23]. At 4 months, if the IOP was >21 mmHg 
with no adverse major complications related to HIFU procedure, the decision was 
made to retreat. Success was defined as IOP >5 mmHg and IOP < 21 mmHg without 
hypotensive medication and vision-threatening complications. Eighteen (45%) eyes 
achieved complete success with a mean IOP reduction of 44.3% at 4 months and 
45.7% at 12 months. At 12 months, success was achieved in 85% of treated eyes 
with a maximum of three HIFU procedures.
9.4.4  Complications
Transient complications such as a fixed and dilated pupil (0–3%), anterior chamber 
inflammation (20–24%), superficial punctate keratitis (13–45%), subconjunctival 
hemorrhage (4–30%), corneal edema (7–20%), IOP spikes (0–7%), induced corneal 
astigmatism (0–3%), macular edema (0–3%), and hypotony (0–2%) have been iden-
tified [18, 20–23]. Loss of three or more lines of best-corrected VA was reported in 
5–20% of patients [18, 22]. Notably, DeGregorio et al. noted scleral thinning in the 
treated sectors in 25% of eyes [23]. This evidence along with AS-OCT data suggest-
ing scleral remodeling after UC3 treatment highlights the importance of further 
analysis of the degree of scleral remodeling and how this may affect future filtration 
surgery. To our knowledge, there are no reports of persistent hypotony or phthisis 
after UC3 treatment.
It is important to note that the UC3 device requires suction to couple the device 
to the ocular surface, which increases the IOP for a period of 2.5 min. Although 
there are no reported cases of associated optic neuropathy, vein/artery occlusion, or 
visual field loss related to this specific device, this should be considered given the 
reports of LASIK-related complications [24].
9.5  Conclusion
Cycloablative treatment options for glaucoma continue to evolve. Recent develop-
ments such as MP-TSCPC and HIFU have improved safety profiles with variable 
results. We encourage the readers to balance the importance of safety and efficacy 
when choosing any surgical procedure, but especially a cycloablative procedure.
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10Controversies in the Use of MIGS
Georges M. Durr, Paola Marolo, Antonio Fea, 
and Iqbal Ike K. Ahmed
10.1  Introduction
In this chapter, the discussion will focus on some of the “gray areas” that surround 
the use of minimally invasive glaucoma surgery (MIGS) in clinical practice. Many 
of the subjects covered review questions that physicians encounter when incorpo-
rating MIGS into their surgical practice. As a relative new-comer in the field of 
glaucoma surgery, these controversies highlight the challenges of implementing 
new technologies and future developments in an effervescent field of 
ophthalmology.
10.2  Phaco Alone Versus Phaco/MIGS, Is It Worth It?
Cataract surgery has a well-documented IOP-lowering effect [1–6]. Surgeons have 
often used this to their advantage in patients with glaucoma or ocular hypertension. 
With phacoemulsification (phaco) replacing extracapsular cataract surgery in the 
last two decades, the complication rates of cataract surgery have dramatically 
decreased, with excellent visual outcomes and rapid recovery. Currently, when a 
cataract is present in a glaucomatous eye, surgery may be offered in an attempt to 
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reduce IOP and improve the visual acuity simultaneously. With the advent of MIGS, 
the surgeon now has a variety of potential methods to assist IOP-lowering at the 
time of cataract surgery. The question is: is there really an added benefit of phaco/
MIGS compared with phaco alone?
There have been numerous publications in the last few years, reporting the effi-
cacy of MIGS in combination with cataract surgery, indicating an additional IOP 
lowering effect when compared with cataract surgery alone. In addition, there are a 
number of randomized clinical trials (RCT) addressing this issue [1–5]. On one 
hand, some large MIGS trials have shown that the additional IOP reduction con-
ferred by MIGS is “only” 1.5–2.3 mmHg, with “only” 14–19.5% less eyes achiev-
ing an IOP reduction >20% compared with phaco alone [1, 3, 5]. Although the 
reported difference in IOP and success rate between phaco and phaco/MIGS seem 
small, these findings are still significant as they occur in the context of normal IOP, 
hence it is not as easy to show a difference between the two groups. Furthermore, 
proportional analyses of relevant clinical outcomes are important. For example, an 
increased proportion of patients in the MIGS groups compared to phaco alone 
remained medication-free at the end of the study period with differential rates vary-
ing between 13 and 35% [1–3, 5]. Some studies have shown that cataract surgery is 
more cost-effective when combined with MIGS than when performed alone [7], 
though more data are required to justify the additional MIGS procedure from an 
economic perspective. Another compelling argument is that phaco/MIGS results in 
fewer glaucoma surgical interventions later than with phaco alone. The HORIZON 
trial demonstrated that, at 3 years, a MIGS procedure could substantially reduce the 
requirement for later definitive glaucoma surgery in patients implanted with a 
Hydrus microstent (0.6%) compared with those who had cataract surgery alone 
(3.9%) [8].
It is difficult to account for surgical technique and verify accurate device place-
ment in such trials. A well-targeted stent or a properly created trabeculotomy, which 
drains aqueous to a large aqueous vein (identified by looking at trypan blue outflow, 
increased trabecular pigmentation or blood reflux in the Schlemm’s canal), is likely 
to enhance the IOP-lowering response [9]. A poor intra-operative view resulting in 
inappropriate device placement and a poor outcome can deter some surgeons. Better 
surgical training and more experience with different MIGS procedures are impor-
tant in optimizing outcomes and maximizing the effect of MIGS implantation as an 
adjunct to cataract surgery.
The question remains as to whether this evidence of modest efficacy is truly 
clinically significant. From a patient’s perspective, a reduction in drop load improves 
compliance, ocular surface irritation, and overall quality of life [10]. As poor com-
pliance leads to glaucoma progression and increased costs to society, by implication 
adjunctive MIGS implantation should reduce both [11, 12]. At the time of cataract 
surgery, surgeons have a unique theoretical opportunity to improve a patients’ qual-
ity of life and potentially delay progression or the requirement for future interven-
tion. Above all, the high safety profile of MIGS gives surgeons more confidence in 
offering earlier surgery and this interventional mindset is now at the forefront of 
glaucoma therapy.
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10.3  Trabecular Meshwork and Canal-Based Procedures: Cut 
Versus Stent Versus Dilate
MIGS options have broadened in recent years. Many of these target Schlemm’s 
canal, a small 36 mm circumferential conduit with an inner diameter of 300–400 μm 
[13]. Currently, there are three main approaches to increase aqueous outflow via this 
conventional outflow pathway: cutting (ostomies) (Kahook Dual Blade [KDB, New 
World Medical, Rancho Cucamonga, CA, USA]); Trabectome  [NeoMedix 
Corporation, San Juan Capistrano, CA, USA]; gonioscopy-assisted transluminal 
trabeculotomy [GATT]) with a suture, iTrack [Ellex Medical Pty Ltd., Adelaide, 
Australia] or OMNI [Sight Sciences Inc., Menlo Park, CA, USA]; and excimer laser 
trabeculostomy [ELT,  Excimer Laser AIDA, Glautec AG, Nürnberg, Germany]), 
dilation (viscocanalostomy with iTrack or OMNI) and stenting (iStent Trabecular 
Micro-Bypass Stent and iStent inject [Glaukos Corporation, San Clemente, CA, 
USA] and Hydrus Microstent [Ivantis Inc., Irvine, CA, USA]) (Table 10.1). All of 
these procedures aim to reduce the primary resistance to outflow, the trabecular 
meshwork (TM), through cutting or stenting to bypass the meshwork or dilating 
Schlemm’s canal to reduce resistance to aqueous transiting the canal to enter the 
collector channels. Success with these procedures depends on the presence of a 
functional distal outflow system (beyond Schlemm’s canal) and on whether the 
healing response subsequently obstructs aqueous flow to Schlemm’s canal.
Cutting techniques either incise, excise, or ablate the TM. The opening size of the 
trabeculotomy required to obtain optimal IOP-lowering is still under debate. Some 
earlier studies looking at outflow resistance have shown that there was only a small 
additional decrease (<10%) in outflow resistance with eyes receiving 360° of trabecu-
lotomy versus 120° [14]. More studies are required to investigate the optimal trabecu-
lotomy opening size required to achieve maximal efficacy in lowering IOP with the 
least amount of bleeding and postoperative hyphema. Upon review of current litera-
ture, hyphema occurs in approximately one-third of the eyes after GATT [15–17], 
~9% of eyes after Trabectome [18–20] and ~8% of eyes after KDB [21–23]. Bleeding 
rates seem to decrease as the opening size of the trabeculotomy decreases. With regard 
Table 10.1 Breakdown of the different procedures separated by the mechanism of action
Cut Dilate Stent
Kahook Dual Blade (New 
World Medical, Rancho 
Cucamonga, CA, USA)
iTrack™ (Ellex 
Medical Pty Ltd., 
Adelaide, Australia)
iStent Trabecular Micro-Bypass Stent 
and iStent inject (Glaukos Corporation, 
San Clemente, CA, USA)
Trabectome 
(NeoMedix Corporation, San 
Juan Capistrano, CA, USA)
OMNI®(Sight 
Sciences, Inc., 
Menlo Park, CA, 
USA)




Excimer Laser Trabeculostomy 
(Excimer Laser AIDA, Glautec 
AG, Nürnberg, Germany)
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to cutting procedures, data on whether goniotomy (only an incision through the TM, 
e.g., GATT) or goniectomy (cut AND excision of the TM, e.g., Trabectome and KDB) 
procedures differ in a long-term efficacy and complication rates are lacking.
Dilation of Schlemm’s canal alone may reduce resistance to aqueous outflow 
from Schlemm’s canal to the collector channels as well as providing a gentle stretch 
to the TM [24]. Studies have shown that herniation of the collector channels with 
the elevation of IOP leads to decreased outflow of aqueous humor [25]. Ab-interno 
canal viscodilation is a relatively new procedure, and although previous studies of 
ab-externo canaloplasty have shown good results, the surgery is more invasive and 
requires conjunctival and scleral dissection to access the canal [26].
Stenting allows aqueous to bypass the TM, the main area of outflow resistance, 
and directly flow into the Schlemm’s canal with less trauma to the meshwork or 
angle than the cutting procedures. The two available options for stenting are the 
iStent (iStent Trabecular Micro-Bypass Stent and iStent inject) and the Hydrus 
Microstent. Both these implants bypass the TM, with the Hydrus Microstent being 
a longer implant, which also scaffolds Schlemm’s canal. The iStent is the smallest 
device implantable in the human body and can be placed at multiple locations in the 
canal. Large randomized control trials have shown that these implants are associ-
ated with a very low risk of complications. Current evidence indicates that the iStent 
inject, the first-generation iStent Trabecular Micro-Bypass Stent and the Hydrus 
Microstent, confer moderate efficacy in lowering IOP, either as solo procedures or 
combined with phacoemulsification [27–30]. The advantage of stenting procedures 
over the cutting and dilating procedures is that it creates a permanent communica-
tion for aqueous to flow from the anterior chamber to the Schlemm’s canal. These 
stents can be obstructed by iris or peripheral anterior synechiae (PAS) (1–2%) [1–
3], but elicit a much smaller inflammatory response than a cutting procedure and 
less blood reflux. Hence, theoretically, trabeculotomies are associated with a higher 
risk of PAS formation, hyphema, and membrane formation than stenting procedures.
Currently, there is no trial comparing the three approaches to Schlemm’s canal. 
The choice of one trabecular bypass procedure over another depends on surgeon pref-
erence and expertise, cost, ease of access to the MIGS devices/procedures, and the 
relative risk of postoperative hyphema. Some may even consider combining stenting 
with dilation or dilation with ablation. The iTrack and OMNI devices allow a combi-
nation of canal dilation and TM ablation to be performed. Based on our clinical expe-
rience, it is likely that viscodilation of the canal decreases the incidence of postoperative 
hyphema by tamponading the reflux bleeding. Stenting, however, remains the least 
invasive trabecular bypass procedure with the lowest incidence of complications. 
Regardless of the surgery chosen, it is important that the surgeon is well-trained in the 
procedure, so as to achieve optimal efficacy with a low rate of complications.
10.4  Endothelial Cell Loss and MIGS
The COMPASS-XT trial (an extension of the COMPASS trial) uncovered a signifi-
cant safety issue with the CyPass Micro-stent (Alcon Laboratories Inc., Fort Worth, 
Tx, USA) [4, 31]. This led to Alcon’s voluntary withdrawal of the device from the 
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market due to concerns of a significant increase in endothelial cell loss (ECL) com-
pared to patients who underwent cataract surgery alone after a 5-year follow-up. 
The only factor that correlated with ECL was the position of the device in the angle. 
The more retention rings that were visible on the CyPass Micro-Stent, the higher the 
likelihood of significant ECL [32]. Importantly, depending on the angle anatomy, a 
device with one ring visible can still be at risk of causing ECL if it remains in close 
proximity to the endothelium. This emphasizes the importance of correct device 
positioning, especially for suprachoroidal devices.
MIGS addresses a void in the conventional glaucoma treatment algorithm, which 
exists between topical drops/laser procedures and conventional glaucoma filtration 
surgery (trabeculectomy and tube implants). The high safety profile of MIGS is an 
important characteristic that allows it to be offered earlier in the glaucoma treatment 
algorithm, either in combination with cataract surgery or as a standalone procedure. 
The recent finding of increased ECL with the CyPass Micro-Stent led to a review of 
all the current MIGS procedures and their risk to the corneal endothelium. 
Fortunately, to date, no other MIGS device (iStent Trabecular Micro-Bypass Stent, 
iStent inject, Hydrus Microstent, Trabectome) is associated with an increase in ECL 
compared to cataract surgery alone (Table 10.2). In contrast, previous studies have 
reported ECL between 8.0 and 18.6% at 2 years for tube shunts and between 9.5 and 
28.0% at 1 year and 9.9% at 2 years for trabeculectomy [33–41].
Much is still unknown with regard to MIGS and its effect on the corneal endo-
thelium as well as the effect of cataract surgery and conventional glaucoma surgery 
on the cornea. Several factors, including device material, aqueous humor dynamics, 
and inflammatory mediators have been hypothesized to play a role in ECL after 
surgery. It is clear from the COMPASS-XT results that the further away the device 
is positioned from the endothelium, the lower the risk of ECL. Hence, the likely 
cause for ECL is mechanical trauma to the corneal endothelium by the device. 
Trabecular bypass MIGS devices (Hydrus Microstent and iStent) are located away 
from the corneal endothelium when correctly implanted in the angle, and early data 
show that they are not associated with an increase in ECL [42, 43]. Dilating or cut-
ting procedures (GATT, OMNI, iTrack, KDB) are unlikely to increase ECL (apart 
from the initial trauma from the surgery) as they do not require a device to be per-
manently implanted in the eye, although this remains to be confirmed [44].
Subconjunctival MIGS devices such as the XEN Gel Implant (Allergan  plc, 
Dublin, Ireland) and PRESERFLO MicroShunt (Santen Pharmaceutical Co. Ltd., 
Osaka, Japan) are bleb-forming procedures which are more effective in lowering 
IOP, hence are typically reserved for patients who need a greater reduction in intra-
ocular pressure. The risk-benefit profile of patients who undergo subconjunctival 
MIGS device implantation differs from that of patients who undergo trabecular 
bypass or suprachoroidal MIGS device implantation. Similar to trabeculectomy and 
tube implants, subconjunctival MIGS devices are often used in the context of more 
advanced glaucoma, and hence, there is a higher tolerance and acceptance of poten-
tial complications in exchange for higher efficacy in lowering the IOP and prevent-
ing glaucoma progression. Only one study has examined ECL after implantation of 
the XEN Gel Implant and showed no significant change in endothelial cell count 
10 Controversies in the Use of MIGS
138
after 1 year [45]. We hypothesize that the risk of progressive endothelial trauma is 
minimized by a properly positioned implant, which is parallel to the iris and enters 
the eye posteriorly to Schwalbe’s line.
10.5  Is the Suprachoroidal Space Dead?
The supraciliary space has long been targeted with the aim of decreasing IOP and 
attempts to access suprachoroidal drainage date back to the 1930s with the use of 
horsehair to increase suprachoroidal aqueous outflow [46]. Several features of this 
space make it an alluring target for surgical therapy. Firstly, the uveoscleral pathway 
accounts for 20–54% of the aqueous humor outflow in a normal eye and this 
decreases with age, with the main restriction to aqueous flow arising from the ciliary 
muscle [47, 48]. Secondly, there is a proven increase in uveoscleral outflow when 
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drugs such as cholinergics and prostaglandin analogs are administered. Prostaglandin 
analogs are now the mainstay of topical glaucoma therapy due to their significant 
efficacy in reducing IOP [47, 48]. Finally, traumatic cyclodialysis clefts may pro-
foundly reduce IOP without bleb formation and this reduction can last for many 
years [47, 48]. Unlike Schlemm’s canal which is lined with endothelial cells, the 
suprachoroidal space is lined with myofibroblasts which predispose to fibrosis and 
scarring, hence the efficacy of suprachoroidal aqueous outflow in lowering IOP is 
more unpredictable. The advantages of draining aqueous to the suprachoroidal 
space include its size (indicating a large capacity for aqueous drainage) and, unlike 
the conventional aqueous outflow pathway, the reduction in IOP is not limited by 
the episcleral venous pressure.
These factors have resulted in the introduction of various implants and proce-
dures to create and maintain a cyclodialysis cleft [49–53]. The disadvantages of 
previous suprachoroidal procedures or devices include high rates of intraoperative 
and postoperative bleeding, unpredictable efficacy in reducing IOP, hypotony, and 
sudden IOP spikes when the cleft closes. Biocompatible materials have been used 
to create a scaffold within the suprachoroidal space, creating a direct communica-
tion between the anterior chamber and the suprachoroidal space. The Gold Glaucoma 
Shunt (GGS, SOLX Ltd., Waltham, MA, USA) [54] and the STARflo Glaucoma 
Implant (iStar Medical, Isnes, Belgium) [55] are ab-externo suprachoroidal devices 
which require conjunctival as well as scleral dissection for implantation. Clinical 
data on the STARflo are limited, while the GGS has been associated with poor sur-
gical outcomes [54]. Hence, the ab-externo approach to the suprachoroidal space 
has been abandoned for newer techniques utilizing an ab-interno approach. Until 
recently, there was only one commercially available ab-interno suprachoroidal 
MIGS device, the CyPass Micro-Stent (Alcon Laboratories Inc., Fort Worth, Tx, 
USA). The withdrawal of the CyPass Micro-Stent due to concerns of long-term 
ECL evident in the 5-year results of the COMPASS-XT trial has cast doubts on 
whether this space is a viable option after all [56, 57]. However, the ECL associated 
with the CyPass Micro-Stent is likely due to the position of the device in the angle 
causing mechanical trauma to the corneal endothelium and does not appear to be a 
consequence of suprachoroidal aqueous drainage. Thus, it is important for supra-
choroidal and other intraocular devices to be positioned away from the cornea, pref-
erably parallel to the iris.
Compared to MIGS devices targeting the Schlemm’s canal, suprachoroidal aque-
ous drainage can potentially reduce IOP to a dramatic extent as the resultant IOP is 
not limited by the episcleral venous pressure. Surgical implantation of suprachoroi-
dal devices is also technically easier compared with the implantation of trabecular 
bypass devices. The disadvantages of suprachoroidal aqueous drainage include 
unpredictable efficacy in reducing IOP and postoperative fibrosis or scarring which 
can result in a sudden IOP spike. For refractory eyes which lack healthy and mobile 
conjunctiva, suprachoroidal aqueous drainage provides a viable alternative to fur-
ther conjunctival filtration surgery [58]. In addition, suprachoroidal MIGS devices 
can be combined with devices or procedures which utilize other routes of aqueous 
drainage (conventional aqueous outflow pathway and subconjunctival drainage) to 
achieve better IOP control.
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The iStent Suprachoroidal Bypass System (iStent Supra, Glaukos Corporation, 
San Clemente, CA, USA) is another microstent that is in development with limited 
data available [59]. A further device currently under investigation, the MINIject™ 
(iStar Medical, Isnes, Belgium), is composed of a biocompatible silicone implant 
with micropores, the same material as the STARflo device. The advantage of this 
material lies in its ability to biointegrate in the suprachoroidal space. Currently, a 
randomized clinical trial (NCT03193736) is underway to evaluate the efficacy and 
safety of the MINIject, with clinical data reported at 6, 12, and 24  months. 
Preliminary results show a 39% reduction in IOP with mean IOP of 14.2 mmHg at 
6 months, with 87.5% of patients being medication-free [60]. Although the supra-
choroidal space is not well understood and much remains to be discovered about the 
optimization and maintenance of suprachoroidal aqueous drainage, current and new 
technologies on the horizon are promising.
10.6  The Great Debate: Subconjunctival MIGS 
and Trabeculectomy
Trabeculectomy is a time-tested glaucoma filtration surgery with multiple studies 
reporting long-term data substantiating its efficacy in reducing IOP by creating a 
filtering bleb [61–65]. However, this surgery is associated with a significant risk of 
complications and unpredictable results. Postoperative bleb management is com-
plex, requiring many interventions (e.g., bleb needling and scleral flap suture 
removal) and visual rehabilitation can be prolonged. The success of trabeculectomy 
is highly dependent on surgical expertise as well as patient characteristics, with the 
creation of the scleral flap, suture tension, timing of suture–lysis, and conjunctival 
closure all having a significant impact on surgical outcomes. Furthermore, trabecu-
lectomy is associated with a significant risk of complications, including hypotony, 
bleb leaks, and suprachoroidal hemorrhage. Ab-interno and ab-externo subconjunc-
tival MIGS devices can potentially reduce the rate of complications, improve the 
predictability of surgical outcomes, and accelerate postoperative recovery. The effi-
cacy of these procedures in reducing IOP has been a topic of debate in the glaucoma 
community and more prospective multicenter randomized trials are needed to com-
pare the outcome of these devices with trabeculectomy.
The XEN Gel Implant is a 6-mm implant made of porcine gelatin cross-linked 
with glutaraldehyde, with an internal lumen diameter of 45 μm. It is implanted ab 
interno through a clear corneal incision into the subconjunctival space to create a 
filtering bleb, bypassing the TM [66, 67]. The length and the inner lumen of the 
device confer 6–8 mmHg of outflow resistance according to the Hagen-Poiseuille 
equation, hence protecting against hypotony. Despite the theoretical advantages of 
this approach, surgical outcomes can still be unpredictable. This is because micro-
stents, which have a small lumen size, are at an increased risk of distal obstruction 
by tenon’s capsule or fibrosis, or internal obstruction by pigment, heme, or fibrin. A 
large retrospective comparison of the XEN Gel Implant and trabeculectomy showed 
no difference in the failure rates and a similar safety profile between the two 
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procedures [67]. In an attempt to position the implant consistently under the Tenon’s 
capsule and to ensure that it is not occluded by the Tenon’s, some surgeons prefer 
ab-externo implantation of the device with conjunctival peritomy or a trans- 
conjunctival approach to surgical implantation. Currently, no data are available 
comparing the different surgical approaches.
The PRESERFLO MicroShunt is a new subconjunctival MIGS device which is 
8.5 mm long, with an internal lumen diameter of 70 μm. It is made of an inert bio-
compatible biomaterial called poly(styrene-block-isobutylene-block-styrene), or 
“SIBS” [68]. The MicroShunt requires conjunctival and Tenon’s layer dissection to 
properly position the implant in the anterior chamber and under Tenon’s. Early data 
from Batlle et al. show promising results in a small sample of patients [69].
Ab-externo XEN implantation and the surgical technique of the PRESERFLO 
MicroShunt both involve conjunctival peritomy to ensure optimal device placement 
under Tenon’s capsule, but there are a few inherent differences between the two 
implants. The MicroShunt was designed to be implanted ab externo; hence, some 
features of the device are more adapted to that placement. Firstly, the fixation fins 
prevent migration of the device and limit peritubular flow. The XEN Gel Implant is 
injected through a needle, which creates a larger track allowing peritubular flow, 
resulting in a higher incidence of early postoperative hypotony. The MicroShunt 
lumen is larger than the XEN Gel Implant and it is a longer and stiffer device. As a 
longer segment of the MicroShunt is located in the anterior chamber compared with 
the XEN Gel Implant, it may be more likely to damage the corneal endothelium or 
be in contact with the iris. Both implants are made of non-inflammatory and bio-
compatible material (SIBS for the PRESERFLO MicroShunt and crosslinked por-
cine gelatin for the XEN Gel Implant).
Subconjunctival MIGS devices control aqueous outflow into the subconjunctival 
space to form a filtering bleb with potentially fewer complications and a more 
uneventful postoperative course. The efficacy of these novel devices is potentially 
comparable to trabeculectomy, with a lower risk of complications and more predict-
able outcomes. Whether these subconjunctival MIGS devices will eventually 
replace trabeculectomy or be used earlier in the glaucoma treatment paradigm 
remains to be seen.
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11.1  Introduction
Good health for all populations is an accepted international goal. Globalization is 
the process of interaction and integration among people, companies, and govern-
ments worldwide and was previously regarded as a predominantly economic pro-
cess. However, it is increasingly perceived as a more comprehensive phenomenon 
with significant implications for global health. The relationship between globaliza-
tion and health is complex and globalization is a multifaceted phenomenon which 
can influence health in a myriad of ways. Globalization facilitates the spread of 
modern medicine and medical devices, extending life expectancy in developing 
countries from 55 years in 1970 to 65 years in 1997. However, it can also exacerbate 
the gap between the rich and the poor, both among and within countries.
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While knowledge of and interest in minimally invasive glaucoma surgery (MIGS) 
has spread across the globe, access is far from global. Prior to 2016, MIGS devices 
were available mainly in Europe and Canada, with the exception of the iStent tra-
becular micro-bypass stent, which was also commercialized in the United States 
and selected countries in Asia (Singapore and Hong Kong). Since 2016, the US 
Food and Drug Administration (FDA) has approved the CyPass Micro-Stent (Alcon 
Laboratories Inc., Fort Worth, Tx USA) (August 2016, subsequently withdrawn in 
August 2018), the XEN Gel Implant  (Allergan plc, Dublin, Ireland) (November 
2016), the iStent Inject (Glaukos Corporation, San Clemente, CA, USA) (June 
2018), and the Hydrus Microstent (Ivantis Inc., Irvine, CA, USA) (August 2018). 
These devices are also slowly making inroads into Asia, Australasia, South America, 
and South Africa.
The global prevalence of glaucoma is anticipated to increase from 64.3 million 
in 2013 to 111.8 million in 2040, disproportionately affecting people in Asia and 
Africa [1]. MIGS companies may foresee a quantum leap in economies of scale by 
serving global markets rather than only a confined domestic market.
11.2  Cost
In view of the costly commercialization process and the expensive acquisitions of 
several MIGS start-ups by multinational companies, MIGS devices are currently 
priced at a premium. For instance, the price of the XEN Gel Implant has more than 
doubled in Europe since Aquesys was acquired by Allergan in 2015. Hence, the go- 
to- market strategy for most MIGS companies has focused on countries where a 
significant proportion of healthcare coverage is provided through private health 
insurance (e.g., United States and Australia) or public health funding (e.g., the 
United Kingdom and Canada). The latter often requires the technology to be 
appraised and recommended by certain national institutes based on clinical and eco-
nomic evidence. For instance, the National Institute for Health and Care Excellence 
(NICE) in the United Kingdom carries out periodic health technology assessments 
of new entrants. While not legally binding, a NICE assessment carries a great deal 
of weight for or against the adoption of new technology.
Some studies have reported MIGS cost-effectiveness in such reimbursement 
environments. In the Canadian healthcare setting, Patel et  al. projected that two 
iStent Trabecular Micro-Bypass Stents were cost-effective compared with standard- 
of- care treatment with glaucoma medication in patients with mild-to-moderate 
open-angle glaucoma for more than 15 years, with quality-of-life gains [2]. Ngan 
et al. compared iStent accompanying cataract surgery with topical glaucoma medi-
cation in a public healthcare setting in New Zealand and found that the iStent is 
reasonably cost-effective, particularly for those using more expensive topical glau-
coma medications [3]. Indeed, the cost-effectiveness of MIGS procedures may vary 
depending on whether brand name or generic eye drops are used. In the Manchester 
iStent study, Tan and Au found that the overall cost of combined cataract surgery 
and iStent implantation was GBP₤7.70 per patient per year more than conservative 
management with brand name eyedrops, but GBP₤131.3 per patient per year more 
C. C. A. Sng et al.
149
if generic eyedrops were used [4]. Nevertheless, a systematic literature review of 
clinical and economic outcomes of MIGS in primary open-angle glaucoma high-
lighted that the available evidence on the cost-effectiveness of MIGS is limited and 
it remains unclear whether the cost of using MIGS is outweighed by cost savings 
through decreased medication and need for further interventions [5]. The price–per-
formance ratio of MIGS is also an important consideration. The Microcatheter 
(iTrack 250A, iScience Interventional, Menlo Park, CA, USA) and Trabectome 
(NeoMedix Corporation, San Juan Capistrano, CA, USA) are available in the 
Chinese market, but these procedures are expensive and the surgical expenses are 
not covered by basic medical insurance. Hence, they are not widely performed in 
China. Evidently, there is still significant room for growth in the large Chinese glau-
coma surgical market.
Ultimately, the global scalability of MIGS would be more dependent on cost and 
ease of implantation than efficacy. Unfortunately, out-of-pocket payments consti-
tute a significant part of the health financing landscape in many countries. While 
MIGS may still be affordable in the wealthier of such countries (e.g., Singapore and 
Hong Kong), the cost of these devices is prohibitive for a significant proportion of 
the world’s population, especially in Asia and Africa. In these large albeit cost- 
sensitive markets, the cheapest MIGS device is likely to prevail and outperform its 
competitors. In particular, current treatment options for glaucoma patients in devel-
oping countries remain limited and unsustainable. Even if these patients are diag-
nosed at an early stage of the disease, their prognosis remains dire. The recurrent 
cost of glaucoma medication renders them unaffordable in the long run. The lack of 
patient understanding of their disease results in poor compliance with medication 
and conventional glaucoma surgery (i.e., trabeculectomy) is often not feasible due 
to the difficulty of postoperative care, unpredictable results, and possible surgical 
complications. New glaucoma surgical treatment options, for example MIGS, that 
are safer and require less postoperative management, are particularly promising in 
this context. Ordonez et al. projected that the iStent Trabecular Micro-Bypass Stent 
would be a highly cost-saving procedure in the Colombian healthcare system due to 
more quality-adjusted life-years related to a lower rate of the population with loss 
of visual acuity in the long term [6]. Despite being potentially vision-saving, the 
cost of these new innovations prohibits their use in developing countries where they 
are most needed and the potential surgical volumes are the highest. Reducing the 
price of these devices in exchange for an increase in sales volume will chart a more 
profitable path in these resource-poor markets.
11.3  Distribution Channels
After Glaukos Corporation, which developed the iStent Trabecular Micro-Bypass 
Stent, staged a hugely successful initial public offering (IPO) in June 2015, the 
MIGS world has been rocked by a series of high-profile and multimillion dollar 
acquisitions. Allergan purchased Aquesys and its XEN Gel Implant with a US$325 
million upfront payment in the third quarter of 2015. This was followed by the simi-
larly expensive acquisitions of Transcend Medical and its CyPass Micro-Stent by 
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Alcon (withdrawn in August 2018) and the InnFocus MicroShunt (now renamed 
PRESERFLO MicroShunt) by Santen in 2016. With these developments, the MIGS 
landscape has evolved rapidly from a medley of start-ups to a battleground of indus-
try heavyweights.
The acquisition of MIGS devices by multinational pharmaceutical and biotech-
nology companies, which have established international distribution channels, will 
undeniably facilitate the globalization of MIGS. In contrast, the smaller MIGS com-
panies that have not been acquired often have to rely on local distributors to access 
international markets and have to be more selective with their target markets. There 
are certainly opportunities for mutually beneficial partnerships to be forged between 
the MIGS companies in their quest for global expansion. An illustrative example is 
a multi-year agreement between Glaukos and Santen whereby Glaukos will become 
the exclusive distributor of the MicroShunt solely in the US market once it is 
approved by the FDA. This will allow Santen to concentrate on the European and 
Asian markets while leveraging on Glaukos’s established distribution and sales 
infrastructure in the United States.
11.4  Surgical Training
A major constraint in the globalization of MIGS is the limited resources available 
for surgeon training and education. The inadequate availability of surgical trainers 
(who may require years of experience before reaching competence) and real patients 
for supervised surgery creates a bottleneck in the training of MIGS surgeons. In 
addition, the number of free training devices provided by MIGS manufacturers is 
often insufficient for surgeons to overcome their learning curve. To address these 
deficiencies and to prevent them from compromising training standards, an expanded 
role for augmented and virtual reality in MIGS surgical training should be explored 
[7]. Virtual reality-based simulators for MIGS surgery may be able to reduce the 
learning curve, improve the conceptual understanding of ocular anatomy and 
enhance visuospatial skills, augmenting (albeit not replacing) the guidance pro-
vided by surgical trainers. Improvements in information technology have also dra-
matically increased the speed and ease of data flow, facilitating the sharing of 
information. To rapidly disseminate didactic training material on MIGS, such 
resources should be made freely available online in various languages. However, 
surgeons should be advised to access such information only through reputable web-
sites and sources, so as to prevent the potentially rapid dissemination of misinfor-
mation. For instance, www.migs.org is a noncommercial site offering patient 
information leaflets in multiple languages. The Asia-Pacific Glaucoma Society has 
established a MIGS Interest Group and developed patient information leaflets for 
MIGS devices which are available online (www.apglaucomasociety.org/migs) 
(Fig. 11.1). Other international and regional glaucoma societies may consider simi-
lar initiatives to improve surgeon and patient education. It is imperative that surgical 
standards are not compromised in the process of globalization, to ensure consis-
tently good outcomes from MIGS.
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11.5  Patients
Currently, the published data on MIGS procedures mostly pertain to Caucasian eyes 
and it remains uncertain whether these devices will be just as effective in Asian or 
African eyes. This is especially relevant for the subconjunctival MIGS devices, as 
Asian and African eyes have a propensity for subconjunctival scarring [8, 9]. The 
Tenon’s capsule is also significantly thicker in African and Asian eyes compared 
with Caucasian eyes, which may predispose to the occlusion of subconjunctival 
MIGS devices. For instance, the XEN Gel Implant is an ab-interno subconjunctival 
MIGS device that is typically implanted without a conjunctival peritomy, but in 
some African and Asian eyes with very thick Tenon’s (Fig. 11.2), it may be neces-
sary to perform a conjunctival peritomy to ensure proper placement of the implant 
(Fig. 11.3). It may also be necessary to apply a higher concentration of antimetabo-
lites intraoperatively and to prescribe a longer duration of postoperative topical 
Fig. 11.1 Asia-Pacific Glaucoma Society patient information leaflets for minimally invasive glau-
coma surgery devices which are available at www.apglaucomasociety.org/migs. (Image provided 
by Chelvin Sng, FRCSEd)
Fig. 11.2 Anterior 
segment photograph of a 
diffuse bleb associated 
with the XEN Gel Implant 
in a Chinese eye with thick 
Tenon’s capsule, showing 
that the implant is not 
visible when it is located 
under the Tenon’s capsule. 
(Copyright Chelvin Sng, 




steroids for subconjunctival MIGS devices to achieve similar rates of surgical suc-
cess as that in Caucasian eyes, although further studies are required to verify these 
hypotheses.
Despite the size of the Chinese market, with a high prevalence of glaucoma, the 
availability of MIGS and other novel glaucoma surgical options is currently very 
limited. One exception is the Microcatheter (iTrack 250A, iScience Interventional, 
Menlo Park, CA, USA), which was introduced in China in 2012 by Wang’s team. 
This typically requires a conjunctival peritomy and the creation of a scleral flap and 
is not considered minimally invasive. Wang’s team subsequently simplified the 
canaloplasty surgical procedure in China to introduce reconstruction of aqueous 
outflow drainage (RAOD) surgery, omitting two steps (creation of the scleral lake 
and Descemet’s membrane window). This simplified procedure has been used to 
treat eyes with multiple failed glaucoma filtration procedures and disrupted 
Schlemm’s canal observed by gonioscopy (relay technique) [10]. They also pio-
neered the use of partial circumferential trabeculotomy with the Microcatheter in 
primary congenital glaucoma after failed angle surgeries, which may achieve simi-
lar postoperative IOP as 360° trabeculotomy. Refractory glaucoma with previous 
failed conventional glaucoma filtration procedures is a significant challenge in 
China and bleb-less surgery may be a viable surgical option for these eyes, although 
the postoperative IOP may not be low enough for advanced glaucoma. The 
Trabectome is also available in China and has been shown to be effective and safe 
in a multicenter retrospective study [11]. With the introduction of such new surgical 
options, trabeculectomy rates in China have gradually declined. The surgical out-
comes of other MIGS procedures in Chinese eyes still require investigation.
Data on MIGS outcomes in glaucoma subtypes besides primary open-angle 
glaucoma are limited. The efficacy of MIGS in certain subtypes of glaucoma, such 
as angle-closure glaucoma which is prevalent in Asia, would need to be established. 
In an exploratory, prospective, interventional case series, Hernstadt et al. showed 
that combined iStent trabecular micro-bypass stent insertion and phacoemulsifica-
tion was effective in lowering the intraocular pressure (14.8 ± 3.9 vs. 17.5 ± 3.8 mmHg 
at baseline; p = 0.008) and the number of glaucoma medications (0.14 ± 0.48 vs. 
Fig. 11.3 Implantation of 
the XEN Gel Implant with 
conjunctival peritomy. 
(Copyright Chelvin Sng, 
FRCSEd; reproduced with 
permission)
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1.49 ± 0.77 at baseline; p < 0.001) for at least 12 months, with a favorable safety 
profile. Despite cataract extraction, postoperative iStent occlusion with iris occurred 
in 27.0% of the eyes, which is much higher than the incidence of stent occlusion 
reported after iStent implantation in eyes with open-angle glaucoma (4–18%) [12]. 
In a prospective, single-masked, randomized study comparing the efficacy of com-
bined phacoemulsification and iStent implantation with standard phacoemulsifica-
tion in eyes with primary angle closure disease, the combined surgery was associated 
with a higher likelihood of complete success at 12 months (87.5% [95% CI 
58.6–96.7 vs 43.8% [95% CI 19.8–65.6]; p = 0.01) [13]. Sng et al. reported that 
combined XEN implantation with cataract surgery was effective in lowering IOP 
and the number of glaucoma medications in 31 Chinese eyes with primary open- 
angle glaucoma and primary angle-closure glaucoma for at least 12 months, with a 
favorable safety profile [14]. However, implant occlusion with iris may occur more 
frequently in angle-closure eyes, even after cataract surgery (Fig. 11.4). This explor-
atory study was unable to distinguish between the IOP-lowering effect of XEN and 
phacoemulsification and more randomized controlled studies comparing combined 
phacoemulsification with MIGS and phacoemulsification alone are required.
Trabecular bypass procedures and newer modalities of cycloablation are attrac-
tive surgical options for patients in less developed nations as they do not require 
much postoperative management or medications. However, cycloablative proce-




Fig. 11.4 Gonioscopy photographs showing iris occlusion of the (a) iStent Trabecular Micro- 
Bypass Stent, the (b) Hydrus Microstent, and the (c) XEN Gel Implant in angle-closure glaucoma 
eyes even after cataract extraction. (Copyright Chelvin Sng, FRCSEd; reproduced with permission)
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conjunctival filtration surgery [15]. Trabecular bypass procedures have a high safety 
profile and spare the conjunctiva, but the modest efficacy of these procedures ren-
ders them more appropriate for patients with the mild-to-moderate disease who 
would otherwise be noncompliant with their glaucoma medications. In reality, due 
to the poor access to healthcare and eye screening programs, a significant number of 
patients in less developed nations present with advanced glaucoma. Subconjunctival 
MIGS devices, such as the InnFocus Microshunt (renamed PRESERFLO 
MicroShunt), are more likely to achieve lower target IOP compared with other 
MIGS devices, with a lower rate of complications compared with trabeculectomy 
[16], but require postoperative bleb management and possibly a longer duration of 
topical steroids. There is currently an unmet need for a MIGS device that requires 
minimal postoperative management and yet is able to reduce IOP sufficiently for 
patients with advanced glaucoma.
11.6  Regulatory Considerations and Other Concerns
Regulatory restrictions remain a roadblock for the globalization of MIGS.  It is 
important for MIGS manufacturers to understand the legal and regulatory climate 
before entering a new market. Such information is vital for strategic decisions about 
where and how to expand globally. Countries with fewer regulatory barriers (e.g., 
Europe, Canada, and Singapore) often have earlier access to MIGS devices. On the 
other hand, certain countries (e.g., United States and China) have more stringent 
requirements. The US-FDA’s strict adherence to evidence-based evaluation of med-
ical devices often results in a notoriously drawn-out and bureaucratic approval pro-
cess. The Chinese FDA (CFDA) requirement for data from Chinese patients is 
similarly challenging. When submitting international multicenter clinical trial data 
for CFDA evaluation, the overseas applicant is obliged to show that the enrolled 
Chinese trial subjects are representative of the relevant patient population in Chinese 
medical practice and that the sample size of Chinese subjects meets statistical 
requirements. As it may be daunting to conduct a clinical trial in China, a feasible 
alternative would be to obtain supplementary data from other countries with pre-
dominantly Chinese populations (e.g., Singapore and Hong Kong). Nevertheless, 
the United States and China are two of the largest markets globally and remain 
coveted despite their regulatory difficulties. While most MIGS manufacturers target 
the US market after establishing their devices in Europe, a notable exception is 
EyeTechCare (manufacturer of High-Intensity Focused Ultrasound [EyeOP1 HIFU, 
EyeTechCare, Rillieux-la-Pape, France]), which received CFDA approval for its 
device ahead of US-FDA approval. This alternative commercialization strategy 
affords the company the first-mover advantage in a large and untapped Chinese 
market, although the long-term advantages of this strategy are yet to be established.
Another consideration in the globalization of MIGS is the protection of intellec-
tual property, which remains a concern in lesser-developed countries despite the 
Agreement on Trade-Related Aspects of Intellectual Property Rights (1994). Indeed, 
C. C. A. Sng et al.
155
it may be difficult to seek legal recourse for intellectual property infringements in 
certain countries, and under such circumstances, the value of novel biomaterials or 
trade secrets may exceed that of patents in intellectual property protection.
11.7  Conclusion
The path to MIGS globalization is fraught with adversity as well as opportunity. 
Despite the economic, logistic, training, legal and regulatory challenges discussed 
earlier, the permeation of MIGS devices internationally is an inevitable reality. 
Ultimately, the success of these devices in the global market will distinguish the 
survivors from the casualties. It is anticipated that the health benefits of globaliza-
tion will outweigh the disadvantages, and glaucoma patients worldwide stand to 
gain from increased access to MIGS devices, which might reduce glaucoma medi-
cation burden and improve quality of life. Whether such new technology can 
decrease the global incidence of glaucoma-related blindness remains to be seen, but 
this is certainly a worthy aspiration.
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 Appendix A: iStent Trabecular Micro-Bypass 
Stent Implantation Narrative Instructions
 
 Step 1: Patient Positioning and Setup
To obtain proper viewing of the anterior chamber angle, turn the patient’s head away 
from you (the surgeon) approximately 35° and turn the microscope toward you by 
approximately 35° (70° total). Position the gonioprism on the cornea to visualize 
the trabecular meshwork and ensure that a good view of the targeted implant site is 
available at the nasal implant location. To mitigate difficulty with patient movement 




 Step 2: Adjusting Microscope and Identifying Landmarks
Adjust the microscope setting to 10–12× and zoom and focus to locate the trabecu-
lar meshwork and identify the targeted stent implantation site. To visualize the tar-
geted stent implantation location for the iStent Trabecular Micro-Bypass Stent® and 
the iStent inject®, focus on the landmarks shown in the image below and look ante-
rior from the iris plane to find the scleral spur. The trabecular meshwork is located 
anterior to the scleral spur and is typically red/brown in color. Schlemm’s canal is 
behind the trabecular meshwork.
  
 Step 3: Accessing Anterior Chamber
Deepen the anterior chamber with a cohesive viscoelastic as needed to maintain the 
chamber. When stent implantation is being performed with cataract surgery, enter 
the eye through the same corneal incision, otherwise create a 1.5 mm clear corneal 
incision for stent insertion. Prior to entering the eye, hold the inserter like a pencil, 
placing your index finger on the release button. Enter the corneal incision and guide 
the inserter across the pupillary margin (3–4 o’clock for the right eye; 8–9 o’clock 
for the left eye) and replace the gonioprism, taking care to avoid contact with the 
lens or cornea.
 Step 4: Accessing Implantation Site
Locate the trabecular meshwork and select an implant location (shown below). 
Move the inserter to the left side (for the left eye) or right side (for the right eye) of 
the incision and engage the curvature of the trabecular meshwork with the tip of the 
stent, which has a self-trephining tip.





 Step 5: Stent Implantation (Left Eye Example)
Gently pierce the trabecular meshwork and advance the stent until the trabecular 
meshwork rides over the first retention arch. Plant the heel of the stent by moving 
the inserter to the opposite side of the incision. Slowly advance the stent to the left, 
engaging the tissue with the stent tip and sliding the stent under the trabecular mesh-
work and into the canal. Continue inserting until the iStent is fully advanced and the 
stent snorkel meets the trabecular meshwork.
If you encounter resistance or globe rotation, gently “tent” the trabecular mesh-
work tissue by pulling back toward the incision to create more space in the canal. 
When you are prepared to release the stent, slightly “dimple” into the trabecular 
meshwork (pushing toward the back wall of Schlemm’s canal) and fully depress the 
inserter button to release the stent. Once the stent is in Schlemm’s canal, gently tap 
the back of the snorkel with the inserter to fully seat the heel of the snorkel into the 
canal and confirm the stent placement by strumming the snorkel lightly up from 
below. Remove the inserter from the eye.
Before concluding the procedure, use gonioscopy to confirm correct placement. 
Minimal blood reflux is a normal physiological response to stent placement, 
although this does not occur in all cases.
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Align With Natural Curve of The Eye
Left Eye
Engage TM Ideal Angle 15° Slide into Canal Too Flat
iStent Insertion Technique (Left eye - reverse for right eye):
1.  Pass iStent across eye, remaining in center of corneal incision; engage trabecular meshwork
    (TM) at 15° angle.
2.  Pass tip of iStent through TM into Schlemm’s canal until tip encounters back wall of the canal.
     Inserter shaft should slide to left side of corneal incision.
3.  Pull gently to lift TM and clear iStent tip from back wall of Schlemm’s canal. Rotate inserter
     handle CCW toward right side of corneal incision. This will naturally advance iStent into the canal
     at the proper angle. Continue to slide until snorkel reaches TM incision.
4.  Wrong location: If too flat or heel contacts with TM instead of tip, stent will not penetrate properly.  
 
 Step 6: Viscoelastic Removal
Using the corneal incision, irrigate and aspirate the anterior chamber with balanced 
salt solution (BSS) to remove all viscoelastic, pressing down on the posterior edge 
of the incision to facilitate complete removal of viscoelastic. Repeat as needed until 
all viscoelastic has been removed. Inflate the anterior chamber with saline solution 
to achieve physiologic pressure. Ensure that the corneal incision is sealed.
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 Appendix B: iStent inject Implantation 
Narrative Instructions
 
 Step 1: Patient Positioning and Setup
To obtain proper viewing of the anterior chamber angle, turn the patient’s head away 
from you (the surgeon) approximately 35° and turn the microscope toward you by 
approximately 35° (70° total). Position the gonioprism on the cornea to visualize 
the trabecular meshwork and ensure that a good view of the targeted implant site is 
available at the nasal implant location. To mitigate difficulty with patient movement 




 Step 2: Adjusting Microscope and Identifying Landmarks
Adjust the microscope setting to 10–12× and zoom and focus to locate the trabecu-
lar meshwork and identify the targeted stent implantation site. To visualize the tar-
geted stent implantation location for the iStent Trabecular Micro-Bypass Stent and 
the iStent inject, focus on the landmarks shown in the image below and look anterior 
from the iris plane to find the scleral spur. The trabecular meshwork is located ante-
rior to the scleral spur and is typically red/brown in color. Schlemm’s canal is behind 
the trabecular meshwork.
  
 Step 3: Accessing Anterior Chamber
Deepen the anterior chamber with a cohesive viscoelastic as needed to maintain the 
chamber. When stent implantation is being performed with cataract surgery, enter 
the eye through the same corneal incision, otherwise create a 1.5 mm clear corneal 
incision for stent insertion. Hold the injector with your index finger comfortably on 
the micro-insertion sleeve retractor and within reach of the delivery button. Guide 
the micro-insertion tube across the anterior chamber just beyond the pupillary mar-
gin and then slide back the micro-insertion sleeve retractor (teal colored) to expose 
the micro-insertion tube and trocar. Replace the gonioprism, taking care to avoid 
contact with the lens or cornea.
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 Step 4: Accessing Implantation Site
Locate the trabecular meshwork and select an implant location (shown below). 
Place the injector perpendicular to the trabecular meshwork and penetrate the tissue 
with the trocar.
 
 Step 5: Stent Implantation
Apply light pressure to the trabecular meshwork or dimple the tissue enough to see 
a “V” when pressing on the trabecular meshwork. Hold steady then deploy the stent 
by squeezing the stent delivery button with your index finger. A single audible click 
will indicate that the first stent has been delivered from the injector through the 
meshwork and into Schlemm’s canal.
Before withdrawing the injector, look through the micro-insertion tube window 
during stent implantation to verify the stent is securely in place within the tissue. To 
withdraw the injector, hold the stent delivery button down and carefully withdraw 
the injector from the trabecular meshwork prior to releasing your finger from the 
stent delivery button. Upon release of the stent delivery button, a second audible 
click will indicate that the next stent is in position and ready to deliver.
While remaining in the eye, carefully move the injector at least 2 clock-hours 
away from the first implanted stent; approach the trabecular meshwork using the 
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same technique. Squeeze the stent delivery button to deploy the second stent and 
remove the injector from the eye.
Confirm proper placement of the two implanted stents, ensuring that each stent 
flange is visible in the anterior chamber. Minimal blood reflux is a normal physio-




 Step 6: Viscoelastic Removal
Using the corneal incision, irrigate and aspirate the anterior chamber with balanced 
salt solution (BSS) to remove all viscoelastic, pressing down on the posterior edge 
of the incision to facilitate complete removal of viscoelastic. Repeat as needed until 
all viscoelastic has been removed. Inflate the anterior chamber with saline solution 
to achieve physiologic pressure. Ensure that the corneal incision is sealed.
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 Appendix C: iStent Supra Narrative 
Instructions
 
 Step 1: Patient Positioning and Setup
To obtain proper viewing of the anterior chamber angle, turn the patient’s head away 
from you (the surgeon) approximately 35° and turn the microscope toward you by 
approximately 35° (70° total). Position the gonioprism on the cornea to visualize 
the anterior chamber angle and ensure that a good view is available at the implant 
location. To mitigate difficulty with patient movement or noncompliance, consider 




 Step 2: Adjusting Microscope and Identifying Landmarks
Adjust the microscope setting to 10–12× and zoom and focus to the targeted stent 
implantation site. To visualize the targeted stent implantation site for the iStent 
SUPRA, focus on the landmarks shown in the image below and look anterior from 
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 Step 3: Accessing Anterior Chamber
Deepen the anterior chamber with a cohesive viscoelastic as needed to maintain the 
chamber and coat the tip of the inserter with a small drop of viscoelastic. When stent 
implantation is being performed with cataract surgery, enter the eye through the 
same corneal incision, otherwise create a 1.5 mm clear corneal incision for stent 
insertion. Enter the anterior chamber and advance across the pupillary margin 
before replacing the gonioprism, taking care to avoid contact with the lens or cornea.
 
 
 Step 4: Accessing Implantation Site
Create a narrow passage into the suprachoroidal space by gently separating the iris 
processes away from the scleral spur with the tip of the insertion trocar until the 
anterior and posterior portions of the sclera spur are fully visible on a very limited 
area (create an approximately 0.5 mm to a maximum of 1 mm width opening). If 
needed, a spatula may be used for this step. Limited bleeding may occur if the 
spatula contacts capillary vasculature structure; if blood obscures the view of the 
implantation site, use viscoelastic to clear the view.
Advance the iStent SUPRA until the anterior surface of the stent is tangent to the 
posterior margin of the scleral spur. With your finger firmly on the inserter trigger in 
the forward position, carefully advance the trocar/stent into the suprachoroidal 
space until the titanium sleeve just passes the scleral spur and enters the supracho-
roidal space. Ensure that approximately half (or 0.4–0.7 mm) of the sleeve portion 
remains in the anterior chamber.
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 Step 5: Stent Implantation
Once the stent is in the correct position at the proper depth, carefully slide the trig-
ger button backward until the stent is released and withdraw the inserter from eye. 
Use the operating microscope and gonioprism to confirm that the stent is in the 
proper position where the proximal end rests in the anterior chamber with an unob-
structed inlet.
 
 Step 6: Viscoelastic Removal
Using the corneal incision, irrigate and aspirate the anterior chamber with balanced 
salt solution (BSS) to remove all viscoelastic, pressing down on the posterior edge 
of the incision to facilitate complete removal of viscoelastic. Repeat as needed until 
all viscoelastic has been removed. Inflate the anterior chamber with saline solution 
to achieve physiologic pressure. Ensure that the corneal incision is sealed.
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 Appendix D: Trabectome













 Step 1: Clear Corneal Incision
Create a 1.8-mm clear corneal incision with slit knife. Flare the incision on the 




It is recommended that Trabectome surgery is performed prior to cataract sur-
gery for the best corneal clarity. However, if cataract surgery is performed before 
Trabectome surgery, it is advisable to suture the corneal incision, so as to decrease 
the size of the incision and reduce leak during Trabectome surgery.
 Step 2: Lower Anterior Chamber Intraocular Pressure 
to Visualize Schlemm’s Canal
Open the corneal incision to allow aqueous humor to leave the anterior chamber, 
lowering intraocular pressure. Blood reflux into Schlemm’s Canal will then pro-
mote visualization of the trabecular meshwork. The anterior chamber is reformed 
by injecting balanced salt solution.
 
 
 Step 3: Microscope Tilt and Head
The microscope is tilted toward the surgeon by approximately 40° and the micro-
scope oculars are repositioned. Sitting temporally, the patient’s head is rotated away 
by approximately 30°. The best view of the trabecular meshwork is achieved when 
the angle of the microscope and the patient’s eye equals 70°.
  




 Step 4: Goniolens Placement
Place the goniolens on the cornea and identify the trabecular meshwork (enhanced 
by Step 2). Ensure that the correct goniolens is used (handle on the left for right- 
handed surgeons and handle on the right for left-handed surgeons). Remove the 
Goniolens and inset the tip with irrigation on. Advance the tip three-quarters of the 
way across the anterior chamber toward the trabecular meshwork, then replace the 
Goniolens and continue advancing tip, contacting trabecular meshwork. Float the 
goniolens on the cornea and do not compress to avoid striae. Do not use viscoelastic 
to pressurize the eye.
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Favorable and less favorable Trabectome handpiece grip techniques are 
shown below:
Favorable             Less Favorable
 
 Step 5: Removal of Trabecular Meshwork
Gently insert the tip into Schlemm’s Canal highlighted with blood congestion. 
Depress the foot pedal to activate aspiration and electrosurgical power. Advance the 
Trabectome tip clockwise within Schlemm’s Canal to remove trabecular meshwork. 
Bring the Trabectome tip in the center of the anterior chamber and rotate 180°, then 
repeat in a counterclockwise direction to remove the trabecular meshwork. Ablate 
as much as you can safely ablate (up to 180° using one incision).
 
 
When entering the TM:
 1. Visual contact with trabecular meshwork
 2. Minimal pressure and gentle compression of trabecular meshwork
 3. Enter tip through wrinkle in trabecular meshwork arcing into Schlemm’s Canal
 4. Slowly advance tip in Schlemm’s Canal to take out the middle third of the width 
of the trabecular meshwork










When removing the trabecular meshwork, ablate along the arc, pointing the tip 
of the footplate forward and power during rotation along the arc, with the footplate 
within Schlemm’s Canal acting as a guide. Ensure that there is continual handpiece 
withdrawal toward the surgeon to minimize friction on the posterior wall of 
Schlemm’s Canal while advancing along the arc, which would damage the collector 
channels.




Location of Schlemm’s Canal  
 
 Step 6: Irrigate, Aspirate, and Suture (With or Without Phaco)
Perform irrigation and aspiration. If Trabectome surgery is NOT combined with 
Phaco, suture the incision to ensure leak-tight closure. If Trabectome surgery is 
combined with Phaco, enlarge the incision and proceed with Phaco, intraocular lens 
insertion then suture to ensure leak-tight closure. Reduce postoperative hyphema by 
pressurizing the eye well after the procedure.
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 Appendix E: Hydrus Microstent Procedure 
Steps
Narrative Instructions By Ivantis, Inc.
 Step 1
After completion of cataract surgery, or as stand-alone approach, adjust the patient’s 
head and surgical microscope to the proper position to assure an adequate view of 
the angle of the eye using a gonioscopic prism lens.
 
 Step 2
Fill the anterior chamber with a cohesive OVD.
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 Step 3
Using gonioscopy, confirm that the angle is open and the angle structures are suit-
able for microstent implantation.
 Step 4
The surgeon should be able to clearly identify the scleral spur and the trabecular 
meshwork (TM).
 Step 5
Use an existing (or create a new) clear cornea incision (minimum of 2 mm) to insert 
the Hydrus delivery cannula.
 
 Step 6
Advance the Hydrus delivery cannula under gonioscopic guidance and approach the 
TM with the cannula tip at a slight upward angle.
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Target the pigmented TM for cannula tip insertion
 
 Step 7
Penetrate the TM so that the beveled portion of the cannula tip is completely through 
the TM and position the back of the cannula tip against the posterior wall of 
Schlemm’s canal (Fig. 3). Use the tracking wheel on the delivery system to slowly 
advance and implant the Hydrus Microstent, while keeping the cannula tip firmly in 
place. As the Hydrus implant advances, relax any upward or posterior pressure, 
while continuing to keep the cannula tip in place. An interlock mechanism will 
release from the microstent inlet when the tracking wheel is fully advanced. The 
interlock mechanism leaves the inlet in the anterior chamber, while the microstent 
scaffold resides in Schlemm’s canal, dilating the canal in a 90° span and providing 
enhanced aqueous access to multiple major collector channels.
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 Step 8
Visual confirmation of the microstent through the TM results in confidence of 
device placement.
 
The microstent position can be adjusted if necessary with surgical micrograsp-
ers. The microstent can be recaptured and removed using the delivery system and 
it’s tracking wheel in a reverse direction. If recapture is necessary, place the cannula 
tip behind the microstent inlet with the interlock mechanism in front of the inlet. 
Using the tracking wheel in reverse direction will result in the interlock mechanism 
capturing the microstent inlet and retrieving the implant into the delivery cannula.
 Step 9
Following successful microstent implantation, remove OVD and close eye per stan-
dard procedure.
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 Appendix G: PRESERFLO MicroShunt 
Glaucoma Device Surgical Technique
Narrative Instructions By Santen Pharmaceutical Co. Ltd.
Authors: Omar Sadruddin MD, Yasushi Kato PhD
Raymund Angeles MD, Leonard Pinchuk PhD.
The PRESERFLO MicroShunt Glaucoma Device is intended for placement 
through a transscleral ab-externo approach allowing the proximal end of the device 
to be placed in the anterior chamber while the distal end of the device is placed 
under the conjunctiva/sub-Tenon’s capsule.
The following description of the procedure is not a substitute for the comprehen-
sive surgeon training provided by Santen to new users. The surgical steps and tech-
nique for the PRESERFLO MicroShunt Glaucoma Device are as follows:
 Preparation of PRESERFLO MicroShunt
Carefully examine the package containing the PRESERFLO MicroShunt for signs 
of damage that could compromise sterility. If damaged, discard the device. Remove 
the PRESERFLO MicroShunt from sterile packaging onto sterile field. Wet the 
PRESERFLO MicroShunt using a solution of Balanced Salt Solution (BSS).
 1.  Anesthesia: The type of anesthesia will be at the 
surgeon’s discretion (e.g., subconjunctival). Standard 
ophthalmic surgery techniques according to institution 
protocol should be used to prepare the patient and the 
eye for surgery
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 2.  Corneal traction and subconjunctival flap: The use 
of corneal traction with 7–0 suture (e.g., Vicryl or silk) 
will be at the surgeon’s discretion. Dissect a fornix-
based subconjunctival/sub-Tenon’s flap at the 
superonasal or superotemporal quadrant over a 
circumference of 90–120° at least 8–10 mm posterior 
to the limbus. Use cautery, if necessary, to achieve 
hemostasis for a bloodless field
 3.  Application of mitomycin C (MMC): Apply sponges 
saturated with 0.2–0.4 mg/mL MMC to the surgical 
site for 2–3 min
 4.  Rinse out Mitomycin C: Remove the sponges from 
the eye and copiously irrigate the surgical site with 
balanced salt solution (>20 mL)
 5.  Preparation of anterior chamber entrance site: 
Using the ruler provided in the PRESERFLO 
MicroShunt kit, after being inked with the gentian blue 
pen, mark a point 3 mm from the posterior border of 
the surgical limbus (blue/gray zone)
Appendix G: PRESERFLO MicroShunt Glaucoma Device Surgical Technique
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  6.  Incise scleral pocket: At the distal marked point on 
the sclera, use the provided 1-mm wide disposable slit 
angle knife to create a shallow scleral pocket, 1–2 mm 
long to tuck the fin portion of the PRESERFLO 
MicroShunt
 7.  Create 25G needle tract: Maneuver the 25 GA needle 
tip, bevel up, into the apex of the scleral pocket and 
create a transscleral tract into the anterior chamber. 
The scleral track’s entrance into the anterior chamber 
should bisect the angle just above the iris plane with 
sufficient clearance from the posterior cornea
 8.  Insertion of the PRESERFLO MicroShunt into the 
anterior chamber: With a pair of forceps, hold the 
promixal end of the PRESERFLO MicroShunt, bevel 
up, 1 mm from tip. Thread the PRESERFLO 
MicroShunt gently into the transscleral tract at 
approximately 1-mm increments, to prevent kinking, 
until the promixal tip is in the anterior chamber. If 
difficulty is encountered during the insertion of the 
PRESERFLO MicroShunt into the anterior chamber, 
consider creating another transscleral tract 
approximately 1–3 mm to either side of the original 
one. A new PRESERFLO MicroShunt may be 
necessary if the previous one was damaged during the 
initial insertion procedure
 9.  Insertion of the fin into the scleral pocket: After 
successful insertion of the PRESERFLO MicroShunt 
into the anterior chamber, wedge the fin into the scleral 
pocket. Ensure that the PRESERFLO MicroShunt is 
not in contact with the iris and the posterior part of the 
cornea.
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 10.  Confirm flow: Confirm consistent percolation of 
aqueous humor at the distal end of the PRESERFLO 
MicroShunt. Slight pressure on the cornea will help 
initiate flow. If flow is not clearly visible in the form 
of percolation or a slowly growing bead of aqueous 
humor, consider using a 23 GA cannula attached to a 
syringe filled with balanced salt solution to prime the 
PRESERFLO MicroShunt. It may also be necessary 
to create a paracentesis to reform the anterior 
chamber.
 11.  Tuck PRESERFLO MicroShunt under Tenon’s 
capsule: Once flow is established, tuck the distal end 
of the PRESERFLO MicroShunt underneath Tenon’s 
and conjunctiva, making sure that it is straight and 
free of tissue
 12.  Conjunctival closure: Reposition the Tenon’s and 
conjunctiva to the limbus and perform closure using 
sutures with a well-established history of successful 
use in glaucoma surgery (e.g., Nylon, Vicryl). 
Consider suturing Tenons first and separately to avoid 
any retraction postoperatively, followed by closure of 
the conjunctiva. Use a moistened fluorescein strip to 
check for leakage from the wound or from 
conjunctival tears. Additional suturing may be 
necessary to control leakage. Verify that the proximal 
end of the PRESERFLO MicroShunt is in the anterior 
chamber and that the distal end is straight. Remove 
the corneal traction suture if used
Note: No cutting or modification of the PRESERFLO MicroShunt is 
recommended.
Postoperatively:
 1. Apply antibiotic and steroid medication postoperatively according to usual prac-
tice for trabeculectomy.
 2. Monitor the intraocular pressure at each standard-of-care follow-up to determine 
if the PRESERFLO MicroShunt is functioning.
 3. If the PRESERFLO MicroShunt is repositioned, removed, and/or replaced with 
another type of device or another PRESERFLO MicroShunt, due to lack of efficacy, 
the conjunctiva should be cut at the limbus in a similar manner to the original 
implantation procedure. The PRESERFLO MicroShunt should be exposed and the 
repositioning or removal conducted thereafter. After the PRESERFLO MicroShunt 
is removed, verify that there is no aqueous leakage from the transscleral tract. 
Suturing of the transscleral tract with Vicryl will be necessary if leakage is detected.
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